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Summary
Perfect synthesis and function of proteins is needed for optimal survival of an organism.
Specific protein functions are dictated not only by the amino acid sequence of a protein but
also from other factors, including post-translational modifications such as glycosylation, and
the localisation of a protein. The hydrolysation of a protein’s peptide bonds is termed
proteolysis and is performed by proteases. The purpose of proteolysis can vary from activation
to degradation of a protein. Although in most cases proteolysis occurs in a hydrophilic
environment, a specific subtype of proteases called intramembrane proteases, is capable of
hydrolysing peptide bonds in the hydrophobic environment of a cellular membrane. This
ability makes these proteases, that are polytopic membrane proteins, both very interesting and
quite hard to study.
Signal-Peptide-Peptidase (SPP) and Signal-Peptide-Peptidase-Like proteins (SPPLs) are a
family of intramembrane proteases that compirse a conserved active site located in a GxGD
motif. Hence, SPP and SPPLs are members of the GxGD family of intramembrane proteases
together with the presenilins, which are well studied due to their crucial role in the pathology
of Alzheimer’s disease. Five members compose the SPP/SPPL family in mammals, SPP,
SPPL2a, SPPL2b, SPPL2c, and SPPL3, with generally a few less members being present in
different organisms. From the five members, SPPL3 and especially SPPL2c were the least
understood until recently.
For SPPL3, it was shown previously that it has the ability to process full-length glycosidases
and glycosyltransferases in vitro and in vivo, leading to a reduction of glycosylation of cellular
glycoproteins. In the first part of this study, the amino acid sequence of two SPPL3
substrates, N-acetylglucosaminyltransferase V (GnTV) and exostosin-like glycosyltransferase 3
(EXTL3), is analysed by introducing mutations to identify amino acids crucial for recognition
and cleavage by SPPL3. Within the transmembrane (TM) domain (TMD) of GnTV, the
presence of two glycines in a GxxxG motif appears to play a role for cleavage, and further
destabilisation of the TM α-helix by introducing a proline at either glycine site increases
processing by SPPL3, however not all results for this motif are consistent. Mutating the
amino acids surrounding the previously identified cleavage site of GnTV and a similar location
on the EXTL3 sequence causes a shift to a SPPL3-independent cleavage for both substrates.
The protease responsible for the cleavage of the mutants remains elusive.
The second part of the study focuses on the in vivo function of SPPL3 initially through the
analysis of a SPPL3 deficient mouse line. SPPL3 knockout is only supported in a mixed
background mouse line. Apart from some deficits in the mating of knockout mice and a
reduced motor activity present in old knockout mice (>12 months), the main phenotype
observed is a severe reduction in the adipose tissue of the SPPL3 deficient mice. To analyse
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this phenotype further, SPPL3 knockout mouse embryonic stem cells (SPPL3 KO ESCs) were
generated with the CRISPR/Cas9 system and were then differentiated to adipocytes in vitro.
The results from the ESCs follow the same tendencies as observed in the mice with a very low
number of adipose cells at the end of the differentiation period for the SPPL3 KO ESCs
compared to control cells, suggesting involvement of SPPL3 in the formation and/or function
of mature adipocytes.
The last part of this study focuses on the purpose of the least understood member of the
family, SPPL2c. Since its discovery, SPPL2c was considered a pseudoprotease due to the lack
of substrates in vitro, while protein levels could not be detected in vivo. After successfully
demonstrating that SPPL2c is indeed expressed in vivo in the testis of humans and mice, this
study effectively identifies and validates physiological substrates of SPPL2c (Niemeyer et al.
2019, Papadopoulou et al. 2019). It also demonstrates that SPPL2c can affect vesicular
trafficking and holds a physiological role in the maturation of spermatozoa.
Taken together, this study focuses on two members of the SPP/SPPL family, SPPL3 and
SPPL2c, and analyses them both in vivo and in vitro revealing new characteristics and
physiological implications of the proteases. The knowledge this work provides is important not
only in the context of these two proteins, but also for the general understanding of the
mechanism and purpose of intramembrane proteolysis.
Zusammenfassung
Die optimale Funktion von Proteinen ist für das bestmögliche Überleben eines Organismus
entscheidend. Spezifische Funktionen werden nicht nur durch die Aminosäuresequenz eines
Proteins definiert, sondern auch durch verschiedene andere Faktoren wie Glykosylierung und
subzelluläre Lokalisierung des Proteins. Außerdem regulieren proteolytische Spaltungen diverse
physiologische Prozesse und steuern beispielsweise durch Aktivierung und Abbau die
Funktionen von Proteinen.
Proteolyse bezeichnet die Hydrolyse der Peptidbindungen eines Proteins. Enzyme, die diese
Reaktion katalysieren, werden als Proteasen bezeichnet. Obwohl Proteolyse bevorzugt in
hydrophilen Umgebungen stattfindet, kann ein spezifischer Subtyp von Proteasen, die
Intramembranproteasen, Peptidbindungen innerhalb einer Zellmembran hydrolysieren. Das
macht diese polytopischen Intramembranproteasen sehr interessant, aber auch schwer zu
untersuchen.
Die Signal-Peptid-Peptidase (SPP) und Signal-Peptid-Peptidase-like Proteine (SPPLs) bilden
eine Intramembranprotease-Familie. Das aktive Zentrum, das durch ein GxGD-Motiv
charakterisiert ist, ist innerhalb dieser und der Presenilin-Familie hoch konserviert. Die
Presinilin-Familie ist aufgrund ihrer entscheidenden Rolle in der Pathologie der
Alzheimer-Krankheit gut untersucht und bildet zusammen mit den SPP/SPPL-Proteasen die
Klasse der GxGD-Intramembran-Aspartyl-Proteasen. Die SPP/SPPL-Familie umfasst in
Säugetieren die fünf Mitglieder SPP, SPPL2a, SPPL2b, SPPL2c und SPPL3. SPPL3 und vor
allem SPPL2c sind die bis dato am wenigsten untersuchten Mitglieder dieser Protease-Familie.
Für SPPL3 konnte gezeigt werden, dass es die Fähigkeit besitzt, Glykosidasen und
Glykosyltransferasen in vitro und in vivo zu hydrolysieren, was zu einer reduzierten
Protein-Glykosylierung führt. Im ersten Teil dieser Studie wird versucht durch gezielte
Mutation der Aminosäuresequenz von zwei bekannten SPPL3-Substraten,
N-Acetylglukosaminyltransferase V (GnTV) und Exostosin-like-Glycosyltransferase 3 (EXTL3),
das für die Prozessierung durch SPPL3 entscheidenden Erkennungsmotiv zu identifizieren. Die
beiden Glyzine innerhalb eines GxxxG-Motiv in der Transmembrandomäne (TMD) von GnTV
scheinen eine wichtige Rolle für seine Spaltung zu spielen. Insbesondere eine Destabilisierung
der α-Helix in der TMD durch den Austausch eines Glyzins gegen ein Prolin beschleunigt die
Prozessierung von GnTV durch SPPL3. Umgekehrt führt in einigen Fällen aber auch die
Stabilisierung der Helix in diesem Bereich zu einer beschleunigten Prozessierung von GnTV,
sodass sich derzeit kein schlüssiges Gesamtbild ergibt. Mutationen im Bereich der zuvor
identifizierten SPPL3-Spaltstelle von GnTV, sowie an einer vergleichbaren Stelle in der
EXTL3-Sequenz, führen zu einer SPPL3-unabhängigen Spaltung beider Substrate. Die
Protease, die für die Spaltung dieser Mutanten verantwortlich ist, konnte bisher nicht
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identifiziert werden.
Der zweite Teil dieser Studie konzentriert sich auf die Analyse einer Sppl3-defizienten
Mauslinie zur Aufklärung der in vivo-Funktion von SPPL3. Überlebensfähige Tiere mit einem
SPPL3-Knockout konnten ausschließlich in einer Mauslinie mit gemischtem genetischen
Hintergrund generiert werden. Diese SPPL3-defizienten Tiere zeigen neben einer reduzierten
Geburtenrate und verringerter motorischer Aktivität, die insbesondere in älteren Tieren (> 12
Monate) beobachtet wird eine starke Reduktion des Fettgewebes. Zur weiteren Analyse dieses
Phänotyps wurden SPPL3-defiziente embryonale Maus-Stammzellen (ESC) mit Hilfe des
CRISPR/Cas9-Systems generiert und anschließend zu Adipozyten differenziert. Am Ende der
Differenzierungsperiode wird im Vergleich zu Kontrollzellen eine verringerte Anzahl von
Adipozyten in SPPL3-Knockout ESC beobachtet. Diese Beobachtung legt nahe, dass SPPL3
an der Bildung und Funktion gereifter Adipozyten beteiligt ist.
Der letzte Teil dieser Studie konzentriert sich auf die Funktion des am wenigsten untersuchten
Familienmitglieds SPPL2c. Seit seiner Entdeckung wurde aufgrund des fehlenden Nachweises
von Substraten und Proteinexpression angenommen, dass SPPL2c eine Pseudoprotease ist.
Nach dem erfolgreichen Nachweis, dass das SPPL2c Protein tatsächlich in vivo in
menschlichen und murinen Hoden exprimiert wird, werden in dieser Studie physiologische
Substrate von SPPL2c identifiziert und validiert. Es wird außerdem nachgewiesen, dass
SPPL2c den vesikulären Transport beeinflussen kann und unter physiologischen Bedingungen
an der Reifung von Spermatozoen beteiligt ist (Niemeyer et al. 2019, Papadopoulou et al.
2019).
Zusammengefasst konzentriert sich diese Studie auf zwei Mitglieder der SPP/SPPL-Familie,
SPPL3 und SPPL2c, und analysiert diese sowohl in vivo als auch in vitro. Dabei werden neue
Eigenschaften und physiologische Funktionen der Proteasen beschrieben. Das neu gewonnene
Wissen ist nicht nur im Zusammenhang mit diesen beiden Proteinen wichtig, sondern auch für
das allgemeine Verständnis des Mechanismus und der Funktion der Intramembranproteolyse.
1. Introduction
Life comes in a multicompartmental, highly organised form, where every single aspect of each
process needs to be finely tuned and function “on-spot” in order to achieve what we refer
to as “healthy/physiological” conditions. Proteins are the main building blocks of organisms,
where the majority of these processes depends upon. It is now very well documented that small
changes in a protein’s expression pattern or function have detrimental results in the overall
prosperity of an organism. Cystic fibrosis, breast cancer and Alzheimer’s disease (AD) are just
a few examples of severe pathologies that can be caused by altered expression or function of a
single protein (Cruts et al. 1996, King et al. 2003, Tang and Gershon 2003, Lim et al. 2017).
There are about 19.000 protein-coding genes in humans (Ezkurdia et al. 2014) and 24.000
in mice (MGI statistics). Despite the importance of proteins in the successful operation of an
organism, so far only a small fraction of these proteins has been studied in detail.
The goal of the current thesis is to shed more light into the role and function of two proteins,
signal peptide peptidase-like 3 (SPPL3) and signal peptide peptidase-like 2c (SPPL2c), both
members of the same family of intramembrane proteases. For SPPL3, it has been shown that
through intramembrane proteolysis, it can regulate sensitive cellular functions, such as protein
glycosylation (Voss et al. 2014a, Kuhn et al. 2015). However, its cleavage mechanism and the
in vivo relevance of its function remain to be discovered. Regarding SPPL2c, there is a vast
lack of knowledge as it was considered a pseudogene for the past 10 years (Golde et al. 2009).
1.1 Protein glycosylation
The function of proteins is not controlled just by their amino acid sequence and structure.
Post-translational modifications, proteolytic processing and the localisation of a protein within
the cell/organism all play important roles in the final functionality of a protein. A large
number of cellular proteins are glycosylated; these are predominantly transmembrane and
secreted proteins, but also cytosolic proteins can be glycosylated (Moremen et al. 2012). The
addition of carbohydrate moieties to a protein, i.e. glycosylation, is found in all kingdoms of
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life and the complexity of the glycans seems proportionate to the complexity of the organism.
Environmental conditions and development are known to affect and alter the glycosylation
pattern of cells and organisms (Moremen et al. 2012).
Glycans are attached to proteins for a number of purposes, from contributing to and
controlling protein folding and function, to cell-cell recognition and communication. There are
more than 700 proteins involved in the formation and attachment of more than 7000 different
glycan structures (Moremen et al. 2012). The importance of a precise regulation of this
procedure can easily be observed in vivo, since a number of animal models are available with
defective glycosylation that present with very severe phenotypes (reviewed in (Hennet 2012)).
Additionally, altered glycosylation has been linked to a number of severe pathologies (Varki
and Freeze 2009), such as cancer (reviewed in (Stowell et al. 2015, Cheng and Oon 2018))
and AD (reviewed in (Schedin-Weiss et al. 2014)).
The two major forms of glycosylation are named according to the linkage formed between the
protein and the glycans. Attachment of glycans to the side chains of luminal asparagine
residues in an N-glycosidic amide linkage is termed N-glycosylation. O-glycosylation
characterises the O-glycosidic linkage of glycans to serine or threonine residues (Moremen et
al. 2012).
1.1.1 Glycan-modifying enzymes
All procedures regarding the attachment and rearranging of glycans are initiated within the
endoplasmic reticulum (ER) and then advanced in the medial- and trans-Golgi network
(TGN) by approximately 200 different enzymes. Their purpose is to extend existing glycan
structures, which they recognise as their substrates, by adding sugars from nucleotide- or
lipid-linked activated donors. Specific glycosidases and glycosyltransferases are responsible for
every alteration and they compete amongst them for their substrates. This competition for
overlapping substrates together with the number of enzymes and activated sugar donors
available is responsible for the characteristic final glycan pattern of a cell (Moremen et al.
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2012). Most of these enzymes are type-II TM proteins with a long C-terminal ectodomain
harbouring their catalytic site and a rather short N-terminal cytoplasmic domain (Varki et al.
2009).
It has been known since many years that the catalytic site-containing ectodomain of
glycosidases and glycosyltransferases is secreted (Lammers and Jamieson 1989, Paulson and
Colley 1989). This secretion negatively regulates the function of these enzymes since despite
retaining their active catalytic site in the cleaved form, they can no longer glycosylate
proteins, most likely due to the lack of substrates and sugar donors outside the Golgi stacks
(Paulson and Colley 1989, Varki et al. 2009). Consequently, regulation of the cleavage of
these enzymes can play a key role in controlling their function thus, quickly and effectively
altering the glycan patterns of a cell. Since 2014, we know that one of the main proteases
involved in the secretion of the glycosylating enzymes is SPPL3 (Voss et al. 2014a, Kuhn et
al. 2015). What still remains to be discovered is under what conditions this process is
activated/deactivated and what is the exact mechanism of substrate recognition for this
cleavage by SPPL3.
1.1.1.1 N-acetylglucosaminyltransferases
N-acetylglucosaminyltransferase V (GnTV) is encoded by the gene MGAT5 and is the best-
studied substrate of SPPL3. As suggested by its name, GnTV belongs to the family of N-
acetylglucosaminyltransferases (GnTs) that are responsible for N-acetylglucosamine (GlcNAc)
branching during the formation of complex N-glycans, and are located in the Golgi (Schachter
2000).
The initial 14-sugar long (Glc3Man9GlcNAc2) N-glycan is synthesized on a lipid anchor in the ER
and is then transferred and linked to an asparagine through a GlcNAc. The receiving asparagine
needs to be within an Asn-x-Ser/Thr acceptor sequence, where the x amino acid cannot be a
proline. This sugar already contains the Man3GlcNAc2 core that is common in all three types
of N-glycans: high mannose, complex and hybrid glycans (Moremen et al. 2012). For non-ER
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resident glycoproteins, this initial high-mannose glycan is trimmed both before leaving the ER
and after arriving to the Golgi, before it can be further processed in the Golgi (Bieberich 2014).
GnTs are responsible for attaching GlcNAc in β-linkage to the different mannose positions on
trimmed N-glycans present in the Golgi. GnTI generates GlcNAcMan5GlcNAc2 that can give rise
to hybrid N-glycans by having more GlcNAc attached to it by GnTIII and GnTIV. Alternatively,
the trimmed N-glycan has two additional mannose molecules removed by Golgi α-mannosidase
II (α-Man II) resulting to GlcNAcMan3GlcNAc2, which can then be further processed by GnTII,
GnTIV and GnTV, giving rise to complex N-glycans (Schachter 2000) (Fig. 1.1). From this
point on, hybrid and complex N-glycans can join the rest of O-glycans and glycolipids to undergo
additional modifications within the Golgi including fucosylation and sialyation of their terminal
GlcNAc residues (Stanley and Cummings 2009, Stanley et al. 2009).
Fig. 1.1: N-glycosylation A. GlcNAc branching. Already trimmed high mannose glycans arrive to the Golgi from the ER, where
they are further trimmed by α-mannosidase I and II (α-Man I, α-Man II). N-acetylglucosaminyltransferases I-VB (GnT-I – GnT-VB)
can act in a relatively sequential manner adding GlcNAc to different mannose positions forming hybrid and complex N-glycans. B.
Depiction of a complex N-glycan indicating which GnT is responsible for the respective connection.
The function of GnTV in vivo has so far been connected to both physiological and pathological
processes. Results obtained from Mgat5 deficient mice indicate that this glucosyltransferase is
involved with tissue and skin renewal, fat storage and response to nutrient conditions (Cheung
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et al. 2007, Miyoshi et al. 2012). Pathologically, increased GnTV expression is detected in early
stages of most cancers and is connected to cancer growth and metastasis through enhanced
signaling of growth factors (Miyoshi et al. 2012, Drake et al. 2015). GnTV expression negatively
correlates with patient survival in specific types of cancer such as renal cancer (Liu et al. 2015),
while positively correlates in other types such as thyroid and liver cancer (Miyoshi et al. 2012).
Recent studies are trying to target GnTV in an effort to treat cancer (Nagae et al. 2018).
1.1.2 Proteoglycans
Proteoglycans are formed from one core protein that has covalently attached one or more
molecules of glycosaminoglycan chains. Disaccharide molecules that consist of one amino sugar
and one uronic acid or galactose molecule are the building blocks of the linear polysaccharides
called glycosaminoglycans (GAGs). Some of these approximately 80 sugar long residues are
chondroitin sulfate, keratan sulfate, heparan sulfate and others. Despite the limited amount
of core proteins detected in nature, proteoglycans are ubiquitously expressed and can be found
in the plasma membrane, the extracellular matrix and secretory granules. The variation of
proteoglycans is very high due to the different chains available that can be used in different
combinations, numbers and positions and that can also be differentially sulfated (Varki 2008).
As with glycosylation, numerous enzymes are involved to ensure the correct synthesis of
GAGs. The synthesis of chondroitin and heparan sulfate starts with a common path when a
xylosyltransferase (XYLT1 or XYLT2) links xylose to a serine residue of the core protein using
UDP-xylose as a donor. The GAG chain is prolonged by addition of two galactose residues by
a β4-galactosyltransferase (B4GALT1, B4GALT7, etc.) and a β3-galactosyltransferase
(B3GALT6, etc.), followed by β3-glucuronosyltransferase (B3GAT3) adding a glucuronic acid.
Heparan sulfates separate from the chondroitin when exostosin-like glycosyltransferase 3
(EXTL3) adds the first GlcNAc residue to the growing GAG chain of heparan sulfates (Varki
2008) (Fig. 1.2).
Interestingly, SPPL3 has been shown to cleave numerous of the enzymes involved in the
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Fig. 1.2: Biosynthesis of chondroitin and heparan sulfate. First a xylose and subsequently two residues of galactose are covalently
attached to the serine of a core protein that has a glycine attached to its carboxy side. After addition of the GlcA, the two sulfates
are separated by the addition of the first hexosamine (GlcNAc for heparan or GalNAc for chondroitin) (Varki et al. 2017).
synthesis of heparan sulfate including XYLT2, B4GALT1, B4GALT5, B4GALT7, B3GALT6
and EXTL3 (Kuhn et al. 2015). This could be of high importance given the ubiquitous
expression of heparan sulfate proteoglycans (HSPGs) in invertebrates and vertebrates. HSPGs
are shown to have a strategical role in cell signaling and the interactions between a cell and its
environment (Gallagher and Hampson 1984, Hook et al. 1984), thus affecting key functions
of the organism, such as cell growth, development (Lin 2004).
1.1.3 Lectins
Initially discovered in plants at the end of the 19th century, lectins are now known to exist in
all forms of life, from viruses and bacteria to animals. Lectins are carbohydrate-binding
molecules that can specifically bind to sugars and simple or complex glycan structures of
glycoproteins. The structures identified by the lectins include N-glycans and O-glycans
amongst others. The recognition takes place through specific pockets present on lectins that
recognise specific structures at the end of the glycan chains (Varki 2008).
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The use of lectins in science started due to their ability to distinguish between the different
blood types during the Second World War. Since then, the scientific use of lectins has
progressed a lot and has become much more detailed and sensitive. Lectins can nowadays be
used in multiple techniques, such as blotting, chromatography, histochemistry and even in
lectin microarrays, requiring minimal amount of sample. They can be used not only to detect
microorganisms, but also to analyse the precise glycosylation fingerprint of a selected sample
(Hendrickson and Zherdev 2018). Such information can be used to identify which glycan
structures are more or less present in certain conditions and thus, which glycosyltransferases
are more or less active.
1.2 Vesicular trafficking
For posttranslational modifications, such as glycosylation, to take place but also to ensure
proper function of all cellular processes, each protein needs to localise at the right place at the
right time. This becomes more complicated when one takes into account that a common
characteristic of all eukaryotic cells is the presence of membrane formed organelles that
compartmentalise and make the cell a functioning unit. For a cell to produce and secrete a
protein, a number of these organelles need to function sequentially forming the “secretory
pathway”. Proteins that are destined for this pathway enter first through the ER and then
pass through the Golgi, before reaching the plasma membrane (PM) or other structures like
the lysosomes. The high degree of membrane-derived compartmentalisation creates the need
for a guided trafficking system. This will take the proteins through the necessary organelles to
ensure that protein synthesis is followed by post-translational modifications, like glycosylation,
before each protein can reach its final destination and fulfil its function, either within or
outside the cell. The main mean of transport between these various organelles is termed
vesicular trafficking and consists of small membrane vesicles that transport cargo proteins
along the secretory pathway (Lee et al. 2004a, Gomez-Navarro and Miller 2016, Wang et al.
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2017).
Small vesicles are formed from a donor membrane, then translocate towards the target
organelle where they tether to the membrane before fusing with it (Lee et al. 2004a,
Gomez-Navarro and Miller 2016, Wang et al. 2017). The first step of this process, vesicle
formation, is performed by cytoplasmic coat proteins that localise to the donor membrane.
Different coat proteins are found along the secretory pathway and their role also extends to
selecting some of the vesicle cargo by identifying and interacting with the cytoplasmic
domains of the cargo proteins, which carry specific signals (Lee et al. 2004a). The coat
proteins at the first part of the secretory pathway include the COPI and COPII coatomer
complexes that function in the retrograde and anterograde trafficking between the ER and
Golgi, respectively (Fig. 1.3). Another abundant coat protein is clathrin, which localises
further along the secretory pathway and mediates trafficking between TGN, endosomes,
lysosomes and PM (Lee et al. 2004a). The trafficking between ER and Golgi has been studied
for years and a number of mechanisms have been discovered to exist in order to ensure the
trafficking of the correct proteins (reviewed in (Lee et al. 2004a)). In principle, only fully
folded proteins can access COPII vesicles and leave the ER. At the same time COPI vesicles
primarily ensure the return of ER-resident proteins from the Golgi (Lee et al. 2004a). The
ER-Golgi intermediate compartment (ERGIC) is located between the ER and the Golgi and
has evolved in metazoan as an intermediate quality control and cargo-sorting step in the
secretory pathway (Fig. 1.3) (Hanna et al. 2018).
The transit of the vesicles is mediated by use of the cytoskeleton and proteins, such as
dynactin and kinesin II, that facilitate the binding and movement of the vesicles along the
microtubules (Deacon et al. 2003). The Rab family of GTPases plays a crucial role in
vesicular transport by regulating the recruitment of different protein complexes required for
each step of the process (Hutagalung and Novick 2011). When the vesicle approaches the
correct membrane, it is tethered by long coiled-coil tethering proteins, such as myosin-shaped
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molecule p115, and large multiprotein tethering complexes. Tethering proteins also facilitate
the formation of soluble NSF (N-ethylmaleimide-sensitive factor) attachment protein receptor
(SNARE) complexes that mediate the fusion of membranes (Appenzeller-Herzog and Hauri
2006).
Fig. 1.3: Vesicular trafficking. COPII vesicles (yellow) transport correctly folded soluble (pink) and TM proteins (dark green)
from the ER to the Golgi. TM proteins, such as glycosyltransferases (dark green), mature within the Golgi and are then ready
to perform their function. Glycosyltransferases, for example, are responsible for the glycosylation of glycoproteins (purple) in the
trans-Golgi. SNARE proteins, including syntaxins (dark blue & light green), VAMPs (light blue) and SNAP25 (orange) participate
in the specific fusion of the vesicles and different combinations of SNAREs are found in different paths of the secretory pathway.
COPI vesicles (aubergine) are responsible for the retrograde transport.
SNARE proteins were discovered and identified as mediators of membrane fusion already in
1988 (Trimble et al. 1988, Jahn and Scheller 2006). The great majority of SNARE proteins
share the same tail-anchored type-II transmembrane orientation (type-IV) (Fig. 1.4) and all of
them comprise at least one SNARE motif at their N-terminal domain. Proteins of the
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SNAP25 family do not have a transmembrane domain and comprise two SNARE motives per
protein. The SNARE motif faces the cytosol and consists of a conserved 60-70 amino
acid-long strand that facilitates the formation of a coiled-coil (Teng et al. 2001, Bonifacino
and Glick 2004, Wang et al. 2017).
The formation of tetrameric SNARE-motif complexes from proteins of the opposing
membranes are required for membrane fusion. The four SNARE motives in most cases derive
from three proteins, two of them having one SNARE motif and one protein with two SNARE
motives. Typically, three of these SNARE motives belong to SNARE proteins localised on the
target-membrane (t-SNAREs) and they form a coiled-coil formation with one
vesicle-membrane SNARE (v-SNARE). This tetrameric SNARE complex is characterised as
trans while the proteins are on opposing membranes and it becomes a cis complex following
the membrane fusion (Bonifacino and Glick 2004). In order to recycle the SNAREs, the cis
complex needs to dissociate with the help of NSF and the soluble NSF attachment protein
(SNAP) and then the v-SNAREs are returned to the donor compartment (Fig. 1.3) (Jahn and
Scheller 2006).
So far, there have been over 38 SNARE proteins identified in mammalian cells (Wang et al.
2017) and their categorization in v- and t-SNAREs does not always match their localisation
on the membranes. Notably, each SNARE motif possesses either a conserved glutamine (Q)
or a conserved arginine (R), which can be used for a more precise categorisation. The
heterotetrameric SNARE complexes are composed by one R-SNARE, corresponding mostly to
the v-SNARE, and three Q-SNAREs (Qa-, Qb- and Qc-SNAREs), which usually correspond to
the t-SNAREs (Jahn and Scheller 2006). The three main components of a SNARE complex
are the syntaxins, the vesicle associated membrane proteins (VAMPs) and the 25-kD
synaptosomal-associated protein SNAP-25. As the name suggests, VAMPs are mainly on the
vesicles and represent the R-SNAREs. Syntaxins and SNAP-25 are at the target membrane
with syntaxins being the Qa-SNAREs. SNAP-25 represents the small number of SNAREs that
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lack a TMD and comprise two SNARE motives, the Qb- and Qc- (Jahn and Scheller 2006).
Different vesicles along the secretory pathway require diverse combinations of SNARE proteins
for successful fusion to the target membrane. The combinations depend on the subcellular
compartments from where the vesicle originates, on where it is targeted and on the cargo of
the vesicles.
1.3 Shedding and Intramembrane Proteolysis
Proteolysis refers to the hydrolysis of peptide bonds leading to the breakdown of proteins. This
process can have two purposes, one is to regulate the function of a protein as a post-translational
modification and the other is to degrade a protein so it can be removed and/or recycled. The
cellular enzymes that catalyse the peptide bonds are referred to as proteases. Although in the
past it was thought that peptide bonds can only be degraded in hydrophilic conditions, and
thus not within the transmembrane span of membrane proteins, the concept of intramembrane
proteolysis is now well accepted (Steiner et al. 2008). The processing of membrane substrates
can also serve different roles, from activation, maturation and secretion of proteins to simply
their degradation and removal from the membrane. As proteolytic cleavage is an irreversible
process, precision of cleavage and tight regulation of proteases are extremely important. In fact,
deregulation of intramembrane proteolysis has been linked to severe and complex diseases such
as rheumatoid arthritis, Alzheimer’s disease (AD), Parkinson’s disease and others (Langosch et
al. 2015).
An organism harbours a variety of essential membrane proteins and the vast majority of them
undergo shedding of their ectodomain by proteases named “sheddases”. In some of those cases,
the ectodomain is secreted from the cell following the cleavage, in which scenario the sheddase
is actually a “secretase”. Most commonly, shedded substrates are processed within the luminal
juxtamembrane domain, close to the TMD, by “canonical sheddases”. Prominent canonical-
sheddases include β-site of APP cleaving enzyme 1 and 2 (BACE 1 and 2), a disintegrin and
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metalloproteinase (ADAM) family and site-1 protease (S1P) (Lichtenthaler et al. 2018).
Fig. 1.4: Types of transmembrane proteins. Depending on the
orientation of the N- and C-termini, single-pass TM proteins are
either considered type-I or -II. Different I-CLIPs have different
preferences, with γ-secretase for example cleaving only type-I
substrates, while SPP/SPPLs type-II. Type-III TM proteins can
be turned into both type-I & II via cleavage of the loop, while
type IV have practically no ectodomain and are C-terminally tail-
anchored.
Numerous of the membrane proteins, either
full-length or shedded, have been also
identified as substrates of intramembrane
cleaving proteases (I-CLIPs), since the
recognition of this phenomenon in the 1990s.
Certain I-CLIPs, such as the rhomboids
and SPPL3, can directly cleave full-length
substrates that span the membrane one or
multiple times and comprise long ectodomains
(Fig. 1.4). These I-CLIPs are named “non-
canonical sheddases” because the cleavage
occurs at the membrane border or within the
TMD of the substrate. Other I-CLIPs, such as the presenilins, are only capable of cleaving
substrates with extremely short ectodomain, and substrates with long ectodomain are only
processed after removal of their ectodomain (Lichtenthaler et al. 2011, Voss et al. 2013). In
this last scenario, I-CLIPs participate in a two-step process termed regulated intramembrane
proteolysis (Lichtenthaler et al. 2018).
1.3.1 Regulated intramembrane proteolysis
This specific type of intramembrane proteolysis was first identified and described in 2000 by
Brown et al. It was named regulated intramembrane proteolysis (RIP) due to the double
processing of the transmembrane substrate in two sequential proteolytic steps. Since its
identification, RIP has been the subject of numerous studies and reviews. RIP is conserved
throughout evolution from single- to multi-cellular organisms and is thought to play a dual
role as initiator of signalling and in the degradation of membrane proteins. Under normal
conditions, RIP has a crucial role in numerous physiological processes, such as the
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development of the embryo and the functionality of the immune and the nervous systems.
Moreover, deregulation of RIP can lead to pathological conditions, such as leukaemia and AD
(Brown et al. 2000, Lichtenthaler et al. 2011).
Substrates of RIP are both single- and multi-pass TM proteins (Lichtenthaler et al. 2011).
The first cleavage occurs within the luminal domain of the substrate and in close proximity to
the TMD. It can either lead to a release of the soluble ectodomain, in case of a single span
TM protein or to the breakage of a loop in a multi-span TM protein. This step is often
referred to as “ectodomain shedding” due to the shortening of the luminal part of the protein
via the removal of a large part of the substrate’s ectodomain. The second cleavage occurs
within the TMD of the substrate and results in the secretion of a small extracellular peptide
and the release of the intracellular domain (ICD) in the cytosol (Fig. 1.5). The second
cleavage tends to depend on the initial cleavage, making ectodomain shedding the
rate-limiting factor in this process (Lichtenthaler et al. 2011).
Fig. 1.5: Regulated Intramembrane Proteolysis. A multi-pass (left of the dotted line) or a single-pass (right of the dotted line)
transmembrane protein can undergo RIP. In the first step (1), a “sheddase” either breaks the loop or releases the substrate’s
ectodomain. The N-terminal (NTF) or C-terminal (CTF) fragment that is left tethered to the membrane serves as the substrate
for the second proteolytic step (2). During this step, an I-CLIP cleaves the substrate within the TMD releasing an extracellular
peptide and an intracellular domain (ICD).
Different families of proteases perform the two distinct cleavages. In most cases, “canonical
sheddases” are responsible for the removal of the ectodomain and depending on the
orientation of the TM protein, they either leave behind a C-terminal fragment (CTF), for
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type-I proteins, or an N-terminal fragment (NTF) for type-II proteins (Fig. 1.4). Some of
these membrane-tethered and membrane-spanning canonical sheddases are characterized as
metalloproteinases due to the requirement of a metal ion, Zn2+, at their active site to ensure
an active state (Edwards et al. 2008, Muller et al. 2016). For some substrates, the initial
cleavage can also be performed by “non-canonical sheddases” (Lichtenthaler et al. 2018).
The CTF or NTF, that is left spanning the membrane after the shedding step, serves as the
substrate for the second cleavage. This time the substrate is cleaved within the TMD by
I-CLIPs. This cleavage is facilitated by the active site of the protease being most likely in a
structural cavity with access to aquatic environment, thus allowing the entering of water and
ions to create a microenvironment favourable to hydrolysis (Wolfe 2013).
1.3.2 Intramembrane-cleaving proteases
All I-CLIPs are multipass transmembrane proteins and their entire active site is located within
their transmembrane segments. This characteristic allows them to cleave their substrates
within or very close to the membrane domain. Intramembrane proteases are classified in four
categories, depending on the respective mechanism of catalysis: metalloproteases, serine
proteases, glutamyl proteases and aspartyl proteases (Wolfe 2009, Manolaridis et al. 2013).
To the current state of knowledge, evidence suggests that all proteases belonging to these
protease classes except γ-secretase, process their substrates without requiring cofactors
(Langosch et al. 2015).
1.3.2.1 Metallo-intramembrane proteases
The class of metallo-intramembrane proteases is represented in mammals by the site-2-protease
(S2P) (Fig. 1.6) that requires binding of a Zn2+ ion to its active site. Their purpose is to
activate membrane-bound proteins by releasing the active fragment from its membrane anchor
(Rawson et al. 1997, Feng et al. 2007). S2P can affect the cholesterol homeostasis via cleavage
of sterol regulatory element-binding protein 2 (SREBP2), a well-studied transcription factor
and long-known substrate of S2P (Hua et al. 1995, Kroos and Akiyama 2013). Other known
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Fig. 1.6: Site-2-Protease. The protease consists of six
TMDs. The Zn2+ ion responsible for the catalytic activity of
this metalloprotease is coordinated from the histidine 54 and 58
in the HExxH motif in TMD2 and the asparagine 148 in the DG
motif in TMD4 (Sun et al. 2016).
S2P substrates include activating transcription
factor 6 (ATF6) and old astrocyte specifically
induced substance (OASIS). Both of these
proteins are transcription factors that are
released and activated by S2P as a response to
ER-unfolded protein stress (Ye et al. 2000b,
Murakami et al. 2006). One common
characteristic of S2P substrates is that they
require initial cleavage by S1P before they can be processed by S2P, although the exact reason
remains speculative (Sun et al. 2016).
1.3.2.2 Serine intramembrane proteases
Fig. 1.7: RHBDL1-3 RHBDL4 consists of six core TMDs (green)
and RHBDL1-3 have additionally a seventh TMD (lime). The
active site consists of the serine (S) in TMD 4 and the histidine
(H) in TMD 6.The L1 loop is conserved in all active rhomboid
proteases and is thought to participate in substrate binding. The
GxxxG motif in TMD 6 is conserved along the whole superfamily
and is thought to help stabilise the protein (Ticha et al. 2018).
Initially discovered in Drosophila melanogaster
due to its crucial role in the epidermal growth
factor receptor signalling (EGFR) (Lee et al.
2001, Urban et al. 2001, Urban et al. 2002),
the rhomboid family of serine proteases is
almost ubiquitously found in all organisms
(Koonin et al. 2003). Four rhomboid-
like proteins are located in the mammalian
secretory pathway, rhomboid “secretases”
RHBDL1, 2, 3 and 4 (Lemberg and Freeman 2007) (Fig. 1.7), and one inside the mammalian
mitochondria, PARL (Strisovsky 2016). A number of substrates have been identified for the
mammalian rhomboids including thrombomodulin, EGF and EGFR. They have been linked to
physiological functions, such as the unfolded protein response via the endoplasmic-reticulum-
associated-protein-response (ERAD), but also to pathological conditions such as type-2 diabetes
and Parkinson’s disease (Urban 2006, Urban 2016).
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Rhomboid proteases are very well understood biophysically (Urban 2016) and one peculiarity
of this family of I-CLIPs lies on the fact that rhomboid proteases, in contrast to many
other intramembrane proteases, can cleave full-length substrates and do not strictly depend
on regulation by shedding. Therefore, rhomboids have been described to act as sheddases
(Bergbold and Lemberg 2013, Urban 2016).
1.3.2.3 Glutamyl intramembrane proteases
Fig. 1.8: Rce1 Glutamyl protease Rce1 consists of eight TM
α-helices and two peripheral α-helices (αA and αB). Four of
its TMDs (TMDs 1-3, 8) are on the outer side of the protein
structure, while the other four (TMDs 4-7) are in the inner part
of the structure. The conserved active site is formed by a catalytic
dyad comprising a glutamine (E) in TMD4 and a histidine (H) in
TMD5 (Manolaridis et al. 2013, Sun et al. 2016).
Glutamyl proteases are represented by the
Ras converting enzyme (Rce1) (Fig. 1.8).
Although the protein has been known since
1997 (Boyartchuk et al. 1997), it was not
until 2013 that its function and structure
were better understood (Manolaridis et al.
2013). Rce1 is found in both prokaryotic
and eukaryotic organisms and is able to cleave
CaaX-type prenyl proteins at their carboxy-
side. The substrates of Rce1 hold key positions in a variety of pathological situations varying
from cancer to infectious disease mortality, so efforts have been put lately to increase the
understanding of Rce1 and to control its activity (Hampton et al. 2018).
1.3.2.4 Aspartyl intramembrane proteases
The importance of all I-CLIPs goes beyond doubt, however, aspartyl intramembrane proteases
have known increasing popularity in research over the past two decades. In 1995, it was
discovered that presenilins, founding members of this family, play a crucial role in the
development of Alzheimer’s disease (AD) pathology (Levy-Lahad et al. 1995a, Levy-Lahad et
al. 1995b, Rogaev et al. 1995, Sherrington et al. 1995, Cruts et al. 1996), although their
function remained elusive until 1998 (De Strooper et al. 1998).
The presenilin family comprises the active site of the γ-secretase complex (Steiner et al.
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2000) and consists of two members in mammals, presenilin 1 (PS1) and presenilin 2 (PS2).
Sequence database analyses, as well as biochemical methods, revealed the existence of five
presenilin homologues that complete this class of proteases in mammals: signal peptide
peptidase (SPP) and signal peptide peptidase-like 2a (SPPL2a), 2b (SPPL2b), 2c (SPPL2c)
and 3 (SPPL3) (Grigorenko et al. 2002, Ponting et al. 2002, Weihofen et al. 2002). These
five proteases form the SPP/SPPL family of aspartyl proteases.
As the name “aspartyl” indicates, these I-CLIPs comprise two aspartic acids (D) at their
catalytic active site. All 7 members of this protease class consist of 9 TMDs and are also
referred to as GxGD proteases because one of the aspartic acids of the active site is always
located within a conserved GxGD motif in TMD 7. The second aspartate is located within a
conserved YD motif in TMD 6. Mutagenesis of either of the two aspartic acids is sufficient to
inactivate these proteases (Steiner et al. 1999, Wolfe et al. 1999, Weihofen et al. 2002,
Fluhrer et al. 2006, Friedmann et al. 2006, Kirkin et al. 2007, Voss et al. 2012, Voss et al.
2014a). Additionally, all aspartyl proteases feature a conserved PAL motif in TMD 9 (Fig.
1.9, 1.11-1.15) (Grigorenko et al. 2002, Ponting et al. 2002, Weihofen et al. 2002).
Mutations of any of the three amino acids comprising the PAL motif (proline, alanine, and
leucine) in presenilin and SPP affects their proteolytic ability suggesting this sequence is also
critical for the function of the proteases (Tomita et al. 2001, Wang et al. 2004b, Wang et al.
2006, Voss et al. 2013).
However, presenilins and SPP/SPPLs can be considered as two separate subfamilies since
despite their similarities they are also divided by some significant differences. The predicted
membrane topology of the 9 TMDs is inverted between the two groups, with PSs having the
N-termini in the cytosol and the C-termini in the lumen, while SPP/SPPLs have the
N-termini in the lumen and the C-termini in the cytosol (Friedmann et al. 2004a, Nyborg et
al. 2004). This means that their active sites are also inverted and can possibly account for
the distinction in the substrates of these GxGD proteases. Presenilins cleave exclusively type-I
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oriented TM proteins, releasing the N-terminus of the protein as soluble ectodomain in the
lumen/extracellular space and a C-terminal ICD. SPP/SPPLs cleave only type-II TM proteins
releasing a C-terminal peptide (C-peptide) in the lumen/extracellular space and an N-terminal
ICD (Fig. 1.4, 1.5) (Voss et al. 2013, Mentrup et al. 2017a). Finally, while presenilins need
the formation of the γ-secretase complex and favour endoproteolysis to be active, SPP/SPPLs
have most likely no such requirements (Weihofen et al. 2002, Edbauer et al. 2003).
1.3.2.4.1 Presenilins
Either of the two mammalian presenilins, PS1 and PS2, together with three more proteins can
form the γ-secretase heterotetrameric complex. Multi-pass membrane protein anterior pharynx
defective-1 (APH-1), single-pass glycoprotein nicastrin and double-pass membrane protein
presenilin enhancer-2 (PEN-2) were all found to associate with presenilins and are
indispensable for a functioning γ-secretase complex (Haass 2004, Wolfe 2013) (Fig. 1.9).
Following the assembly of the complex, presenilin is autocatalytically endoproteolysed in the
cytoplasmic loop between TMD 6 and 7. This leads to the formation of a NTF and a CTF,
each of which contains one of the two aspartic acids forming the active site (Wolfe et al.
1999, Fukumori et al. 2010). The two subunits of presenilin are closely interacting with each
other, forming a physically and catalytically stable complex as a heterodimer (Capell et al.
1998).
It took 10 years from their discovery (Levy-Lahad et al. 1995a, Levy-Lahad et al. 1995b,
Rogaev et al. 1995, Sherrington et al. 1995, Cruts et al. 1996) to clarify the topology of PS1.
We now consider this the “typical” 9-TMD topology of the GxGD proteases (Fig. 1.9)
(Laudon et al. 2005, Oh and Turner 2005). It took another 10 years to achieve an atomic
structure of human γ-secretase (Bai et al. 2015a, Bai et al. 2015b). The fact that all four
subunits of γ-secretase are needed for an active protease, points to distinct and important
roles for each subunit and these roles have been studied over the years (Kimberly et al. 2003,
Takasugi et al. 2003). PS provides the active centre of the protease with the two aspartic
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acids in TMD 6 and 7. Already in 1999, it was shown that mutating one of these aspartates
to alanines almost completely inhibits the proteolytic activity of the gamma secretase complex
(Steiner et al. 1999, Wolfe et al. 1999). PEN-2 is not only essential for the proteolytic
activity of the protease, but also for the endoproteolytic cleavage of PS and the stabilisation of
the deriving CTF and NTF (Capell et al. 1998, Prokop et al. 2004, Bai et al. 2015a). APH-1,
comprises seven TMDs and is believed to act as a connecting subunit, keeping nicastrin, PS
NTF and PS CTF together through the presence of a GxxxG motif (Lee et al. 2004b).
Nicastrin, finally, has only one TMD but is equipped with a very large and heavily glycosylated
ectodomain, which would enable it to act as the gatekeeper of the complex responsible for
selective recognition of substrates with a short ectodomain (Shah et al. 2005) (Fig. 1.9).
Fig. 1.9: γ-secretase complex. The complex consists of four proteins, PEN-2 (yellow), presenilin (green), APH-1 (orange) and
nicastrin (brown, NCT). Presenilin is autocatalytically endoproteolysed giving rise to two pieces, the NTF (dark green) and the
CTF (light green). The two catalytic aspartates (D) are located within the conserved motifs YD and GxGD in TMD 6 and 7. The
interactions between the different members of the complex suggest an arrangement on the membrane as depicted below. PEN-2
interacts with the PS NTF, while nicastrin interacts with Aph-1. The PS NTF can interact with the PS CTF, which also interacts
with Nicastrin/Aph-1 (Fukumori et al. 2010, Wolfe 2013). Lipid bilayer is depicted in red and grey.
The discovery of presenilins came through studying cases of early-onset familial Alzheimer’s
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disease (FAD) and detecting mutations in the genes PSEN1 and PSEN2, which code for PS1
and PS2, respectively (Levy-Lahad et al. 1995a, Levy-Lahad et al. 1995b, Rogaev et al. 1995,
Sherrington et al. 1995, Cruts et al. 1996). AD is a severe neurodegenerative disease and its
pathophysiology is characterized by a significant loss of both neurons and synapses in the
affected brain. Hallmarks of the disease’s pathogenesis are the deposition of amyloid-beta
(Aβ) plaques in the brain, which are aggregates of Aβ peptides, and the appearance of
neurofibrillary tangles of hyperphosphorylated tau (Huang and Mucke 2012). The generation
of Aβ peptides through proteolytic processing of the amyloid precursor protein (APP) is
considered the trigger that eventually leads to neuronal cell death through a cascade of
events. Presenilins were discovered to hold a key role in the processing of APP (Selkoe 1991,
Hardy and Higgins 1992, Hardy and Selkoe 2002, Haass 2004, Haass and Selkoe 2007,
Lichtenthaler et al. 2011).
APP was one of the first three proteins ever identified to undergo RIP, already in 1999 (Brown
et al. 2000), and although the physiological function of APP remains unknown, a lot of effort
has been devoted in understanding its processing (Fig. 1.10). As a type-I TM protein, APP
first undergoes shedding of the ectodomain generating soluble APP (sAPP) and a CTF. This
CTF is then cleaved inside the membrane by γ-secretase (Hardy and Selkoe 2002, Haass
2004, Haass and Selkoe 2007).
Despite the recognition of some additional enzymes, the first cleavage of APP is mainly
performed by two different sheddases, ADAM10 and BACE1 (Lichtenthaler et al. 2018). Each
of the two sheddases prefers a distinct cleavage site and this can already partially determine
the generation or not of toxic Aβ peptides (Lichtenthaler et al. 2011). When APP
ectodomain is shedded by an “α-secretase” (Esch et al. 1990), mainly ADAM10 (Kuhn et al.
2010), this is considered as “non-amyloidogenic processing”. It takes place closer to the
membrane and gives rise to longer soluble APPα (sAPPα) and the shorter CTFα (83 amino
acids). Processing of CTFα by γ-secretase does not release Aβ into the extracellular space
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but p3 (Lichtenthaler et al. 2011). p3 is a significantly smaller peptide, less hydrophobic and
less prone to aggregation compared to Aβ, so it practically lacks the disease-causing attributes
of the Aβ (Dulin et al. 2008). On the other hand, shedding of APP by BACE1, a
“β-secretase”, releases the shorter sAPPβ in the extracellular space and leaves the longer
CTFβ bound to the membrane. This 99-amino acid long CTF (C-99) is further processed by
γ-secretase giving rise to Αβ, making this the “amyloidogenic” processing of APP (Selkoe
1991, Hardy and Higgins 1992, Haass and Selkoe 2007, Wolfe 2013). In both scenarios there
is also the release of an APP-ICD (AICD) inside the cell, which gets rapidly degraded (Fig.
1.10) (Lichtenthaler et al. 2011). Despite the fact that AICD is suggested to have
transcriptional functions similarly to the Notch ICD, no solid evidence exist so far to confirm
this hypothesis (Schettini et al. 2010, Bukhari et al. 2017).
Fig. 1.10: Processing of APP. There are two possible processing pathways. Depicted on the left is the non-amyloidogenic processing
that cannot lead to an amyloid pathology, on the right, the amyloidogenic processing that produces Aβ. In the cases of Alzheimer’s
disease (AD) Aβ aggregates and forms plaques. The first cleavage can be performed by either an “α-secretase” or a “β-secretase”
and this determines the processing pathway. The second cleavage takes place intramembranously and is performed by γ-secretase.
A key point in the “amyloidogenic processing” is the sequential cleavage of C-99 by
γ-secretase that can give rise to Aβ peptides of different lengths, mostly varying between 37
and 43 amino acids. While the shorter Aβ species are less prone to aggregation and less toxic
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for the organism, the longer, more hydrophobic species (Aβ42, 43) tend to aggregate and are
considered the most neurotoxic (Haass and Selkoe 2007, Holtzman et al. 2011, Lichtenthaler
et al. 2011, Saito et al. 2011). Mutations causing FAD can be found predominantly in the
PSEN1 gene, but also in the PSEN2 and APP genes (Levy-Lahad et al. 1995a, Levy-Lahad
et al. 1995b, Rogaev et al. 1995, Sherrington et al. 1995, Cruts et al. 1996). The mutations
in the proteases show an increased production of Aβ42 and Αβ43 without necessarily
increasing the total amount of Aβ (Scheuner et al. 1996, Kretner et al. 2016). These findings
demonstrate that differential processing of C-99 by γ-secretase can either prevent or cause the
disease. This makes γ-secretase a very attractive pharmaceutical target for treatment and
prevention of AD by modulation or inhibition of its function. Unfortunately though, none of
the so-far tested treatments can specifically target the processing of APP by γ-secretase
without affecting the processing of the other γ-secretase substrates.
To date, an increasing number of physiological γ-secretase substrates have emerged, such as
N-cadherins, CD44, low density lipoprotein receptor, Nectin-1 and others (Hemming et al.
2008, Haapasalo and Kovacs 2011, Wolfe 2013, Muller et al. 2016). However, the most
prominent of these γ-secretase substrates, responsible for the great majority of adverse effects
observed upon γ-secretase-targeted treatment are the Notch receptors. The Notch signalling
pathway is involved in cell-to-cell communication and plays a crucial role in cell-fate and
differentiation both during development and in the adult organism (reviewed in (Bray 2016)).
Notch was found to undergo RIP at the same time as APP (Brown et al. 2000) and further
research has shown how important the fine-tuning of this process is. Lack of functional
γ-secretase in mice can recapitulate the severe developmental effects observed in transgenic
Notch-deficient mice (Wong et al. 1997, Li et al. 2003, Serneels et al. 2005, Bammens et al.
2011). Another example of Notch’s importance is the case of Semagacestat, a γ-secretase
inhibitor that aimed to reduce Αβ production and made it to phase-III clinical trials but had to
be terminated due to effects of chronic Notch inhibition leading to increased incidents of skin
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cancer (De Strooper 2014).
1.3.2.4.2 Signal Peptide Peptidase
SPP was initially discovered and named due to its ability to remove the signal peptides that
remain embedded in the ER membrane after their separation from the protein they are guiding
by Signal Peptidase (SP) (Weihofen et al. 2000). The removal of the signal peptides falls
into the category of RIP as the substrates are first cleaved by SP and then the intramembrane
cleavage occurs (Fig. 1.11A).
Fig. 1.11: SPP and SPP-mediated signal peptide cleavage. A. SP performs the first cleavage (1) removing the signal peptide
(light blue) of nascent secretory proteins (dark blue) synthesised at the ER translocon. The liberated signal peptides are then
endoproteolysed within their transmembrane domain by SPP (2). B. SPP shares the nine TMD topology characteristic of GxGD
proteases, the two aspartic acids YD and GLGD and the conserved PAL motif. It also has two presumed N-glycosylation sites at
its N-terminus and an ER retention signal at the C-terminus.
In 2002, SPP was identified as a “presenilin-type aspartic protease” and since then it is known
to belong to the family of the GxGD-aspartyl proteases (Weihofen et al. 2002). In concordance
with the rest of the family members, SPP has nine TMDs and two aspartic acids at its active
centre. Additionally, it is glycosylated and it has an ER-retention signal at its C-terminus
(Weihofen et al. 2002) (Fig. 1.11B). Due to its expression pattern, it was assumed since early
on that it holds a key role in the development of metazoan and especially their nervous system
(Urny et al. 2003). Moving from drosophila to zebrafish to mice, the deficiency of SPP always
causes a severe phenotype including neuronal cell death and embryonic/larval lethality (Casso
et al. 2005, Krawitz et al. 2005, Voss et al. 2013, Aizawa et al. 2016, Mentrup et al. 2017a).
A variety of signal peptides from a number of proteins fall within the preferences of SPP.
Prolactin signal peptide cleavage was one of the first followed in detail (Martoglio et al. 1997)
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and was later attributed to SPP (Weihofen et al. 2000, Weihofen et al. 2002). In some cases,
the cleavage of these peptides aims solely in facilitating their removal from the ER membrane
and proteosomal degradation (Kilic et al. 2010), while in other cases it serves the removal
of potentially toxic peptides from the cell (Wu and Chang 2004). SPP can also be involved
in immunosurveillance by generating peptides for the major histocompatibility complex (MHC)
class I either in collaboration with signal peptidase from MHC class I-signal peptides (Lemberg
et al. 2001) and from non-MHC-signal peptides (El Hage et al. 2008), or independently of
signal peptidase, directly from multipass TM proteins (Oliveira et al. 2013).
Despite what the name signal peptide peptidase suggests, SPP is also capable of cleaving a
variety of non-signal peptides. Through a proteomic approach, certain C-terminally tail anchored
type-II oriented (type-IV) TM proteins (Fig. 1.4) were identified as SPP substrates. As these
substrates have either an extremely short or practically no extracellular domain, the cleavage
by SPP does not require initial shedding and these substrates do not undergo RIP but direct
intramembrane cleavage. Among the substrates identified were cytochrome B5A (CYB5A),
ribosome-associated membrane protein 4 (RAMP4) and heme-oxygenase-1 (HO-1) (Boname
et al. 2014). SPP-dependent HO-1 cleavage proved of crucial importance for the nuclear
translocation of HO-1, which in turn increases the tumorigenicity of HeLa cells via boosting
their proliferatory and migratory abilities, proving that SPP can indeed have a regulatory role
(Hsu et al. 2015, Mentrup et al. 2017a).
SPP was also found capable of cleaving the X-box binding protein 1 (XBP1u). What makes
this discovery interesting is that in contrast to the cleavage of signal peptides, shedding of
the 59 amino acid long ectodomain is not required in this case prior to the intramembrane
cleavage. Although a 59 amino acid-long ectodomain might be considered short enough to
allow direct intramembrane cleavage, as seen for γ-secretase (Struhl and Adachi 2000) and
SPPL2b (Martin et al. 2009), there is also another possibility. The interaction of SPP with
Derlin-1, a catalytically inactive homologue of the rhomboids, observed under certain conditions
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could play a role in the recognition of XBP1u’s ectodomain (Chen et al. 2014). This study by
Chen et al, clearly indicates that SPP is involved in the ERAD, since cleavage of XBP1u by
SPP initiates its ERAD and also releases its splice variant, XBP1s, from their heterodimer to
induce the unfolded protein response (UPR) (Chen et al. 2014, Mentrup et al. 2017b). This
procedure is not limited to metazoan as the SPP-yeast orthologue Ypf1 has also been linked to
ERAD by a novel regulatory pathway (Avci et al. 2014).
1.3.2.4.3 Signal Peptide Peptidase-Like 2 subfamily
The SPPL2 subfamily is less conserved throughout evolution than SPP or SPPL3 (Voss et al.
2013). Drosophilas appear to completely lack SPPL2s, since they have only two members of
the SPP/SPPL family that resemble mostly SPP (Casso et al. 2005) and SPPL3 (Casso et
al. 2012). The SPPL2 subfamily consists of only one member in zebrafish (Krawitz et al.
2005), and just in mammals 3 different family members exist, SPPL2a, SPPL2b and SPPL2c
(Grigorenko et al. 2002, Ponting et al. 2002, Weihofen et al. 2002, Voss et al. 2013). All three
members possess an N-terminal signal sequence and a long glycosylated N-terminal extracellular
domain, in addition to the nine TMDs (Friedmann et al. 2004a). The level of understanding of
these proteases decreases from SPPL2a, where some in vivo functions are known, to SPPL2b,
where the cleavage mechanism has been investigated in vitro, to lastly SPPL2c, which so far is
not a proved active protease.
Fig. 1.12: Signal Peptide Peptidase-Like 2c. SPPL2c shares
the same membrane topology and active site as the other
SPP/SPPLs, the two aspartic acids YD and GFGD and
the conserved PAL motif. It also has one presumed N-
glycosylation site at its N-terminus.
Although the SPPL2C gene can potentially give
rise to a proteolytically active protease (Fig.
1.12) (Friedmann et al. 2004a), SPPL2c remains
an orphan protease with no substrates assigned
to it so far. SPPL2C ’s polymorphism through
evolution together with its intronless structure
has made it a candidate pseudoprotease (Golde et
al. 2009). To this point, all knowledge regarding
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the SPPL2 subfamily derives from the other two proteases, SPPL2a and SPPL2b (Fig. 1.13A,
B) (Voss et al. 2013, Mentrup et al. 2017a).
A number of “canonical” RIP substrates have been identified in vitro for SPPL2a and SPPL2b,
such as tumour necrosis factor α (TNFα) (Fluhrer et al. 2006, Friedmann et al. 2006), Fas
ligand (FasL) (Kirkin et al. 2007), integral membrane protein 2B (ITM2B) (Martin et al.
2008) and cluster of differentiation 74 (CD74) (Beisner et al. 2013, Bergmann et al. 2013,
Schneppenheim et al. 2013). All of these substrates first undergo shedding of their ectodomain
by ADAM 10 or 17, or by lysosomal proteases and then cleavage within the TMD by SPPL2a
or SPPL2b (Mentrup et al. 2017a). Apart from the type-II TM proteins mentioned above, also
proteins with two TMDs can be cleaved by SPPL2a/b after opening of the loop by a different
protease, such is the case for the foamy virus envelope protein (FVenv) (Voss et al. 2012) and
for neuregulin 1 type III (NRG1 type III) (Fleck et al. 2016).
Fig. 1.13: Signal Peptide Peptidase-Like 2a and 2b. A. SPPL2a has the typical GxGD characteristics with 9 TMDs, two aspartic
acids within a YD and GFGD motif, and the conserved PAL motif. It also has numerous N-glycosylation sites at its N-terminus
and a lysosomal sorting signal at its C-terminus. B. As the other members of the SPP/SPPLs, SPPL2b has two aspartic acids
embedded in a YD and GFGD motif, and the conserved PAL motif. It also has N-glycosylation sites at its N-terminus and in the
loop between TMD 6 and 7.
The purpose of the SPPL2a/b cleavage can differ from “simple” removal of the leftover
membrane fragment, to induction of signalling either by the release of the ICD or the secretion
of the extracellular peptide. In the case of the in vivo cleavage of CD74, it appears that
both purposes are served (Beisner et al. 2013, Bergmann et al. 2013, Schneppenheim et al.
2013, Schneppenheim et al. 2014a, Mentrup et al. 2015). The CD74 ICD is assumed to
have functions within the nucleus where it translocates after its liberation by SPPL2a (Mentrup
et al. 2015). Additionally, SPPL2a deficiency leads to an accumulation of CD74 NTF in B-
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lymphocytes of SPPL2a-/- mice (Beisner et al. 2013, Bergmann et al. 2013, Schneppenheim et
al. 2013). This accumulation not only disturbs intracellular trafficking (Schneppenheim et al.
2013), but it also increases the expression of pro-apoptotic genes via the PI3K/Akt signalling
(Huttl et al. 2015). The splenic B cell maturation is halted under these conditions but it can
improve with additional CD74 deficiency (Beisner et al. 2013, Schneppenheim et al. 2013)
demonstrating the importance of the removal of the CD74 NTF.
Some of the substrates discovered in vitro, like TNFα (Fluhrer et al. 2006, Friedmann et al.
2006), ITM2B (Martin et al. 2008) and NRG1 type III (Fleck et al. 2016) are cleaved by
both proteases, however, there are also some protease-specific substrates. For instance, FasL
is cleaved only by SPPL2a, while the transferrin receptor 1 (TfR1) is only cleaved by SPPL2b
(Zahn et al. 2013). Interestingly, only cleavage by SPPL2a has been confirmed in vivo , while
the physiological function of SPPL2b remains elusive (Mentrup et al. 2017a). Functionally, the
cleavage of CD74 by SPPL2a in vivo is the only well-understood process and it seems conserved
in both mice and humans (Beisner et al. 2013, Bergmann et al. 2013, Schneppenheim et al.
2013, Schneppenheim et al. 2014a). However, evidence supports non-redundant functions for
the two proteases. First, the proteases localise differentially within the cell with SPPL2a being
predominantly found in the lysosomes and late endosomes, while SPPL2b localises mainly
to the cell membrane (Friedmann et al. 2006, Behnke et al. 2011). Second, there is a
differential expression in tissues in vivo, while SPPL2a is ubiquitously expressed; SPPL2b is
predominantly expressed in the central nervous system (CNS), bone marrow and the lymphoid
glands (Schneppenheim et al. 2014b). In vivo data regarding the function of SPPL2b would
be needed to clarify further the point of non-redundancy.
1.3.2.4.4 Signal Peptide Peptidase-Like 3
Even though SPPL3 was initially believed to be a redundant protease with functions similar
to SPP (Krawitz et al. 2005, Nyborg et al. 2006), today we know that this is not the case
and a number of SPPL3 substrates have been reported ((Voss et al. 2012, Voss et al. 2014a,
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Fig. 1.14: Signal Peptide Peptidase-Like 3. SPPL3 is the smallest
member of the family and it does not have any glycosylation sites. It has
the two aspartic acids in TMD 6 and 7, YD and GIGD, and the conserved
PAL motif in TMD 9.
Kuhn et al. 2015), reviewed in (Mentrup
et al. 2017a)). SPPL3 is the smallest
member of the SPP/SPPLs, it lacks the
N-terminal signal peptide and is the only
non-glycosylated member of this family
(Fig. 1.14) (Friedmann et al. 2004a).
It possesses the nine TMD topology
characteristic of all GxGD proteases
(Friedmann et al. 2004a) and its proteolytic activity was finally proven in 2012, when Voss
et al. showed in a cell culture model system that the FVenv is a substrate of proteolytically
active SPPL3 (Voss et al. 2012).
Together with the identification of the first substrate, two very interesting characteristics of
SPPL3 became apparent. First, SPPL3 activity cannot be inhibited by typical GxGD protease
inhibitors, such as DAPT or 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)-amino acetone ((Z-
LL)2-ketone). Second, no ectodomain shedding of the substrate was required prior to SPPL3
cleavage, since SPPL3 was capable of processing full length FVenv, a hairpin type-III TM
protein, at the C-terminal of the first TMD, which adopts a type-II orientation (Voss et al.
2012). The function of SPPL3 as a “type-II sheddase” was confirmed by two more studies
demonstrating that SPPL3 can cleave numerous full-length substrates at a close proximity to
the border between the TM and the extracellular domain (Voss et al. 2014a, Kuhn et al. 2015).
In contrast to SPP, that was shown to have sheddase abilities only under specific circumstances
(Chen et al. 2014), SPPL3 exclusively acts as a sheddase.
In compliance with the high conservation of SPPL3 through evolution suggesting an important
physiological function for this aspartyl protease, Voss et al. showed in 2014 that SPPL3
is capable of regulating cellular N-glycosylation through shedding and secretion of glycan
modifying enzymes (Voss et al. 2014a). A year later, these results were reinforced with
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the use of a new proteomic method named SPECS, for secretome protein enrichment with
click sugars. Using this technique, the secretome of cells overexpressing or lacking SPPL3 was
compared to that of control cells in regards to the amount of secreted ectodomains of membrane
proteins. All type-II TM proteins the ectodomains of which were significantly increased in SPPL3
overexpression and/or decreased in absence of SPPL3 were considered as potential substrates.
Most of the confirmed substrates are involved in the complex N- and O-glycosylation and the
glycosaminoglycan biosynthesis (Kuhn et al. 2015).
SPPL3 can cleave the ectodomain of Golgi-resident glycosidases and glycosyltransferases, such
as GnTV and EXTL3, leading to the secretion of their active-site containing domain in a soluble
form. Processing of these enzymes by SPPL3 leads to a decrease of their intracellular levels.
Secreted glycosidases and glycosyltransferases are considered deactivated due to their reliance
on sugar donors in order to function, these donors are known to be present within the ER and the
Golgi but not in the extracellular space (Paulson and Colley 1989, Freeze and Elbein 2009, Varki
et al. 2009). Thus, increased amount of SPPL3 causes a reduction in glycosyltransferases and
a hypoglycosylation phenotype, while decreased presence of SPPL3 leads to an accumulation of
glycosyltransferases and a hyperglycosylation phenotype (Fig. 1.15) (Voss et al. 2014a, Kuhn
et al. 2015, Mentrup et al. 2017a). A large number of glycoproteins can be affected by changes
in the SPPL3 expression and these results have been confirmed in vivo (Voss et al. 2014a).
Despite the crucial role of SPPL3 in cellular glycosylation, SPPL3-/- mice are viable; however,
this is true only on a mixed background of C57Bl6/129S5. The mice are characterised by
mild growth-related phenotypic anomalies and reduced reproduction (Tang et al. 2010). As
SPPL3 is ubiquitously expressed, a hyperglycosylation phenotype is observed on glycoproteins
from all analysed organs (Voss et al. 2014a). Various other studies have also touched on
other phenotypic characteristics of the SPPL3 knockout mice, apart from the reproduction
difficulties. From the initial generation of this mouse line, a phenotype of reduced natural
killer (NK) cells was observed by Tang et al. and was later confirmed in the doctoral thesis of
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Fig. 1.15: Physiological function of SPPL3. SPPL3 (red) is located in the Golgi where glycosidases and glycosyltransferases
(green) undergo maturation while moving from the cis- to the trans-Golgi. The mature glycosylation enzymes add glycans on
glycoproteins (purple) in the trans-Golgi. SPPL3 can shed and remove the active site of these enzymes, which then is secreted in
the extracellular space. The physiological balance can be disturbed both by high and low levels of SPP3 leading either to reduction
of enzymes and hypoglycosylation or accumulation of enzymes and hyperglycosylation, respectively. The differences in glycosylation
are depicted through the complexity of the glycan branches. Adapted from (Voss et al. 2014a)
Matthias Voss (Tang et al. 2010, Voss et al. 2014b). More effort has been placed recently
in the underlying mechanism of this reduction and a targeted SPPL3-knockdown mouse model
was used. SPPL3 deficiency in the hematopoietic system causes a cell autonomous decrease in
maturation efficiency of NK cells and a decrease in clearance of MHC class I-deficient tumours
(Hamblet et al. 2016). Although this phenotype appears to be dependent on the proteolytic
ability of SPPL3, since it cannot be rescued by proteolytically inactive SPPL3, the substrates
responsible for this effect remain elusive (Hamblet et al. 2016). As NK cells are linked to the
growth of tumours, SPPL3 might indeed play a role in tumorigenicity as some single nucleotide
polymorphisms (SNPs) in the coding region of SPPL3 have recently been linked to breast
cancer as a risk factor (Noh et al. 2015).
Despite the increased insight into the substrate spectrum of SPPL3 and the initial understanding
of its in vivo function, many gaps remain regarding both the regulation of SPPL3 expression
and the mechanism of substrate recognition and cleavage.
1.3.3 Substrate Requirements
One question that arose early on within the context of intramembrane cleavage and still
lingers is how these proteases recognise and cleave their substrates. The active sites of
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proteases are known to almost exclusively bind to β-strand conformations, however all I-CLIP
substrates consist of transmembrane α-helices. Based on this knowledge, intrinsic instability
of the substrate’s α-helix surrounding the cleavage site is believed to be a key feature for the
determination of a substrate (Tyndall et al. 2005, Madala et al. 2010).
Different proteases have more or less strict substrate requirements. Rhomboids (1.3.2.2) have
some of the most specific requirements from their substrates. In 2007, it was discovered that
helical instability is not the only common feature shared by rhomboid substrates (Akiyama
and Maegawa 2007). Comparing cleavage sites and other key characteristics of a physiological
bacterial substrate revealed the requirement for both a hydrophobic TMD and a six-amino
acid long linear sequence, termed “recognition motif”. P1, N-terminally of the cleavage site,
commonly requires a small amino acid, while P4 and P2’, N- and C-terminally of the cleavage
site, respectively, often require large hydrophobic amino acids (Strisovsky et al. 2009,
Strisovsky 2017). Structural visualisation of protease-inhibitor complexes have allowed for a
better understanding of the various interactions (Zoll et al. 2014, Cho et al. 2016). However,
not all rhomboids share the exact same “recognition motif”, and some of them have
additional requirements (Strisovsky 2017). This would explain the differences in the substrate
spectra (Strisovsky 2016). Despite the existence of a “recognition motif”, there is still some
flexibility in their selection of rhomboid substrates, as non-substrates can also be cleaved upon
chemical alteration of the membrane composition or destabilisation of the α-helix of the TMD
through mutagenesis (Moin and Urban 2012, Urban and Moin 2014).
Regarding the substrate requirements of SPP, it appears that relatively short but not
necessarily shedded ectodomains can be recognised and cleaved by SPP, as seen for XBP1u
(Avci et al. 2014). Interestingly however, the importance of α-helix destabilising amino acids
within the TMD and in close proximity to the cleavage site was demonstrated when the
C-peptide release of the ceramide synthase Trh4 was studied (Oliveira et al. 2013). These
data are in accordance with similar observations regarding SPPL2b (Martin et al. 2008,
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Martin et al. 2009).
As with SPP (Oliveira et al. 2013), substrate analysis by introduction of mutations in the
TMD of Bri2 for SPPL2b (Martin et al. 2009, Fluhrer et al. 2012) or CD74 for SPPL2a
(Huttl et al. 2016) revealed that even though none of the substrate’s TM regions is absolutely
crucial for the cleavage, removal of α-helix breaking sequences from within the TMD reduces
cleavage efficiency (Mentrup et al. 2017a).
2. Aims of Study
The main goal of this study is to deepen our understanding of SPPL3 and SPPL2c in particular,
and of the GxGD-type aspartyl protease family in general.
As the first physiological substrates of SPPL3 have already been identified and validated in
previous studies (Voss et al. 2014a, Kuhn et al. 2015), the first aim is to analyse the substrate
requirements of SPPL3 by mutating amino acids in key positions of selected substrates.
The second focus of this study is the physiological role of SPPL3 in vivo. To this end, a
SPPL3-deficient mouse line (Tang et al. 2010) will be analysed for phenotypical anomalies.
Furthermore, the potential mechanism underlying these characteristics will be studied.
The last part of this study is devoted on the last orphan protease of this family, SPPL2c.
Using a cell culture and a murine model it will be investigated whether SPPL2c is indeed a
pseudoprotease as believed or whether it actually has a catalytic ability. If SPPL2c is indeed
an active protease with physiological substrates, efforts will concentrate on identifying the
physiological function of this protease.
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3. Materials and Methods
3.1 Materials
3.1.1 Instruments, consumables and reagents
Centrifuges Heraeus Pico, Heraeus Frisco 17, 21, Megafuge 40R, Biological Safety Cabinet
Safe2020 and cell culture incubator Heraeus from Thermo Fisher (Waltham, USA).
ThermomixerC and Research plus pipettes from Eppendorf (Hamburg, DE). Accu-jet pro
pipette boy from Brand (Wertheim, DE). SDS Gel electrophoresis and western blotting
equipment by Biorad (California, USA). Agarose electrophoresis from Peq Lab (Erlangen, DE).
1.5, 2, 15ml, 50 ml reaction tubes, 2, 5, 10, 25 ml pipettes, and pipette tips from Starstedt
(Nuembrecht, DE). PCR Mastercycler by Eppendorf and 7500 Fast Real-Time PCR System by
Applied Biosystems (California, USA). Special instruments, consumables and reagents will be
mentioned when applicable.
Table 3.1: List of chemical reagents
Chemical Company
1kb Plus DNA Ladder Invitrogen
Acetic Acid Merck
Acrylamide/Bis 40% 29:1 BioRad
Acrylamide/Bis 40% 37.5:1 Invitrogen
Agarose Invitrogen
APS (10%) Merck
Brilliant Blue R Sigma
Bromphenolblue Fluka
BSA Uptima
CaCl2 Merck
DDM Calbiochem
DMSO Roth
dNTP Roche
DTT Biomol
EDTA Merck
EGTA Serva
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Chemical Company
EtOH Merck
GelRed Biotium
Glucose Merck
Glycerine Merck
Glycine Biomol
Hepes Biomol
Tropix R© I-Block Applied Biosystems
Isopropanol Merck
KCH3COO Sigma
KCl Merck
KH2PO4 ·H2O Merck
Mg(CH3COO)2 Fluka
Na2HPO4·2H2O Merck
NaCl Roth
NaHCO3 Merck
NaOH Merck
Orange G Sigma
PierceTM ECL Western Blotting Substrate & Plus Thermo Fisher
PI-Mix Sigma
SDS Serva
See Blue Plus 2 Standard Invitrogen
Sucrose Sigma
TEMED Roth
Tris Biomol
Triton X100 Merck
Tween20 Merck
Westar Supernova Cyanagen
β-mercaptoethanol Sigma
3.1.2 Plasmids
pcDNA3.1 Hygro(+) was purchased from Invitrogen, as well as pcDNA4/TO/myc-his A used
for SPPL3 WT and D/A. pcDNA4/TO A used for the SPPL2c constructs was purchased from
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Thermo Fisher. The pCMV-Cas9-GFP plasmids were purchased from Sigma Aldrich (St. Louis,
USA).
3.1.3 cDNA constructs
The coding sequence of human SPPL3 (isoform 2), SPPL3 D271A, human SPPL2C (isoform
A) and SPPL2C D448A in the original plasmid were kindly provided by Bruno Martoglio.
These sequences were later C-terminally HA-tagged (AYPYDVPDYA) and cloned into
pcDNA4/TO in the laboratory of Regina Fluhrer. The human GnTV coding sequence (gene
name MGAT5) (OCABo5050G0617D/100061790) and the human EXTL3 (IMAGE ID
4131101/IRAu33 E12 (M13F)) were obtained from Source BioScience (Nottingham, UK). An
N-terminal Flag (DYKDDDDK) epitope tag after the initiating methionine residue and a
C-terminal in-frame V5 (GKPIPNPLLGLDST) epitope tag (Flag-GnTV-V5) were added to
both cDNAs.
3.1.4 Cell lines
Table 3.2: cDNA constructs established in this study for stable and transient transfections. The name of each construct includes
the plasmid used, the tags, the cDNA and the restriction enzymes used for subcloning.
cDNA Constructs
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVWT-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG22A-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG26A-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG22,26A-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG22L-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG26L-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG22,26L-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG22P-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG26P-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVG22,26P-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVM27A-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVM28A-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVL29A-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVL30A-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVH31A-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVF32A-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVMM27AA-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVLH30AA-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVH31L-V5-XhoI pcDNA3.1Hygro(+)-KpnI-Flag-GnTVH31R-V5-XhoI
pcDNA3.1Hygro(+)-KpnI-Flag-GnTVH31D-V5-XhoI pcDNA3.1Hygro(+)-HindIII-Flag-EXTL3WT-V5-XhoI
pcDNA3.1Hygro(+)-HindIII-Flag-EXTL3H48A-V5-XhoI pcDNA3.1Hygro(+)-HindIII-Flag-EXTL3H48L-V5-XhoI
pcDNA3.1Hygro(+)-HindIII-Flag-EXTL3H48R-V5-XhoI pcDNA3.1Hygro(+)-HindIII-Flag-EXTL3H48D-V5-XhoI
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All cell lines used are included in the table below with their name, genetic alterations, specific
antibiotic resistances and the source that provided them.
Table 3.3: Cell lines used in this study. Genetic alterations include stably transfected plasmids or genetic modifications with the
CRISPR/Cas9 system. Antibiotic resistance required for culturing the cells and source are also mentioned in the table.
Cell line name Genetic alteration Antibiotic Resistance Source
T-RexTM-293 (TR) pcDNATM6/TR Blasticidin
Invitrogen
Cat. No. R710-07
TR-GnTV WT
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV AG
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-G22A-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV GA
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-G26A-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV AA
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-G22A,G26A-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV M27A
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-M27A-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV L30A
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-L30A-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV H31A
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-H31A-V5
Blasticidin
Hygromycin
Current Study
TR-GnTV F32A
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-GnTV-F32A-V5
Blasticidin
Hygromycin
Current Study
TR-EXTL3 WT
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-EXTL3-V5
Blasticidin
Hygromycin
Current Study
TR-EXTL3 H48A
pcDNATM6/TR
pcDNA3.1Hygro(+)-Flag-EXTL3-H48A-V5
Blasticidin
Hygromycin
Current Study
TR SPPL2c WT
pcDNATM6/TR
pcDNA4/TO-SPPL2cWT-HA
Blasticidin
Zeocin
Martina
Haug-Kröper
TR SPPL2c D/A
pcDNATM6/TR
pcDNA4/TO-SPPL2cD448A-HA
Blasticidin
Zeocin
Martina
Haug-Kröper
TR SPPL2c WT
GnTV WT
pcDNATM6/TR
pcDNA4/TO-SPPL2cWT-HA
pcDNA3.1Hygro(+)-Flag-GnTV-V5
Blasticidin
Zeocin
Hygromycin
Current Study
TR SPPL2c D/A
GnTV WT
pcDNATM6/TR
pcDNA4/TO-SPPL2cD448A-HA
pcDNA3.1Hygro(+)-Flag-GnTV-V5
Blasticidin
Zeocin
Hygromycin
Current Study
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Cell line name Genetic alteration Antibiotic Resistance Source
TR SPPL3 WT
pcDNATM6/TR
pcDNA4/TO-SPPL3WT-HA
Blasticidin
Zeocin
Voss et al, 2012
LMU Munich
TR SPPL3 D/A
pcDNATM6/TR
pcDNA4/TO-SPPL3D271A-HA
Blasticidin
Zeocin
Voss et al, 2012
LMU Munich
TR SPPL3 KO
clone 11
pCMV-Cas9-GFP gRNA2 hSPPL3 Blasticidin Current Study
TR SPPL3 WT
GnTV WT
pcDNATM6/TR
pcDNA4/TO-SPPL3WT-HA
pcDNA3.1Hygro(+)-Flag-GnTV-V5
Blasticidin
Zeocin
Hygromycin
Current Study
E14TG2a
(ES WT)
—– —– ATCC
CRL 2255
E14TG2a clone 27
(ES 27)
pCMV-Cas9-GFP gRNA1 mSppl3 —– Current Study
E14TG2a clone 38
(ES 38)
pCMV-Cas9-GFP gRNA2 mSppl3 —– Current Study
E14TG2a clone 40
(ES 40)
pCMV-Cas9-GFP gRNA2 mSppl3 —– Current Study
3.1.5 Mouse lines
B6;129S5-Sppl3Gt(OST279815)Lex/Mmucd mice have been generated by Lexicon
Pharmaceuticals (The Woodlands, USA) and Genentech (San Francisco, USA) and are made
available for research purposes. They were obtained through the Mutant Mouse Regional
Resource Centre (MMRRC) at the University of California at Davis (USA). The 129S6/SvEv
mice used for the back crossing were purchased from Taconic (Ejby, DK). The mice were
crossed back for 10 generations. The SPPL2c transgenic mice, as well as their wild-type
littermates, were kindly provided Dr. Bernd Schröder and are described in detail in Niemeyer
et al. 2019.
3.1.6 Antibodies
All primary and secondary antibodies used for Western Blotting were diluted in 1 x PBS
supplemented with 2% (w/v) Tropix I-BlockTM and 0.5% (v/v) Tween 20. All primary and
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secondary antibodies used for immunofluorescence (IF) were diluted in 1 x PBS supplemented
with 5% BSA.
Table 3.4: Primary antibodies used in this study. The table contains the antigen (h=human, m=mouse). The host indicates
the species of origin and the specific type of the antibody is mentioned (mAb=monoclonal antibody, pAb=polyclonal antibody).
Commercial and scientific sources are mentioned, as well as clone when available. Each method the antibody was used is indicated,
WB = Western Blot, IH = Immunohistochemistry, IF = Immunofluorescence, as well as the dilution used for each method.
DSHB=Developmental Studies Hybridoma Bank
Antigen host & type Source Clone Method Dilution
B4GALT1 mouse, mIgG2b R&D Systems MAB 3609 WB 1:1000
Cab-45 rabbit, pAb Dr. von Blume —
IH
IF
1:500
1:300
Calnexin rabbit, pAb Enzo —
WB
IF
1:3000
1:100
EXTL3 mouse, mAb Santa Cruz G-5 WB 1:500
Giantin mouse, mIgG1 Enzo ALX-804-600 IF 1:1000
GM130 rabbit mAb Abcam EP892Y IF 1:50
GnT-V mouse, mIgG2A R&D Systems 706824 WB 1:1000
Membrin mouse, mIgG1 Thermo Fisher 4HAD6 WB 1:500
GRP78 BiP rabbit, pAb Abcam — IF 1:1000
hLamp2 mouse, mAb DSHB H4B4 WB 1:500
hSPPL2a mouse, mAb Dr. Feederle 6E9 WB 1:20
hSPPL2c mouse, IgG2a/k Dr. Feederle 1A1 WB 1:10
mSPPL2c rabbit, pAb Dr. Schröder — WB 1:500
Nicastrin rabbit, pAb Sigma-Aldrich N1660 WB 1:10000
OGFOD3 goat, pAb Santa Cruz F-19 WB 1:200
SPP rat, mAb Dr. Feederle 5H7 WB 1:10
SPPL3 mouse, mAb Dr. Feederle 7F9 WB 1:10
Syntaxin 18 mouse, mIgG2b Santa Cruz 10 WB 1:200
Syntaxin 5 mouse, mIgG1 Santa Cruz B-8
WB
IF
1:1000
1:50
Syntaxin 6 rabbit, mAb Cell Signaling C34B2 WB 1:2000
Syntaxin 8 mouse, mIgG1 Santa Cruz A-9 WB 1:100
TGN46 sheep, pAb Acris AP32693PU IF 1:300
3.1 Materials 41
Antigen host & type Source Clone Method Dilution
TMEM 192 rabbit, pAb Dr. Schröder — WB 1:1000
V5 tag (mono) mouse, mIgG2A Life Technologies R960-25
WB
IF
1:2000
1:400
V5 tag (poly) rabbit, pAb Millipore AB3792
WB
IF
1:5000
1:500
VAMP8 rabbit, mAb Abcam — WB 1:10000
VAPA rabbit, mAb Abcam — WB 1:10000
VAPB rabbit, pAb Abcam — WB 1:500
β-actin mouse, IgG2a Sigma A5316 WB 1:2000
Table 3.5: Secondary antibodies used in this study.The table contains the target organism as well as the host where the
antibody was raised. Coupling indicates the detection mechanism, HRP = Horseradish peroxidase-conjugated, Alexa = Fluorescent
dye. Commercial sources are mentioned, as well as the method the antibody was used is indicated, WB = Western Blot, IF =
Immunofluorescence, and the dilution used for each method.
Target organism Host Coupling Source Method Dilution
mouse goat Alexa 555 Thermo Fisher IF 1:400
rabbit goat Alexa 488 Thermo Fisher IF 1:400
mouse donkey Alexa 555 Thermo Fisher IF 1:400
sheep donkey Alexa 568 Thermo Fisher IF 1:400
mouse goat HRP Promega WB 1:10.000-15.000
rat goat HRP Millipore WB 1:10.000
rabbit goat HRP Promega WB 1:20.000
goat donkey HRP Santa Cruz WB 1:10.000
3.1.7 Small-interfering RNAs
Small interfering RNAs were used for transient knockdown of protein expression in T-RexTM-
293 cells. All siRNAs were purchased from Dharmacon (Lafayette, USA) and are from the
siGENOME SMARTpool siRNA line. They were all applied at a final concentration of 20
nM using LipofectamineTM RNAiMAX according to the manufacturer’s instructions (Thermo
Fisher, Waltham, USA). siRNAs were diluted in 4 parts RNA-free water (Qiagen) and one part
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5xRNA buffer (GE Healthcare, Illinois, US).
Table 3.6: Small interfering RNAs.The table contains the target protein and the catalogue number of each siRNA used in this
study.
Name Catalogue number
siGENOME Non-Targeting siRNA Pool 1 D-001206-13
SMARTpool siGENOME Human GORS2 siRNA M-010980-02
SMARTpool siGENOME Human SPPL3 siRNA M-006042-02
SMARTpool siGENOME Human SPPL2a siRNA M-006040-01
SMARTpool siGENOME Human SPP siRNA M-005896-02
SMARTpool siGENOME Human STX18 siRNA M-020624-00
SMARTpool siGENOME Human STX5 siRNA M-017768-01
SMARTpool siGENOME Human STX8 siRNA M-019873-02
SMARTpool siGENOME Human VAMP8 siRNA M-013503-01
SMARTpool siGENOME Human VAPA siRNA M-021382-01
SMARTpool siGENOME Human VAPB siRNA M-017795-00
3.1.8 Kits and Enzymes
All kits used in this study are commercially available and were always used according to the
manufacturer’s instructions.
Table 3.7: Commercially available kits. The company the kits were obtained from and the purpose of use are indicated.
Kit name Company Purpose
AmaxaTM P4 Primary Cell 4D Nucleofector Lonza Embryonic Stem cell transfection
BCA Assay Solutions Interchim Protein quantification
Go Taq polymerase Promega Genotyping & other PCRs
High Capacity cDNA
Reverse Transcription Kit
Applied Biosystems Reverse Transcription
LipofectamineTM 2000 Thermo Fisher
cDNA transient &
stable transfection
LipofectamineTM RNAiMAX Thermo Fisher siRNA transient transfection
NucleoSpin R© & NucleoBond R© Mackerey & Nagel Plasmid purification
Pfu Turbo Polymerase Agilent technologies High Fidelity PCRs
Protease Inhibitor mix (PI mix) Sigma Aldrich Protein isolations (1:500)
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Kit name Company Purpose
Pwo polymerase PEQLAB Construct PCRs
Quick-RNATM Mini Prep Plus Kit Zymo Research mRNA extraction
T4 ligase Thermo Fisher Ligation of DNA
3.1.9 Cell Culture media and antibiotics
A series of different media were used depending on the characteristics of each cell line and the
purpose of the experiments. The base media for all T-RexTM-293 cells was DMEM GlutaMAXTM
(Thermo Fisher, Waltham, USA). Stem cells were always cultured in Stempan E14 GMEM
from PAN Biotech (Aidenbach, DE) in presence of ESGRO R© mLIF Medium Supplement by
Millipore. All solutions used in cell culture were sterilised either by autoclave or by sterile
filtration. Autoclaving was done at 120◦C and 1.2 bar for 20 min.
Table 3.8: Cell culture media and supplements. Media and supplements used in cell culture for this study.
Name Company
Blasticidin Life Technologies
DMEM GlutaMAXTMI Life Technologies
Doxycycline Carl Roth
ESGRO R© mLIF Medium Millipore
Fetal Bovine serum (FBS) Sigma Aldrich
Hygromycin Life Technologies
L-Glutamine (L-Gln) Life Technologies
OptiMEM R©I + GlutaMAXTMI Life Technologies
Penicillin/streptomycin (P/S) Life Technologies
Poly-L-lysine Sigma
Stempan E14 GMEM PAN Biotech
Trypsin (0.05%) -EDTA (1x) Life Technologies
Zeocin Life Technologies
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Table 3.9: Specific Media Composition. Composition and purpose of use of all cell culture media used in this study.
Name Composition Purpose
Antibiotic free medium -
Doxycycline (ABF + Dox)
DMEM GlutaMAX
10% v/v FCS
1 μg/ml Doxycycline
Induction of SPPLs expression
Antibiotic free medium (ABF) DMEM GlutaMAX
10 % v/v FCS
Experiment conditions
Transfection
Basic Medium
DMEM GlutaMAX
10 % v/v FCS
1% v/v P/S
1% L-Gln
Short term culture
and resuspension
Blast Hygromycin Medium (B/H)
DMEM GlutaMAX
10 % v/v FCS
1% v/v P/S
1% L-Gln
5 μg/ml Blasticidin
100 μg/ml Hygromycin
Culture of stably transfected
TR cells
Blast Medium
DMEM GlutaMAX
10 % v/v FCS
1% v/v P/S
1% L-Gln
5 μg/ml Blasticidin
Culture of TR cells
Blast Zeocin Hygromycin Medium
(B/Z/H)
DMEM GlutaMAX
10 % v/v FCS
1% v/v P/S
1% L-Gln
5 μg/ml Blasticidin
200 μg/ml Zeocin
100 μg/ml Hygromycin
Culture of stably transfected
inducible TR cells
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Name Composition Purpose
Blast Zeocin Medium (B/Z)
DMEM GlutaMAX
10 % v/v FCS
1% v/v P/S
1% L-Gln
5 μg/ml Blasticidin
200 μg/ml Zeocin
Culture of inducible TR cells
E14 - LIF Stempan E14 GMEM
Basis for differentiation
of ES cells
E14 + LIF Stempan E14 GMEM 60μl
mLIF Medium
Culture of Stem cells
3.1.10 Buffers
When no dilution media is mentioned, double-distilled water was used. Protease inhibitor mix
(PI mix) was always added freshly to the buffer shortly prior to use.
Table 3.10: Buffers used in this analysis. List of buffers that were not commercially acquired with the specific composition and
“purpose”.
Name Composition Purpose & Comments
4% (w/v) PFA (100 ml)
4 g PFA (Sigma)
80 ml PBS (ca. 60◦C)
stir 1 M NaOH until clear
filter, cool and adjust pH 6.9 (HCl)
a.d. 100 ml with PBS
Fixation of cells for IF
(-20◦C, 4◦C after dilution to 1x)
CaCl2 buffer
50 mM CaCl2 10 mM
Tris pH 8.0
Obtaining heat shock-
competent cells
DNA sample buffer (10x)
100 mM Tris pH 9.0
10 mM EDTA
50% (v/v) glycerol
0.5% (w/v) Orange G
Preparation of DNA samples
for agarose electrophoresis
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Name Composition Purpose & Comments
gDNA Lysis Buffer (1L)
5 ml 2M Tris-HCl pH 7.5
20 ml 0.5M EDTA
2 ml 5M NaCl
5 g sarcosyl (N-lauryl sarcosine)
10 μg/ml Proteinase K (before use)
Isolation of genomic DNA
gDNA precipitation Buffer
(10 ml, slurry)
0.3 ml 5M NaCl
9.7 ml 100% EtOH
Isolation of genomic DNA
(prepare fresh)
I-Block solution
2% (w/v) I-BlockTM (life technologies)
0.1% (v/v) Tween 20 in PBS
Antibody dilution,
PVDF membrane blocking
LB agar plates
LB medium
15 g/l agar
autoclaved at 120◦C at 1.2 bar 20 min
100 μg/ml ampicillin or spectinomycin
Growth of E.coli
transformations
LB medium
1% (w/v) bactotrypton
0.5% (w/v) yeast extract
1% (w/v) NaCl
Bacteria growth
Lower Tris (4x)
1.5 M Tris
0.4% (w/v) SDS, pH 8.8
Gel electrophoresis (4◦C)
Mass Spec Lysis Buffer
150 mM NaCl
50 mM TrisHCl pH 7.5
2 mM EDTA
1% Triton X-100
Dissolving membrane pellets
for Mass Spec (4◦C)
Mowiol
6.0 g glycerol
2.4 g Mowiol 4-88 (Carl Roth)
12.0 ml 0.2 M Tris x HCl pH 8.5
6.0 ml double-distilled water
25 mg/ml DABCO (Carl Roth)
Fixing of coverslips for IF
(-20◦C, heat prior to use)
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Name Composition Purpose & Comments
Organ-lysis buffer
5 mM Tris x HCl, pH 7.4
250 mM sucrose
5 mM EGTA,
PI mix 1:500
Homogenisation of tissue
and whole organs (4◦C)
PBS (10x)
140 mM NaCl
10 mM Na2HPO4
1.75 mM KH2PO4
pH 7.4
Multiple uses
Running buffer
25 mM Tris
200 mM Glycine
0.1 (w/v) SDS
Gel electrophoresis (4◦C)
Sample buffer (5x) –
diluted 2.5 times for
sample buffer (2x)
50% (v/v) glycerol
7.5% (w/v) SDS
7.5% (w/v) DTT
bromophenol blue (traces)
dissolved in 4x upper Tris buffer
denature proteins and
charge them negatively
in preparation of WB
(-20◦C -> RT)
(heat prior to use)
STE-Buffer
250mM sucrose
5mM Tris pH 7
1mM EGTA
PI mix 1:500
Opening cells for
Mass Spectrometry (4◦C)
STEN Buffer
50 mM Tris pH 7.5
150 mM NaCl
2 mM EDTA
1% NP-40
PI mix 1:500
Lysis of cells for Lectin array
(4◦C)
Stripping buffer
62.5 mM Tris x HCl pH 6.7
2% (w/v) SDS
0.7% (v/v) β-mercaptoethanol
Removal of primary and
secondary Ab from PVDF
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Name Composition Purpose & Comments
TAE buffer (50x)
40 mM Tris pH 8.0
20 mM Na(CH3COO)2
2 mM EDTA
Agarose gel electrophoresis
TBE Buffer (10x) 1L
108 g Tris
55 g Boric Acid
40 ml 0.5 M Na2EDTA pH 8.0
Agarose gel electrophoresis
<500 base pairs
TBS-T
50 mM Tris
150 mM NaCl
0.05% (v/v) Tween 20
pH 7.6
Washing of PVDF membranes
Transfer buffer
25 mM Tris
200 mM glycine
Electroblotting
Upper Tris (4x)
0.5 M Tris
0.8% (w/v) SDS
pH 6.8
Gel electrophoresis (4◦C)
Hypotonic buffer
10 mM Tris pH 7.6
1 mM EDTA
1 mM EGTA, pH 7.6
PI mix 1:500
Opening of cells (4◦C)
Membrane lysis buffer/
Basic Buffer
40 mM Tris pH 7.8
40 mM KCH3COO
1.6 mM Mg(CH3COO)2
100 mM sucrose
0.8 mM DTT
PI mix 1:500
Solubilisation of membranes
for WB (4◦C)
Tail lysis buffer
100 mM Tris, pH 8.5
5 mM EDTA
0.2% (w/v) SDS
200 mM NaCl
proteinase K (100 μg/ml, Roche)
proteinase K is freshly added
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3.1.11 Acrylamide gels
Two types of acrylamide gels were used in this study. One type was used for protein analysis
and the other type to analyse DNA as it gives a very precise running behaviour depending on
the matching of the double-stranded DNA and it is sensitive enough to detect mismatched base
pairs.
Table 3.11: Acrylamide gels composition for protein analysis. Three different percentages of acrylamide were used depending on
the molecular weight of the protein in question.
Running gel (8%) Running gel (10%) Running gel (12%) Stacking gel
H2O 4.4 mL 4 mL 3.6 mL 3.25 mL
Acrylamide/Bis
37.5:1
1.6 mL 2 mL 2.4 mL 0.5 mL
Lower Tris 2 mL 2 mL 2 mL -
Upper Tris - - - 1.25 mL
TEMED 15 μl 15 μl 15 μl 15 μl
APS (10%) 15 μl 15 μl 15 μl 15 μl
Table 3.12: Acrylamide gels composition for DNA analysis. Only 8% Polyacrylamide gels were used to analyse 50-400 bp DNA
size. In this gel the front is at 45bp.
Running gel (8%)
H2O 8.4 mL
Acrylamide/Bis 29:1 2.4 mL
10 x TBE 1.2 mL
TEMED 10 μl
APS (10%) 200 μl
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3.2 Methods
3.2.1 Molecular Cloning
3.2.1.1 DNA Amplification by PCR
DNA was amplified by PCR when new DNA was received in the lab or when the DNA stocks were
running low. Additionally, this technique was used to add tags, restriction enzyme sequences,
signal sequences etc. to the construct.
For the PCR, 5-10 ng of clonal DNA were used together with 0.5 μM forward and reverse
primer, 400 μM dNTPs, 5 μl 10x Buffer, 1 μl Pwo-PoI polymerase and 39 μl H2O.
Table 3.13: PCR Program. *Steps 2-4 were repeated 30 times.
PCR Program
1 5 min 95◦C
2 30 sec* 95◦C
3 1 min* 55◦C
4 4 min/kb* 68◦C
5 10 min 68◦C
6 ∞ 10◦C
3.2.1.2 Transferring of cDNA to desired vector
Commercially purchased DNA required transferring to an appropriate vector for subsequent use
in human cells. To this end, the following steps were taken.
3.2.1.2.1 Digestion
The insert DNA and the plasmid were digested with the same restriction enzymes that were
predefined and their restriction sites were cloned into the construct. Digestion was performed
at 37◦C for 2-4 hours. The restriction endonucleases were obtained from commercial sources
(Thermo Fisher or NEB).
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Table 3.14: DNA Digestion. List of all the components required for digestion of insert DNA and a vector. x+y=30
Vector’s DNA 2 μg
Construct’s DNA 5-10 μg
x μl
Buffer matching enzymes 3 μl
Enzyme 1 1 μl
Enzyme 2 1 μl
H2O a.d. 30 μl y μl
3.2.1.2.2 Ligation
The digested DNA samples were run on an agarose gel and the band depicting the expected
nucleotide length was cut out and eluted from the gel. The two complementary samples were
then ligated for 2 hours at RT or overnight at 4◦C or 14-18 hrs at 14◦C. A control ligation was
also done in absence of the insert. 10 μl of the ligated samples were used to transform 100 μl
E.coli (3.2.1.4).
Table 3.15: Ligation of plasmids.
Control Probe
cleaved vector 2 μl 2 μl
Insert — 15 μl
T4 ligase buffer 10x 2 μl 2 μl
T4 ligase 1 μl 1 μl
H2O ad. 20 μl 15 μl —
3.2.1.3 Quick Change
This technique was used to introduce mutations into existing plasmids. Up to 7 nucleotides
can be changed with this technique at once. Primers for Quick change were designed using
the online software by Agilent Technologies (http://www.genomics.agilent.com/
primerDesignProgram.jsp) and purchased by Sigma Aldrich, or Thermo Fisher when primer
size exceeded 120 nucleotides.
After the PCR, 1μl of DpnI enzyme per reaction was added for 1.5h at 37◦C to degrade the
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original template. 10 μl of each reaction when then used to transform 50 μl of E.coli
(3.2.1.4).
Table 3.16: PCR mix for Quick Change. List of all components of the Quick Change PCR.
PCR Mix
Template 10 ng (i.e. 1μl of 1μl/μg diluted 1:100)
Primer fw (125 ng, 1 μl of 10 μM)
Primer rv (125 ng, 1 μl of 10 μM)
dNTP Mix (Roche, 10 mM) 2 μl
Buffer (10x) 5 μl
Pfu Turbo (Agilent) 1 μl
ddH2O 39 μl
Table 3.17: PCR program for Quick Change Program used on the PCR machine. *Steps 2-4 were repeated 16 times.
PCR Program QUICK
1 1 min 95◦C
2 30 sec* 95◦C
3 30 sec* 55◦C
4 2 min/kb* 68◦C
5 20 min 68◦C
6 ∞ 10◦C
3.2.1.4 Competent cells DH5α and transformation
Heat shock-competent cells were obtained as follows. Overnight culture of E. coli DH5α was
diluted in fresh LB medium and incubated at 37◦C and 250 rpm until it reached an OD600 of
0.5. Bacteria were then centrifuged at 1500 g at 4◦C for 5 min. The pellet was resuspended
in ice-cold CaCl2 buffer and left on ice for 30 min. After another round of centrifugation, the
cells were resuspended in 1 ml CaCl2 buffer and aliquots were stored at -80◦C.
For transformation, 50-100 μl competent cells were thawed on ice for 10 min and mixed with
bacterial plasmids, 10 μl for a ligation reaction, 1 μl for a site-directed mutagenesis reaction or
50 ng of intact plasmid. The cells were then incubated on ice for another 10 min and the mixture
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was incubated at 42◦C for 2 min and instantly chilled on ice for 2 more min. 1 ml of sterile LB
medium was added and samples were shaken at 37◦C for 1 h. The mixture was then spun down
at 2500 rpm for 2 min and the pellet was resuspended in 80 μl fresh LB-medium, before being
either plated on LB agar plates or used to inoculate sterile LB medium. In either case, media
were supplemented with the antibiotic according to the plasmid to select for transformed cells.
3.2.1.5 Agarose gel electrophoresis
DNA plasmids and fragments were analysed by submerged agarose gel electrophoresis (SAGE).
Samples for analysis were mixed 1:4 with DNA sample buffer and separated using either 1 x
TAE-buffered or TBE-buffered gels containing 1 to 2 % (w/v) agarose and 0.2 μg/ml GelRed
depending on the base-pair length. Commercially available 1kb Plus DNA ladder was used to
assess the length of the DNA under UV illumination. When further processing was required,
DNA fragments of the expected size were cut from the gel and eluted using the NucleoSpin Gel
and PCR clean-up kit according to the manufacturer’s instructions.
3.2.1.6 Plasmid preparation
Plasmids were isolated from bacterial cultures shaken overnight at 37◦C, 200 rpm using
commercially available kits according to the manufacturer’s instructions (Macherey-Nagel).
DNA concentration was determined using a UV-Vis NanoPhotometer (Implen, Munich,
Germany) and was adjusted commonly to 1 μg/μl using autoclaved H2O.
3.2.1.7 Sequencing
Empty plasmids were sequenced prior to use. Plasmids containing the desired constructs were
sequenced to confirm the presence of the constructs and the absence of unwanted mutations.
DNA of stem cells CRISPR clones were also sequenced to confirm mutations. All DNA was
sequenced by Eurofins Genomics (Ebersberg, DE) and prepared for sequencing according to
their standards. Sequence information was obtained by Sanger sequencing using standard
sequencing primers or, alternatively, internal, pre ordered, sequencing primers, for longer
constructs. Sequence analysis was performed using the CLC Main Workbench, v6.9.
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3.2.2 Cell Culture
3.2.2.1 T-RexTM-293
3.2.2.1.1 TR Culturing
All cells were cultivated in water-jacket incubators in a humidified atmosphere containing 5%
(v/v) CO2. All treatment of cells in culture was done under luminar flow hoods. Under non-
experimental conditions, the cells were cultured in the presence of appropriate antibiotics listed
in table 3.3 in the media mentioned in table 3.9. Cells were split every 3-4 days to a dilution
that would ensure reaching confluency by the next splitting day. Trypsin-EDTA was used to
detach the cells and was either neutralised by the FCS present in the media or the cells were
centrifuged 5 min x 1000 rpm and resuspended in absence of trypsin.
When plated for experiments, all additives except FCS were removed from the culture medium
(ABF +/- Dox). Poly-L-Lysine (100 μg/ml in 1xPBS) was used for coating the cell culture
plates used in experiments (1 hour of coating followed by 3 washes with 1xPBS).
3.2.2.1.2 TR Transfection
Cells were plated the day before and kept in ABF medium at a 60-80% confluency. Transient
cDNA transfections were achieved using LipofectamineTM 2000 according to the manufacturer’s
instructions; no selection by antibiotic was performed. For one well of a 6-well plate, 6 μl
Lipofectamine were preincubated in 250 μl OptiMEM (solution A) and 1.5 μg DNA in 250 μl
OptiMEM (solution B) for 5 min at room temperature (RT). Then solutions A and B were
mixed and incubated for further 5 min at RT before being added to the well. 24 hours later
the media was changed removing the Lipofectamine. For a 6-cm plate 8 μl Lipofectamine were
used in 500 μl OptiMEM (A) and 2 μg DNA in 500 μl OptiMEM (B).
For transient knockdown, cells were plated either the day before or the same day. The cells
were transfected with siGENOME SMARTpool siRNA from Dharmacon (table 3.6) at a final
concentration of 20 nM using LipofectamineTM RNAiMAX according to the manufacturer’s
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instructions. For one well of a 6-well plate, 250μl OptiMEM with 8 μl LipoRNAiMAX and 2 μl
siRNA were used, the mixture was incubated for 10 min before being added to the well. For a
6-cm and an 8-cm plate 12 μl LipoRNAiMAX and 4 μl siRNA were used. After 24 hours, the
media was exchanged with fresh media.
For some experiments that required both DNA and siRNA transfections, cells were treated on
experimental day 1 with the siRNA and on experimental day 2 or 3 with the cDNA depending
on their confluency.
3.2.2.1.3 TR Cell line generation
SPPL2c and SPPL2c D448A expressing cells were generated by stably transfecting the
respective cDNAs into doxycycline-inducible TR cells and keeping the cells in the presence of
zeocin. Single cell clones with desirable expressions were selected after analysis of the
expression by immune blotting. TR cells expressing SPPL3 with a C-terminal HA-tag under a
doxycycline inducible promoter were generated similarly and have been described previously
(Voss et al. 2014b). Expression of the SPPL-proteases was induced by 1 μg/ml of doxycycline
in the culture medium (ABF +/- Dox) for at least 48 hours, unless differently indicated.
Cells stably expressing cDNA constructs (such as Flag-GnTV-V5, table 3.3) were generated by
transfecting the respective plasmid using LipofectamineTM 2000 according to the
manufacturer’s instructions. Four days after transfection, cells were selected by addition of
100 μg/ml hygromycin to the culture medium and were kept in this medium to ensure
continuous expression of the protein.
3.2.2.1.4 Inhibitor Treatment
Cells were treated with inhibitors in 2 ml media in 6-well plates. PI mix 4.5 μl, Roche
inhibitors 4.5 μl, Bafilomycin 30 nM, E64 50 μM, EDTA 2 mM, Pepstatin 1 μM, X-Merc 1
μΜ, Epoxomycin 1 μM, Caspase3 30 μM and MG132 10 μm final concentration, for 24 hours
before being collected.
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3.2.2.1.5 Generation of SPPL3 knockout HEK293 via CRISPR/Cas9
The TR cells were used for this method and the knockout was done according to the 2013
publication by Ran et al. (Ran et al. 2013).
3.2.2.1.5.1 Transfection and single-cell sorting
The HEK293 cells were transfected with the pCMV-Cas9-GFP gRNA plasmids (Sigma, table
3.2) as described above (3.2.2.1.2). One day after transfection, the GFP expression was checked
using an LSM 710 Zeiss Observer Z.1 confocal microscope to confirm the transfection’s success.
A day later, the cells were subjected to single cell-sorting at the FACS sorting facility of the
Helmholtz Centre (Munich, DE) using a BD FACSAriaTM III. The cells were sorted into 96-well
plates, two plates of cells with high GFP expression and two plates with low GFP expression for
each of the two gRNAs used. The single cell colonies that survived (about 20%) were allowed
to grow sufficiently before being passaged progressively to bigger plates (24-wells, 12 wells,
6-wells). At the 6-well stage, each clone was frozen and protein, as well as DNA were collected
to assess the success of the genetic modification. The clones were analysed progressively.
3.2.2.1.5.2 Protein analysis of single cells clones by Western Blot
The proteins from the single cell clones were extracted (as described in 3.2.3) and the expression
levels of SPPL3 for each of the clones were analysed by Western Blotting (3.2.4). Only the
clones that showed no remaining SPPL3 expression in this step were further subjected to analysis
of their genomic DNA.
3.2.2.1.5.3 Genomic DNA analysis
For the extraction of the genomic DNA (gDNA), cells were span down at 3500 rpm for 5 min,
washed two times with 1xPBS, resuspended in 500 μl of gDNA Lysis buffer and placed in -80◦C
for 1 hour. After thawing, 1.5 ml of gDNA precipitation buffer was added to each tube and
incubated for 30 min at RT. Samples were spun down at 13500 rpm for 15 min at 4◦C and
washed with 1 ml 70% EtOH. After another 5 min centrifugation at max speed the wash buffer
was removed and the pellets were dried before being resuspended in 100 μl of TE buffer. 1
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μl of DNA was used for the PCR amplification. All of the clones and 3-4 WT samples were
included in the analysis.
In order to ensure the specific amplification of only the required part of the genetic material,
as this is a crucial step for the efficiency of the analysis, nested PCR was performed with two
sets of primers for each gRNA. The first pair amplified a region 700-1000 base pairs, while the
second pair amplified 200-400 base pairs.
Table 3.18: PCR primers for nested PCR of gRNA targets on DNA of SPPL3 in HEK293 cells. List of all forward and reverse
primers for “outer” and “inner” nested PCR of both target sites.
human gRNA 1
1st PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer TCAAAGACTCTCTCCTTAACC 21 120810510 120810530 54.32 42.86
Reverse primer ATGCAGGCTTTACCTCATC 19 120811308 120811290 54.92 47.37
Product length 799 bp
human gRNA 1
2nd PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer GTTTTGGTACCAGCACTTTC 20 120810729 120810748 55.1 45
Reverse primer AAGCTCCATTAGGACTCACT 20 120810943 120810924 55.54 45
Product length 215 bp
human gRNA 2
1st PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer TCCTGTGTACTTGCCAATTT 20 120768637 120768656 55.15 40
Reverse primer ATGAAAGGGGGTGCTATCTA 20 120769424 120769405 55.26 45
Product length 788 bp
human gRNA 2
2nd PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer GTACGACTTTTCAGCAAACA 20 120768770 120768789 54.5 40
Reverse primer AATTGCAAACTCTGTGAAGG 20 120769154 120769135 54.39 40
Product length 385 bp
All the clones that had showed no SPPL3 expression on the protein level were sent for
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sequencing (3.2.1.7).
3.2.2.2 E14TG2a mouse Stem Cells (ES cells, ESCs)
3.2.2.2.1 ESCs Culturing
ESCs were cultivated in water-jacket incubators in a humidified atmosphere containing 5%
(v/v) CO2. All treatment of cells was done under luminar flow hoods and contaminations
with other cell lines were strictly avoided. All solutions used in cell culture were sterilised
either by autoclaving or sterile filtration. To inhibit differentiation, cells were grown in the
presence of mouse leukaemia inhibitory factor (mLIF). Cells were split every 2-3 days to a
dilution that would ensure reaching a maximum of 80% confluency by the next passage to
avoid differentiation. Cells were grown in special flasks (Starstedt) that allow attachment of
cells and help the formation of colonies. Trypsin-EDTA was used to detach the cells and was
either neutralised by the FCS present in the media or the cells were centrifuged 5 min x 1000
rpm and resuspended in absence of trypsin. Cells were exchanged after approx. 50 passages.
3.2.2.2.2 Generation of SPPL3 knockout ESCs via CRISPR/Cas9
The principle of this method was done according to the 2013 publication by Ran et al. (Ran
et al. 2013).
3.2.2.2.2.1 Transfection and single-cell sorting
Low passage ESCs were transfected with the pCMV-Cas9-GFP gRNA plasmids (Sigma, table
3.2) using the P4 Primary Cell 4D-NucleofectorTM X Kit (Lonza) 100 μl format and a 4D-
NucleofectorTM (Lonza), according to manufacturer’s instructions. Following the transfection,
cells were seeded as usual and one day later, the GFP expression was checked using an LSM
710 Zeiss Observer Z.1 confocal microscope to confirm the transfection’s success. Two days
after transfection the cells were subjected to single cell-sorting at the FACS sorting facility of
the Helmholtz Centre (Munich, DE) using a BD FACSAriaTM III. ESCs were sorted into 96-well
plates. For each of the two gRNAs used, 2 plates of cells with high GFP expression and 2
plates with low GFP expression were sorted. The cells were kept always under the presence of
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LIF. The single cell colonies that survived (50%) were allowed to grow sufficiently before being
passaged progressively to bigger plates (24-wells, 12 wells, 6 wells). At the 6-well stage, each
clone was frozen and protein as well as DNA were collected to assess the success of the genetic
modification. The clones were analysed progressively.
3.2.2.2.2.2 Genomic DNA analysis
The genomic DNA of the cells was isolated and analysed as described in 3.2.2.1.5.3. The
primers for this analysis were designed in the same principle as before.
Table 3.19: PCR primers for nested PCR of gRNA targets on DNA of Sppl3 in ESCs. List of all forward and reverse primers for
“outer” and “inner” nested PCR of both target sites.
mouse gRNA 1
1st PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer GGTGAGAGAGATGTGGTTTT 20 115061202 115061221 54.98 45
Reverse Primer TCCCAGATAAACTCTGCTTC 20 115062057 115062038 54.46 45
Product length 856 bp
mouse gRNA 1
2nd PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer CTGTCCGAGTATCTTTGGTT 20 115061418 115061437 54.8 45
Reverse primer ATGCTTCCTCTATCTGCAAC 20 115061687 115061668 55.22 45
Product length 270 bp
mouse gRNA 2
1st PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer TCTCTGATGACCTGTTACCT 20 115082037 115082056 54.87 45
Reverse primer AGCTGTGATTAGCTGTCAATA 21 115082763 115082743 54.74 38.1
Product length 727 bp
mouse gRNA 2
2nd PCR
Sequence (5’->3’) Length Start Stop Tm GC%
Forward primer TTAGGTGACATCAGTGCATC 20 115082090 115082109 55.17 45
Reverse primer ATGGCATGGCACATACATTA 20 115082399 115082399 55.14 40
Product length 310 bp
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Part of the sample from the second PCR was loaded on a 1.5% agarose in TBE to confirm the
amplification of a single band. After the agarose gel analysis, the samples were denatured and
reannealed either on their own, or in combination with the DNA from WT ESCs.
Table 3.20: Denaturing and reannealing sample composition
Self reannealing Reannealing with WT
2 μl 2nd PCR product
1.5μl 2nd PCR product
+ 1.5 μl WT PCR
2 μl T7 Buffer 2 μl T7 Buffer
16 μl H2O 15 μl H2O
Table 3.21: Denaturing and reannealing PCR program
Denature/Reannealing PCR program
95◦C 2 min
-2◦C/s to 85◦C —
-0.1◦C/s to 25◦C —
16◦C ∞
Following the reannealing, 15μl of each sample were mixed with 4μl DNA loading buffer and
were loaded on DNA Acrylamide gels. The gels were run for 4-5 h in 1 x TBE at 30 Volt and
subsequently were incubated for 30 min in TBE with 0.2 μg/ml GelRed. Commercially available
1kb Plus DNA ladder was used to assess the length of the DNA under UV illumination and a
picture of each blot was taken.
With this method, homozygous dsDNA runs as a single band, while mismatched DNA runs as
multiple bands. The clones that had different DNA from the WT (mismatch in the reannealing
with the WT) but were homozygous (single band at the self-reannealing) were selected. These
clones were sequenced (3.2.1.7) and three clones with early stop codons were selected.
3.2.2.2.3 Differentiation of Stem cells to Adipocytes
Wildtype and knockout stem cells were differentiated to adipocytes following the protocol
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from Cuaranta-Monroy et al. (Cuaranta-Monroy et al. 2014). In brief, cells were cultured
in “hanging drops” (2000 cells/drop, 20 μl) for two days without LIF to prom the formation
of embryonic bodies (EBs). On day 2, the EBs from one 15 cm plate were transferred in
one well of a 6-well gelatin-coated plate. On days 3-5, the cells were daily treated with fresh
media containing 1 μM retinoic acid (RA) and 12.5 μg/ml ascorbic acid (AsA). On day 6, the
RA was removed and on days 7-11, the cells were given daily fresh media containing 0.5 μM
Rosiglitazone, 0.5 μg/ml Insulin, 3 nM T3 hormone and 12.5 μg/ml AsA. On day 12, the cells
were dispersed with trypsin and split into different wells in media containing 0.5 μg/ml Insulin,
3 nM T3 hormone to serve experimental purposes. Some cells were plated on poly-lysine coated
cover slips for Oil Red stainings (Abcam). On day 13, 0.5 μM Rosiglitazone and 12.5 μg/ml
AsA were added on the cells. From day 15 to 20, the media was changed every second day and
contained 0.5 μM IBMX, 0.1 μM Dexamethasone, 20 μg/ml Insulin, 0.5 μM Rosiglitazone, 0.06
mM Indomethacin and 12.5 μg/ml AsA. On day 21 and 24, the media was changed to media
containing 20 μg/ml Insulin, 0.5 μM Rosiglitazone, 12.5 μg/ml AsA and 3 nM T3 hormone.
On day 27, the adipocyte cultures were evaluated. Oil Red staining was performed according
to the manufacturer’s instructions.
3.2.3 Protein Extraction/Preparation
To extract and further analyse the majority of intracellular proteins, cells were washed with
fresh ice cold 1xPBS and harvested on ice. The cells were pelleted by 5 min centrifugation at
4◦C and 3500 rpm. The supernatant was removed and the cells were lysed using ice-cold STEN
buffer without BSA, 100 μl or 300μl were used for 6-well plates or 6 cm plates, respectively.
Samples were resuspended and incubated on ice for 30 min, the cell debris was removed by
centrifugation at 17000 g at 4◦C for 30 min. BCA assay was used to determine the total
protein concentration in the cell lysates, and inconsistencies between sample-concentrations
were normalized appropriately.
For analysis of TM proteins, cellular membranes were isolated. To this end, cell pellets were
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collected as before and resuspended in hypotonic buffer by pipetting and incubated on ice for
10 min. Cells were lysed with a 23-gauge needle (10-15 times) and centrifuged at 5000 rpm at
4◦C for 5 min, to remove cell debris and nuclei. The supernatant was transferred to a fresh tube
and centrifuged at 13000 rpm at 4◦C for 45 min. The final membrane pellet was resuspended
with membrane lysis buffer.
For analysis of secreted proteins, conditioned media was collected after 24-48 hours incubation
and centrifuged at 17.000 g at 4◦C for 20 minutes to remove any cell debris and dead cells.
Subsequently, samples were most commonly directly mixed 4:1 with 5x sample buffer and
heated at 65◦C for 10 minutes before being subjected to gel electrophoresis (SDS-PAGE). For
the detection of secreted endogenous proteins, the supernatant was TCA precipitated (3.2.3.1).
3.2.3.1 Trichloroacetic acid precipitation
For this procedure, cells were cultured in absence of FCS for 24 hours to avoid precipitation of
albumin during trichloroacetic acid (TCA) precipitation. 800 μl of conditioned media were mixed
with 200 μl freshly prepared aqueous 100% (w/v) TCA and incubated for 1 h on ice. Samples
were centrifuged at 13000 rpm at 4◦C for 30 min and the pellets were washed twice with ice-cold
acetone (-20◦C). The samples were dried and the precipitated proteins were resuspended in 2x
sample buffer. Judging by the colour of the samples, the pH was adjusted by adding 1-3 μl of
1M Tris x HCl, pH 7.8. The samples were incubated at 65◦C for 10 min and stored at -20◦C.
3.2.4 Electrophoresis/Immunoblotting
Proteins from lysates, membrane preparations, conditioned media or TCA-precipitations were
separated by SDS-polyacrylamide (SDS-PAGE) gels. The amount of total protein loaded
varied (5-40 μg) and depended on the abundance of the protein in question. The proteins
were separated on an acrylamide gel. To determine the percentage of the SDS-gel, the
molecular weight of the protein in question was taken into account. The gels were run at 70
Volt until the proteins surpassed the stacking gel and then at 120V until the required end
point. 10 μl of See Blue Plus protein ladder were used for estimating the apparent molecular
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weight of the proteins.
The proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (PVDF;
immobilon P transfer membrane, 0.45 μm pore width; Millipore) by wet transfer using transfer
buffer, 400 mAmp/chamber for 1 hour. The PVDF membranes were activated for 1 min in
isopropanol, then washed for 1 min in destilled water and then incubated in transfer buffer
until use.
Following the transfer, membranes were incubated in blocking solution at RT for 30 min to 1
h before being incubated with the primary antibody overnight at 4◦C. Membranes were
washed three times for 15 min with TBS-T and then incubated with the secondary,
HRP-conjugated antibodies for 1h at RT. All antibodies were diluted in 1xPBS supplemented
with 2% (w/v) Tropix R© I-BlockTM and 0.5% (v/v) Tween 20. The membranes were washed
again three times for 15 min with TBS-T and then the proteins were visualized using enhanced
chemiluminescence technique (ECL) PierceTM ECL Western Blotting Substrate (Thermo
Fisher) or Westar Supernova (Cyanagen, Bologna, Italy) for increased sensitivity, and detected
on Super RX-N X-ray films (Fuji, Tokyo, Japan) with Cawomat 2000IR developer. Developed
films were scanned with an Epson Perfection V700 PHOTO scanner (Epson, Suwa, Japan).
For quantification, proteins were detected using the PierceTM ECL Plus Western Blotting
Substrate (Thermo Fisher). The chemiluminescence signals of at least three independent
experiments were measured with a CCD camera-based imaging system (ImageQuant
LAS-4000 Fuji Film). The intensity values were obtained using the software Multi Gauge v3.0.
In case the same membrane needed to be detected by another antibody, primary and
secondary antibodies were removed from the membranes by incubation in stripping buffer at
50◦C for 30 min. The membrane was then extensively washed with TBS-T and the
immunodetection procedure was repeated starting from the initial blocking step.
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3.2.5 Quantitative Real-Time PCR
Cells and tissues were carefully collected to avoid trans-contaminations between the samples.
The samples were stored in DNA/RNA shield (Zymo Research, Freiburg, DE) at -80◦C until
analysis. Total cellular RNA was isolated from cells using Quick-RNATM Mini Prep Plus Kit
RNA (Zymo Research) and the concentrations were determined by UV-Vis spectroscopy.
mRNA samples were stored at -80◦C. Equal amounts of RNA (2-5 μg) were
reverse-transcribed with the High Capacity reverse transcription kit (Applied Biosystems)
according to the manufacturer’s instructions and cDNA products were stored at -20◦C.
Quantitative real-time PCR was performed using 2x TaqMan master mix (Applied
Biosystems) and pre-designed FAM-labelled 20x TaqMan probes targeting SPPL3 (Applied
Biosystems (Cat. Hs00293370-m1)) and VIC-labelled probes targeting GAPDH ((Applied
Biosystems) (Cat. Hs02786624-g1)) mRNAs. Reactions were performed with a 7500 Fast
Real-Time PCR System (Applied Biosystems). Signals were normalised to levels of GAPDH
mRNA and relative mRNA levels were calculated with the ΔΔCT method. For the Stx8
qPCR, UPL assay system from Roche was used by Torben Mentrup. The housekeeping gene
used was Tuba1a (fw: 5’-CTGGAACCCACGGTCATC-3’, rv: 5’-GTGGCCACGA
GCATAGTTATT-3’). The Stx8 primers were (fw: 5’-ATGACCTTGTCACCCGAGAG-3’, rv:
5’-CTTTGCTTCTTCGCTCATCA).
3.2.6 Animals
Mice were kept at specific pathogen-free conditions at the Centre for Stroke and Dementia
Research, Munich, Germany.
3.2.6.1 Genotyping
Mouse genotyping was conducted on genomic DNA isolated from ear or tail clips, tissue samples
were kept in -20◦C until isolation. Each sample was agitated at 55◦C for 4-16 hours in 500 μl
tail lysis buffer and debris was removed by centrifugation at 13000 rpm for 5 min. For DNA
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precipitation from the clear supernatant, 400 μl isopropanol were added to each sample, mixed
well and centrifuged at 13000 rpm at 4◦C for 20 min. The pellet (not visible) was washed
with 70% (v/v) ice-cold ethanol and dried at 55◦C. The DNA was resuspended in 200 μl sterile
water and incubated at 55◦C for 1 h. Following the isolation, samples were kept at 4◦C.
Table 3.22: Primers for genotyping the Sppl3 KO mouse lines. The first PCR only gives rise to product when there is a WT
allele present. The second PCR recognises the presence of the genetrap. If both PCRs give a band then the mouse is heterozygous,
while if only one of the two gives a band the mouse is either WT or KO.
WT allele – 1st PCR Sequence (5’->3’)
p95-Fw-Wt-mouse-Papadopoulou GCAGGCATCTGCAGAACTCATG
p96-Rv-Wt-mouse-Papadopoulou GCCGTGACACAGCAAGTGCA
Product length 440
Genetrap – 2nd PCR Sequence (5’->3’)
p97-fw-genetrap-mouse-Papadopoulou AAATGGCGTTACTTAAGCTAGCTTGC
p98-rw-genetrap-mouse-Papadopoulou AAACCTTTACTAGGGAGAGGCGTCA
Product length 220
Different quantities of each primer were used to avoid unspecific bands (table 3.24). A common,
“touch-down”, PCR program (table 3.23) was used for both PCRs and both negative and
positive controls were always included in the analysis. The PCR products were separated on a
1.5% Agarose in 1xTAE.
Table 3.23: PCR program for genotyping. The same PCR program was used for the genotyping of both alleles.
Genotyping PCR program
94◦C 10 min
94◦C 30 sec Decrease
1◦C/cycle x 10
68◦C 30 sec
72◦C 45 sec
94◦C 15 sec Repeat 25-30
cycles
58◦C 30 sec
72◦C 45 sec
72◦C 5 min
10◦C ∞
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Table 3.24: PCR mix for genotyping. The mix for each PCR differed in the primer amount to ensure specificity.
Template 1 μl WT allele Genetrap
Forward primer (10 μM) 0.25 μl 0.5 μl
Reverse Primer (10 μM) 0.25 μl 0.5 μl
5x Green Buffer 5 μl 5 μl
dNTPs 0.5 μl 0.5 μl
Taq Polymerase 0.5 μl 0.5 μl
ddH2O 17.5 μl 17 μl
3.2.6.2 Rotarod Performance Test
The mice were analysed in groups of littermates containing wildtype, heterozygous and knockout
animals. Each group was brought into the rotarod room 15 min before the start of the test
to acclimatise to the environment. The rotarod was set on a stable speed of 3 rpm and the
mice were placed on the rotating beam. When all mice were stable on the beam the speed
increase was activated going from 3 to 30 rpm in 480 sec (8 min). The time in sec the mice
were walking on the rotarod from the beginning of the acceleration period was measured. Every
time a mouse fell, the timer was automatically stopped. Each group of mice had no training
session but three trials per session and 15 minutes of break between each of the trials.
3.2.6.3 Metabolic cages
Mice were individually housed for five days in metabolic cages from Tecniplast (Buggiate, Italy).
Mice were provided with a house, dry food and water. The food and water were weighed at
the beginning of each day before and after supplementing the mice with fresh food and water.
The faeces and urine of the mice were collected daily and separately by the structure of the
cage. After the five days period the mice were placed back in the original cages.
3.2.7 Tissue Homogenates from mouse and human samples
For homogenisation of tissue and organs from mice and humans, the same protocol was used.
Organs analysed include brain, heart, liver, kidney, testis, muscle and others. The organs were
removed from the mouse post mortem and snap frozen in liquid nitrogen. Human testis samples
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were previously described (Mayer et al. 2016). The patients had granted written Informed
Consent, for the scientific use of the samples and the Ethical Committee (Ethikkommission,
Technische Universität München, Fakultät für Medizin, München, project number 5158/11) has
approved the study. All relevant guidelines and regulations were followed in the experimental
procedures. All samples were kept in -80◦C until analysis.
Organs (100-250 mg) were thawed on ice and were homogenized in ice cold organ-lysis buffer
using a Wheaton tissue grinder (Thermo Fisher) and 23G needles. Samples were first centrifuged
at 500 g, 4◦C for 5 min to remove big remains and then the supernatant was subjected to further
centrifugation at 100.000 g, 4◦C for 60 minutes. Pellets were resuspended in organ-lysis buffer
containing 2% (v/v) Triton X-100 to solubilise the cell membranes and incubated for 30 min
on ice. To remove cell debris, samples were centrifuged at 17000 g, 4◦C for 30 min and the
supernatants were used for protein quantification by BCA and further analysis by immunoblot.
3.2.8 Immunostaining and Confocal Imaging
This technique was used for visualising localisation of intracellular proteins, and shape and
condition of intracellular organelles. Cells were seeded at low confluency (30%) on 15mm Poly-
L-Lysine-coated coverslips and where indicated, treated with siGENOME siRNA during seeding
(3.2.2.1.2). All cells used for the imaging were stably transfected with cDNA plasmids. On
day 3, the media was removed from the cells and they were washed with filtrated PBS one
time before being fixated for 20 min at RT, under luminal flow, in 4% paraformaldehyde (PFA)
in PBS. Following fixation, cells were washed three times with PBS and were permeabilized
using 5% (w/v) BSA supplemented with 0.2% (v/v) Triton X-100 and 0.5% (w/v) SDS for 5
min. Unspecific binding was blocked at RT with 5% (w/v) BSA for one hour. After blocking,
cells were incubated with primary antibodies diluted in 5% (w/v) BSA for 16-20 hours at 4◦C,
taking care that the samples would not dry. After extensive washing (6 times with 1xPBS), the
cells were incubated with secondary antibodies diluted 1:400 in 5% (w/v) BSA for one hour
at RT. Cells were washed another 6 times with 1xPBS and in order to visualise the nuclei,
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incubated for 5 min with 1:10000 4,6-Diamidin-2-phenylindol (DAPI, 5μg/mL) solution at RT.
The coverslips were loaded onto glass plates facing down using Mowiol mounting media and left
to dry overnight avoiding direct lighting. Pictures were taken using a LSM 710 Zeiss Observer
Z.1 confocal microscope with a 40x-60x oil lens, and 1-2x optical zoom. Airy Unit (AU) 1 was
preferred when possible and AU2 was used when necessary. The intensity of the pictures was
increased for visualization purposes with the ZEN lite 2011 program. Scale bars were inserted
using the same software.
3.2.9 Histological analysis
Histological analysis of murine testis was performed by our collaborator Artur Mayerhofer.
The samples were fixed by immersion in Bouin’s solution and were embedded in paraffin
according to standard procedures. The paraffin sections were immunohistologically stained
using the ABC System (Vector Laboratories, California, USA) and diaminobenzidine as
peroxidase substrate. Anti-Cab45 was the only antibody utilized in this analysis in 1:500
dilution. To control for unspecific binding, rabbit polyclonal control IgG (BioLegend) was used
as a negative control. Hematoxylin was used to visualize the nuclei. Images were taken with a
Zeiss Axiovert microscope equipped with an Insight Camera (18.2 Color Mosaik) and Spot
advanced software 4.6 (SPOT Imaging Solutions, Sterling Heights, MI, USA). For the
quantifications, 14 images were used, each containing one stage VII/VIII seminiferous tubule.
These stages were selected because they are characterized by two generations of spermatids
and can be reliably recognized in immuno-stained sections (also by the presence of residual
bodies (Meistrich and Hess 2013)). Three equally sized squares were positioned randomly
around each seminiferous tubule and the pre-acrosomal resembling structures within each
square were counted. The average of the three squares was assigned to each tubule.
3.2 Methods 69
3.2.10 Mass Spectrometry
Mass Spectrometry analysis was performed by our collaborator Stephan Müller. Cells were
harvested and centrifuged at 1000 rpm for 5 min at 4◦C, the cell pellets were resuspended in
STE-Buffer and lysed with a 27-gauge needle. Samples were centrifuged for 10 min at 800 g to
remove cell nuclei, then 10 min at 15000 g to remove mitochondria and finally ultracentrifuged
for 1 hour 100.000 g to pellet the membranes. The membrane pellets were washed two times
with 100 mM Na2CO3 and centrifuged for 30 min at 100.000 g after each wash. The cleaned
pellets from membrane preparations were dissolved in lysis buffer and the protein concentration
was calculated using the Pierce 660nm protein assay (Thermo Fisher Scientific, US). 15 μg
of protein were subjected to proteolytic digestion with trypsin and LysC (Promega, Germany)
using the filter-aided sample preparation (FASP) with Vivacon centrifugal concentrators (30
kDa cut-off, Sartorius, Germany) according to published protocol (Wisniewski et al. 2009).
The peptides were enriched and desalted using a stop and go extraction with self-packed C18
Tips (3M Empore, US) (Rappsilber et al. 2003). Eluted peptides were then dried by vacuum
centrifugation and dissolved in 20 μl 0.1% formic acid. Finally, the peptides were analysed
on an Easy nLC 1000 nanoHPLC (Thermo Scientific, US), coupled online via a Nanospray
Flex Ion Source (Thermo Scientific, US) equipped with a PRSO-V1 column oven (Sonation,
Germany) to a Q-Exactive mass spectrometer (Thermo Scientific, US). 1.3 μg of peptides were
separated on an in-house packed C18 column (30 cm x 75 μm ID, ReproSil-Pur 120 C18-AQ,
1.9 μm, Dr. Maisch GmbH, Germany) using a binary gradient of water (A) and acetonitrile
(B) supplemented with 0.1% formic acid (0 min., 2% B; 3:30 min., 5% B; 137:30 min., 25%
B; 168:30 min., 35% B; 182:30 min., 60% B) at 50◦C column temperature. Data dependent
acquisition method was used and full mass spectrometric scans were acquired at a resolution
of 70,000 (m/z range: 300-1400, AGC target: 3E+6). The ten most intense peptide ions per
full MS scan were chosen for peptide fragmentation (resolution: 17,500, isolation width: 2.0
m/z, AGC target: 1E+5, NCE: 25%). A dynamic exclusion of 120 sec was used for peptide
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fragmentation.
Data was analysed with the software Maxquant (maxquant.org, Max-Planck Institute Munich)
version 1.5.5.1 (Cox et al. 2014). The acquired data was compared against a reviewed fasta
database of Homo sapiens from UniProt including protein isoforms (downloaded: August 8th
2017, 42219 entries). The defined protease was trypsin with two missed cleavages allowed
for the database search. The option “first search” was used to recalibrate the peptide masses
within a window of 20 ppm. For the main search peptide and the peptide fragment, mass
tolerances were set to 4.5 and 20 ppm, respectively. Carbamidomethylation of cysteine was
defined as static modification. Acetylation of the protein’s N-terminal, as well as oxidation
of methionine were set as variable modifications. The false discovery rate (FDR) for both
peptides and proteins was adjusted to smaller than 1%. At least two ratio counts of razor
peptides were required for label free quantification (LFQ). Only unique peptides and razor were
used for quantification. For the data analysis, the software Perseus (version 1.5.8.5) was used.
The protein LFQ intensities were log2 transformed and a two-sided student’s t test was applied
to evaluate the significance of proteins with changed abundance. Finally, a permutation based
false discovery rate estimation was also used (Tusher et al. 2001).
3.2.11 Pathway Analysis
Using the online STRING 10.5 (https://string-db.org/) program a bioinformatic analysis of the
SPPL2c candidate substrates that were identified through the mass spectrometric approach
was performed. All potential type II and type IV TM proteins were uploaded to the programme
and the possible interaction networks were visualised. Using the function “More” of STRING
10.5, potential SPPL2c substrates that were missed by the proteomic analysis were identified.
3.2.12 Lectin chip microarray (LecChip)
Lectin analysis was performed by our collaborator Merav Shmueli on spermatozoa collected
from the SPPL2c transgenic mice by Torben Mentrup and Johannes Niemeyer. Mature
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spermatozoa of SPPL2c knockout and wildtype mice were recovered from the cauda
epididymides (n = 4 per group) as described in (Niemeyer et al. 2019) and were used for
lectin chip microarray analysis (LecChip). Samples were lysed in STEN-Buffer, incubated on
ice for 30 min, centrifuged at 10000 g for 10 min and brought to a protein concentration of
0.05 mg/ml in TBS. Reagent Cy3 NHS ester (PA13101, GE Healthcare Life Sciences),
dissolved in dimethyl sulfoxide, was added at a final concentration of 0.05 mg/ml for 1 hour
at RT. Excess reactive reagent was inactivated with free lysine (final concentration, 0.05 mM;
L5501, Sigma-Aldrich). Probing Solution (provided by the manufacturer) was used to wash
three times the LecChip (GlycoTechnica Ltd.), and to add the Cy3-labeled sperm lysates (1
μg/ml) (n = 4 per group) to the wells (100 μl per well). Samples were incubated overnight at
18◦C and the following day the LecChip was washed 30 min with TBS and 30 min with
double-distilled water. An InnoScan 710 Microarray scanner (Innopsys) was used to scan the
LecChip and the results were analysed with CLIQS Array Professional software (TotalLab). In
total, 45 lectin intensities were measured per sample. All samples had an average Pearson
correlation coefficient calculated at 0.98 and above. Lectin intensities were log2 transformed
and a two-sided student’s t test was used to evaluate the significance of lectin binding with
changed abundancy.
3.2.13 Statistical analyses
All statistical analyses concerning WB quantification and the count of preacrosomal structures
were conducted with GraphPad Prism 7 (Graphpad, La Jolla, USA) and details are indicated in
the respective figure legends. In general, at least three biological replicates were performed for
statistical analysis. Values that had to be transformed to ratios to allow an equal comparison
and visualisation were then transform to log2 for the statistical analysis. For comparison of 2
groups with equal size simple unpaired, two-tailed student’s t test was used. If the 2 groups
were not of equal size, a Welch’s t test was used. If more than two groups were being compared
to the same control data set, multiple unpaired, two-tailed t tests were performed and then
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corrected by the Holm-Šídák method. For the mouse data with multiple measurements per
mouse and per genotype, a 2-way ANOVA test with Sidak multiple corrections was used. The
significance threshold was set with *p < 0.05, **p < 0.01 and ***p<0.001.
4. Substrate requirements of SPPL3
A wide variety of SPPL3 substrates have been identified in the past few years and the vast
majority of them are implicated in glycosylation being either glycosidases or glycosyltransferases,
such as N-acetylglucosaminyl-transferase V (GnTV) and exostosin-like glycosyltransferase 3
(EXTL3) (Voss et al. 2014a, Kuhn et al. 2015). In all cases, SPPL3 is capable of cleaving the
full length substrate and the cleavage site has been analysed for GnTV (Voss et al. 2014a, Kuhn
et al. 2015). The aim of this part is to understand the substrate requiremnets of SPPL3 in more
detail and to this end, point mutations were generated on the substrates to identify amino acid
residues important for intramembrane proteolysis. Such strategy has been successfully employed
in the past to define a consensus cleavage site of rhomboid I-CLIPs (Strisovsky et al. 2009)
and the sequence requirements of Bri2 for SPPL2b cleavage (Fluhrer et al. 2012).
4.1 Results
4.1.1 Impact of the GxxxG sequence of GnTV on cleavage by SPPL3
The best-characterised SPPL3 substrate is GnTV and it was chosen as the first target for
mutagenesis. Analysing the amino acid sequence of GnTV, the first area of interest was found
within the TMD and consists of two glycines that are separated by 3 amino acids (GFIWG),
we refer to this sequence as GxxxG (Fig. 4.1). A similar GxxxG sequence is also present in Bri2
(GVILG), a substrate of SPPL2a/b, but was found not to be of importance for the cleavage of
Bri2 by SPPL2b (Fluhrer et al. 2012).
Glycines have the ability to slightly destabilise an α-helix when located within the TMD. To
test their importance as α-helix destabilising residues, a series of mutants that would either
increase or decrease the α-helical stability at the respective position were generated. Alanines
(A) are capable of stabilising an α-helix, although they function more effectively outside of the
membrane. Leucines (L) are the most effective α-helix stabilisers within the boundaries of the
TMD. In contrast, prolines (P) are the strongest α-helix-destabilising amino acids within the
TMD. All three amino acids were used and either replaced one of the glycines from GxxxG
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motif at a time or both simultaneously (Fig. 4.1). Based on proteases preference to bind on
more open structures, like β-strands, to perform cleavage, it is expected that a looser α-helix
would constitute a more favourable substrate (Tyndall et al. 2005, Madala et al. 2010).
Fig. 4.1: GnTV GxxxG mutants. The amino acid sequence of a part of GnTV is depicted together with the respective nucleotides
triplets of the mRNA. The predicted TMD is annotated within the red arrow, which also depicts the N- to C-terminal orientation
of the protein. The α-helix destabilizing glycines are marked in bold G. Below the sequence of GnTV the respective amino acid
sequences of the three sets of mutations are shown. The mutated amino acids are marked in red.
4.1.1.1 Effect of GxxxG mutants on GnTV shedding
To assess cleavage of wildtype GnTV (GnTV WT) and its mutants, double-tagged variants of
all substrate constructs were expressed in T-RexTM-293 (HEK293) cells. These cells have an
endogenous expression of SPPL3 that efficiently cleaves GnTV. Using the N-terminal Flag-tag,
only full length GnTV is detected, while with the C-terminal V5 tag both the full length (FL)
and the secreted, soluble GnTV (sGnTV) are detected. However, the sGnTV is detected in the
supernatant of the cells, while the FL only within the cells (Fig. 4.2).
Certain glycine mutations of the GxxxG sequence affected the ratio of secreted sGnTV compared
to full length GnTV. More specifically, for the glycine to alanine mutations, only one alanine at a
time was not enough to significantly reduce secretion. However, simultaneously mutating both
glycines to alanines induced a small (30%) but statistically significant decrease in the secretion
of sGnTV (Fig. 4.3A). Although mutation of the first glycine in the GxxxG to leucine had the
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expected effect (LG mutant) and significantly decreased the secretion of sGnTV, mutating the
second glycine (GL mutant), or both at the same time, notably and significantly increased the
shedding of GnTV (Fig. 4.3B).
Fig. 4.2: Cleavage of double-tagged GnTV. Ectopically expressed GnTV is tagged with a Flag tag on the N-terminus and a V5
tag on the C-terminus. Full-length GnTV (FL GnTV) can be detected by both tags in cell lysates. Cleavage by SPPL3 leads to the
release of soluble GnTV (sGnTV) that can be detected only with the V5 tag in conditioned media. The GnTV ICD is very small
in size (4kDa) and gets rapidly degraded making it thus, non-detectable.
Lastly, introducing an α-helix-destabilising proline instead of one glycine (PG, GP mutants)
significantly increased the cleavage of GnTV. This is in accordance with data suggesting that
less stable α-helices make for better substrates of intramembrane proteases. Also in the case
of proline substitutions, the two glycine-positions have a noticeable difference in the intensity
of the effect they cause, with the position closer to the cleavage site appearing more crucial,
still they both show the same tendency to increase shedding (Fig. 4.3C). However, inserting
two prolines simultaneously into the TMD of GnTV strongly interferes with the expression and
maturation of the protein, as can be seen by the lack of mature GnTV in the lysates (Fig.
4.3C). Therefore, no quantification or assessment of the double P mutants was possible.
To analyse whether introducing the mutations on the substrate might affect the intracellular
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Fig. 4.3: Cleavage of GnTV GxxxG mutants. A-C. Western blots depicting ectopically expressed WT GnTV and mutants of
the GxxxG motif in HEK293 cells. Secretion of soluble GnTV (sGnTV) is visible in the supernatant (sup.) while the full length
GnTV is detected in the lysates by V5 monoclonal antibody. Calnexin was used as a loading control. For quantifications, sGnTV
was compared to the amount of full-length GnTV (FL GnTV), including mature (GnTVmat) and immature (GnTVim) GnTV. The
secretion of WT GnTV was set to 1. Three biological replicates are depicted in the bar graphs (mean + SD). Multiple unpaired,
two-tailed t tests with Holm-Sidak multiple comparisons correction *p<0.05, **p<0.01.
localisation of GnTV, ectopically expressed wildtype GnTV and all three G to A mutants were
visualised by immunofluorescence via the V5 tag in HEK293 cells. As GnTV is expected to
localise predominantly in the Golgi, the Golgi protein Giantin was used as a marker. GnTV
WT and all three mutants tested were found to share similar staining patterns and colocalised
primarily with Giantin (Fig. 4.4). This suggests that SPPL3 should still be able to catalytically
process mutant GnTV, as both protease and substrate localise in the Golgi. Due to technical
limitations, the localisation of the other mutants was not analysed so far but is assumed to
follow the patterns of WT GnTV, as is the case for the G to A mutants.
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Fig. 4.4: Immunofluorescent stainings of GnTV GxxxG to A mutants. Ectopically expressed WT and mutated GnTV was
visualized using the anti-V5 antibody. The Golgi was stained using the anti-Giantin antibody. All GnTV mutants tested appear to
predominantly colocalise with the Golgi marker, similarly to WT GnTV. Scale bar 5 μm.
4.1.2 Impact of GnTV cleavage site on cleavage by SPPL3
The second evident area of interest in GnTV is the cleavage site (MMLLHF) that was identified
by analysing the cleavage of a truncated tagged GnTV by MALDI-TOF mass spectrometry
(Voss et al. 2014a). Primary and secondary cleavage sites were identified by this technique and
were later confirmed (Kuhn et al. 2015). Interestingly, TNFα, a substrate of SPPL2a/b, also
shares a similar sequence at its cleavage site comprising LLHF. To analyse the contribution of
this site to substrate recognition and cleavage, all amino acids surrounding the cleavage sites
were mutated to alanine, one at a time or in pairs. The aim was to assess whether a more
stable α-helix around the cleavage site would decrease shedding of GnTV by SPPL3 or whether
a specific amino acid is crucial for the processing (Fig. 4.5).
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Fig. 4.5: GnTV cleavage site mutants. The nucleotide and amino acid sequence of GnTV is depicted as in Fig. 4.1. The cleavage
sites of GnTV by SPPL3 are marked by the blue arrows, while the primary cleavage site is marked with a thicker line. Underneath
all initially tested mutations for this site are listed in red.
4.1.2.1 Effect of cleavage site mutants on GnTV Shedding
The effect of the mutations on the cleavage of GnTV was assessed as before (compare Fig.
4.3). Although some of the mutations did not strongly alter the shedding rate of GnTV, three
mutations (M27A, L30A and F32A) showed an increase of shedding and one mutation
(H31A) a decrease (Fig. 4.6).
Fig. 4.6: Processing of GnTV cleavage site mutants. Western blots depicting ectopically expressed WT GnTV and GnTV cleavage
site mutants in HEK293 cells. Secretion of soluble GnTV (sGnTV) is detected in the supernatant (sup.) while the full length GnTV
in the lysates. Calnexin was used as a loading control. For quantifications, sGnTV was compared to the amount of full-length
GnTV (FL GnTV), including mature (GnTVmat) and immature (GnTVim) GnTV. The secretion of WT GnTV was set to 1. Open
arrows point to increased mutants while the filled arrow marks the decreased mutant. Two biological replicates are depicted in the
bar graphs (mean +/- SD), no significance testing performed.
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Fig. 4.7: Selection of GnTV cleavage site mutants. Western blots depicting ectopically expressed WT GnTV and selected mutants
of the cleavage site in three technical replicates in HEK 293 cells. Calnexin was used as a loading control. For the quantifications,
sGnTV was compared to the amount of full-length GnTV (FL GnTV), including mature (GnTVmat) and immature (GnTVim)
GnTV in three biological replicates for each mutant. The secretion of WT GnTV was set to 1 (mean +/- SD). Multiple unpaired,
two-tailed t tests with Holm-Sidak correction *p<0.05, **p<0.01.
These mutants were further analysed and were all found to be altered with the GnTV H31A
mutant being the only significantly less secreted (Fig. 4.7). The localisation of all four
mutants with altered processivity was visualised by immunofluorescence, as before, and
appeared unaffected by the mutations (Fig. 4.8). Both the Golgi and the ER were indicatively
stained to compare the localisations.
Fig. 4.8: Immunofluorescent stainings of GnTV cleavage site mutants. Anti-V5 monoclonal antibody was used to visualise
ectopically expressed WT and mutated GnTV. The Golgi was stained using the anti-GM130 antibody and the ER using an anti-BIP
antibody. All GnTV mutants appear to colocalise predominantly with the Golgi marker, similarly to WT GnTV. Scale bar 5 μm.
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4.1.2.2 Importance of histidine at the border of the substrate’s TMD
The histidine in position 31 of GnTV is of interest not only because it is the only position that
significantly decreased GnTV shedding when mutated to an alanine, but also because of its
positive charge. What made this histidine at the border of the TMD even more intriguing is
the fact that EXTL3, another confirmed SPPL3 substrate (Kuhn et al. 2015), also has a
histidine close to the border of its TMD, where the cleavage site of SPPL3 was predicted.
In order to analyse the role of this amino acid in the shedding of GnTV in more detail, both
substrates were further mutated using either a different positively charged amino acid
(arginine, R), a negatively charged amino acid (aspartic acid, D), or an α-helix stabilising
neutral amino acid (leucine, L) (Fig. 4.9).
Fig. 4.9: GnTV and EXTL3 histidine mutants. The amino acid sequences of a part of GnTV and EXTL3 are depicted. In both
sequences, the predicted TMD is marked by a red arrow, which also points the N- to C-terminal direction. The histidine mutated
in both substrates is marked by its positive charge. Underneath each WT protein, there is a list of all histidine mutations in red
and the charge of the amino acids is marked when present.
The results from the GnTV to some degree matched our expectations. Alanine and leucine
are predicted to stabilise the TM α-helix of GnTV and both decreased the secretion of sGnTV
in a statistically significant manner (Fig. 4.10). However, both mutations decreased the
secretion of GnTV only by a small fraction (20-30%), indicating that the histidine facilitates
cleavage but is not a prerequisite.
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In contrast, both the negatively charged aspartic acid and the positively charged arginine
significantly increased processing of GnTV (Fig. 4.10).
Fig. 4.10: Processing of GnTV H31 mutants. Western blots depicting ectopically expressed WT GnTV and mutants of histidine
31 in HEK 293 cells show the level of soluble GnTV (sGnTV) in the supernatant (sup.) and the full-length GnTV in the cell in
three technical replicates. Calnexin was used as a loading control. For quantifications, sGnTV was compared to the total amount of
full-length GnTV (FL GnTV), including mature (GnTVmat) and immature (GnTVim) GnTV. The secretion of WT GnTV was set to
1. Three biological replicates are depicted in the bar graph (mean +/- SD). Multiple unpaired, two-tailed t tests with Holm-Sidak
correction *p<0.05, **p<0.01, ***p<0.001.
Unexpectedly, the results on EXTL3 did not follow the exact same tendencies as for GnTV.
While mutating the histidine to leucine did not significantly alter the cleavage of EXTL3,
mutating the histidine to alanine strongly increased the secretion of EXTL3 (Fig. 4.11). This
observation is counter intuitive and further testing was used to control whether this increase
of EXTL3 secretion is dependent on SPPL3 (4.1.3.1).
Mutation of the histidine into a different positive amino acid, arginine, significantly decreased
ETXL3 secretion. Mutating the histidine to the negatively charged aspartic acid significantly
increased shedding (Fig. 4.11).
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Fig. 4.11: Processing of EXTL3 H48 mutants. Western blots depicting ectopically expressed WT EXTL3 and mutants of histidine
48 in HEK 293 cells show the level of soluble EXTL3 (sEXTL3) in the supernatant (sup.) and the full-length EXTL3 in the lysates
in three technical replicates. Calnexin was used as a loading control. For quantifications, the amount of sEXTL3 was compared to
the amount of intracellular full-length EXTL3. The secretion of WT EXTL3 was set to 1. Three biological replicates are depicted
in the bar graph (mean +/- SD). Multiple unpaired, two-tailed t tests with Holm-Sidak correction *p<0.05, ***p<0.001
4.1.3 Ability of SPPL3 to process the GnTV and EXTL3 mutants
In order to confirm that SPPL3 is the major protease responsible for the cleavage of the
GnTV and EXTL3 mutants, we analysed whether processing of the mutants decreases in
absence of SPPL3. To this end, the CRISPR/Cas9 genome editing technique was used to
generate a HEK293 SPPL3 KO cell line. Two different, commercially available guide RNAs
(gRNA1 and gRNA2) were used to target the SPPL3 gene as described in 3.2.2.1.5. gRNA1
gave rise to only heterozygously mutated single cells clones, but gRNA2 gave rise to three
clones with identical homozygous mutations that lead to an early stop codon in the mRNA.
They were all characterised by the insertion of one nucleotide (T) at the targeted site (Fig.
4.12A) that led to an early stop codon in the mRNA (Fig. 4.12B) and no detectable SPPL3
levels in western blotting (Fig. 4.12C). Clone 11 was chosen for further experiments.
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Fig. 4.12: HEK293 SPPL3 knockout (KO) cell line. A. Comparison of the wildtype human SPPL3 genomic DNA with KO clone
11 is depicted confirming the presence of homozygous insertion of a thymidine, highlighted in red. B. mRNA sequence of clone 11
with the thymidine insertion and the amino acid sequence resulting from this nucleotide sequence. An early stop-codon is generated
as indicated by a red arrow. C. Western blot analysis of control HEK293 cells and the three clones deriving from the CRISPR/Cas9
treatment, showing the absence of SPPL3 protein expression. Calnexin was used as a loading control.
Control HEK293 cells and HEK293 SPPL3 KO cells were transiently transfected with the WT
substrates and the mutants, and the shedding efficiency was compared between the two cell
lines. Regarding the GxxxG mutants, although WT GnTV appears to be the most consistently
decreased substrate, all mutants are also significantly less secreted in absence of SPPL3
suggesting that they are all at least partly processed by SPPL3 (Fig. 4.13).
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Fig. 4.13: Shedding of GnTV GxxxG mutants upon KO of SPPL3. Three biological replicates each consisting of three technical
replicates were used for quantifications. All samples were analysed by Western Blot with Calnexin as loading control and endogenous
SPPL3 expression was checked. For each construct, the amount of soluble GnTV (sGnTV) was compared to the total amount of
full-length GnTV in the cells (as in Fig. 4.3). The secretion of GnTV for the control HEK293 cells was set to 1. Mean +/- SD,
unpaired, two-tailed t tests *p<0.05, **p<0.01.
Regarding the cleavage site mutants of GnTV and EXTL3, the results upon SPPL3 KO are
more unexpected, as it appears that a number of mutants are in fact only affected to a minor
effect by the lack of SPPL3 expression. Apart of EXTL3 H48L, the levels of which are
decreased to similarly to WT EXTL3, all other substrates appear to be cleaved by one or more
additional proteases to different extents (Fig. 4.14). Some substrates, like GnTV H31A, H31L
and EXTL3 H48D are partially but not consistently decreased. Meanwhile, other mutants
such as GnTV H31D and EXTL3 H48A remain unaffected by the lack of SPPL3. Efforts to
identify which protease is responsible for the secretion of these mutants were concentrated on
the analysis of the cleavage of EXTL3 H48A, as the cleavage of this mutant was increased by
several fold (Fig. 4.11).
Fig. 4.14: Shedding of histidine mutants of GnTV and EXTL3 upon KO of SPPL3. Three biological replicates each consisting
of three technical replicates were used for quantifications. All samples were analysed by Western Blot with Calnexin as loading
control and endogenous SPPL3 expression was checked. For each construct, the amount of soluble substrate (sGnTV or sEXTL3)
was compared to the total amount of full-length GnTV or EXTL3 in the cells (as in Fig. 4.10 and 4.11). The secretion of GnTV
or EXTL3 for the control HEK293 cells was set to 1. Mean +/- SD, unpaired, two-tailed t test, *p<0.05, **p<0.01, ***p<0.001.
4.1 Results 85
4.1.3.1 Analysis of EXTL3 H48A cleavage
Treating HEK293 cells stably and ectopically expressing either EXTL3 WT or EXTL3 H48A
with either control siRNA or siRNA targeting SPPL3, confirms that the cleavage of EXTL3
H48A is not catalysed by SPPL3. While secretion of EXTL3 WT is significantly decreased
upon SPPL3 knockdown, the secretion of the H48A mutant remains unaffected as expected
from the previous results (Fig. 4.15A).
Fig. 4.15: Cleavage of EXTL3 H48A is SPPL3-independent and can be inhibited by (Z-LL)2-ketone. A. Western blots of
ectopically expressed EXTL3 WT and H48A mutant in HEK293 cells. Levels of soluble EXTL3 (sEXTL3) in the supernatant and
the full-length EXTL3 in the lysate are depicted. Cells were treated with control siRNA (Ctr) and SPPL3 targeting siRNA as
indicated, secretion of EXTL3 H48A remained unaffected. SPPL3 levels serve as a knockdown control and Calnexin as loading
control. B. HEK293 cells ectopically expressing EXTL3 H48A were treated with different inhibitors as indicated. Only (Z-LL)2-
ketone treatment (Z-LL) shows a decrease in EXTL3 H48A secretion. C. HEK293 cells ectopically expressing EXTL3 H48A were
treated with increasing concentrations of (Z-LL)2-ketone as indicated, secretion of sEXTL3 H48A was reduced in a dose-dependent
manner. D. Western blots of ectopically expressed EXTL3 H48A mutant in HEK293 cells treated with siRNA to specifically reduce
the expression of the indicated SPP/SPPL-family members. None of the siRNAs had an effect on the secretion of EXTL3. Calnexin
was used as a loading control.
Trying to determine which protease is responsible for the shedding of EXTL3 H48A, a variety
of inhibitors was tested including bafilomycin, E64, EDTA, pepstatin, MG132, Epoxomycin,
caspase 3, but only 1,3-di-(Ncarboxybenzoyl-L-leucyl-L-leucyl) amino acetone ((Z-LL)2-ketone)
affected EXTL3 H48A secretion (Fig. 4.15B). (Z-LL)2-ketone reduced secretion of EXTL3
H48A in a dose-dependent manner showing strong inhibition from a low dose (Fig. 4.15C).
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This inhibitor is known to inhibit SPP and SPPL2a/b, however knockdown of any of the three
proteases by specific siRNA did not affect secretion of EXTL3 H48A (Fig. 4.15D). Further
testing will be needed to identify the protease responsible for this cleavage.
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4.2 Discussion
This study demonstrates that SPPL3 substrate cleavage is sensitive to single amino acid
mutations in the predicted TMD and juxtamembrane domain (JMD) of the substrate.
However, despite the fact that such mutations can increase or reduce the cleavage of the
substrates by SPPL3, no specific region or amino acid has been found so far to be
indispensable for substrate processing. In other words, it was so far impossible to turn a
SPPL3 substrate into a non-substrate.
The cleavage mechanism of intramembrane cleaving proteases is a subject of numerous
studies (Ye et al. 2000a, Lemberg and Martoglio 2002, Lemberg et al. 2005, Martin et al.
2008, Martin et al. 2009, Fukumori et al. 2010, Fluhrer et al. 2012, Zoll et al. 2014, Huttl et
al. 2016). This is not only because intramembrane cleaving proteases are involved in
numerous physiological and pathological processes, but mainly because they seem not to
follow the “rules” of classical proteolysis. “Classical” proteolysis is considered to take place
under hydrophilic conditions and is catalysed by soluble proteases. Under these conditions, it
has been shown that in order for substrates to be processed they need to present their
cleavage site as an extended β-strand conformation for the protease to bind and cleave
(Tyndall et al. 2005). At the same time, α-helical structures are well “protected” from the
proteases (Madala et al. 2010). However, intramembrane cleaving proteases are not only
capable of cleaving their substrates in a hydrophobic environment, but it is well accepted that
the TMDs of the substrates adapt an energetically favourable, α-helical conformation within
the lipid bilayer (Popot and Engelman 2000). Due to proteases requirement for a β-strand to
bind to their substrates, it is presumed that in most cases, in order to facilitate processing by
intramembrane proteases, the substrates’ TMDs need to have a lower α-helical-content than
would be normally expected for a TM region. Lowering the α-helical stability can be achieved
through the presence of α-helix-destabilizing amino acids, glycine, proline, aspragine and
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serine (Li and Deber 1994, Madala et al. 2010). Results in favor of this hypothesis have
already been published regarding SPPL2b, SPP, S2P and rhomboids (Ye et al. 2000a,
Lemberg and Martoglio 2002, Urban and Freeman 2003, Akiyama and Maegawa 2007, Fluhrer
et al. 2012).
The model substrate of SPPL3 chosen in this study, GnTV, comprises two
α-helix-destabilising glycines within its TMD (Fig. 4.1). It is interesting to point that the
arrangement of these glycines is in a “GxxxG” motif, which has previously been seen in a
SPPL2b substrate (Bri2) and in numerous γ-secretase substrates, including the best-studied
substrate, APP (Eggert et al. 2009, Fluhrer et al. 2012, Sykes et al. 2012). The GxxxG motif
within the TMD has been shown for APP to facilitate dimerization of TMDs (Munter et al.
2007), so far however, there have been no indications suggesting the dimerization of GnTV
through this motif or a preference of SPPL3 towards cleaving homodimeric substrates.
Bearing that in mind, only the α-helix-destabilising properties of the glycine were taken under
consideration.
Reducing the α-helical-capacity of GnTV’s TMD even further by mutating either of the two
glycines to prolines does indeed increase the secretion of GnTV (Fig. 4.1, 4.3C). However,
exchanging both glycines to prolines impaired the maturation and consequently the secretion
of GnTV. The double proline mutant is most likely degraded due to high destabilisation of the
construct’s TMD caused by the prolines. As only fully matured GnTV is cleaved by SPPL3,
the cleavage of the GnTV PP mutant is practically absent (Fig. 4.3C) and was thus, not
taken into consideration.
Interestingly, the results deriving from stabilisation of the TM α-helix by mutating the glycines
to alanines or leucines are variable and do not all appear to completely agree with the
hypothesis of reducing cleavability of the substrate. The effect of the alanines appears to be
as expected, but only very mild and only simultaneous mutation of both glycines induces a
small (15-20%) but significant reduction on GnTV secretion (Fig. 4.3A).
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The α-helix stabilisation achieved by alanine is inferior to that achieved by leucine, which
would imply that the glycine to leucine mutants should show a more striking decrease in
GnTV shedding. While mutation of the first glycine to leucine achieves a significant 30%
reduction of GnTV secretion, mutating the glycine in the second position causes an increase of
secretion by 20%. Even more unexpectedly, mutating both glycines to leucines simultaneously
does not balance-out their contribution but further increases GnTV secretion by 50% in total
(Fig. 4.3B). Leucines are expected to form a perfect α-helix within the TMD so our initial
hypothesis that stabilisation of the α-helix would hinder shedding seems incomplete.
CD spectroscopy of Bri2 substrate in lipid vesicles had shown that the glycines within the
GxxxG motif, as well as one further C-terminally glycine, were not important for
α-helix-destabilisation and cleavage of Bri2 by SPPL2b. However, a glycine at the N-terminus
of Bri2’s TMD (G60) was responsible for the destabilization of the α-helix and determined the
cleavability of the substrate (Fluhrer et al. 2012). It is possible that like for Bri2, the two
glycines in position 22 and 26 of GnTV do not have such a strong effect in the α-helical
conformation of the TMD. The GnTV TMD also contains an additional glycine in position 15,
however, this is only the second amino acid of GnTV’s predicted TMD, as opposed to the
glycine G60 of Bri2 that holds position 6 within the Bri2 TMD (Fig. 4.1). GnTV’s G15 was
thought less likely to affect cleavage by SPPL3 and was thus omitted from the analysis so far.
A CD spectroscopy study of the conformation of GnTV’s TMD along with mutations of G15
could provide crucial information in determining which of the glycines are responsible for the
helical instability of the TMD.
Another hypothesis is connected to SPPL3’s resemblance of the rhomboids, given its ability to
cleave full-length substrates without requiring previous shedding of the ectodomain (Voss et
al. 2014a). Similarly to rhomboids, SPPL3 might also need to recognise a rigid α-helix at one
part of the substrate (recognition site), in order to cleave at the cleavage site at a different
part of the substrate (Strisovsky et al. 2009). So far, there have been no indications, for the
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existence of a “consensus” sequence in SPPL3 substrates, however it would still be possible
that SPPL3 follows some of the rules related to rhomboid cleavage.
Although this hypothesis would not agree with the increased shedding observed upon
destabilisation of the α-helix with prolines, it is very well imaginable that the shedding of the
proline and the leucine mutants takes place at a different cleavage site. Following the idea of
a potential shift of the cleavage site in some of the mutants, GnTV already contains a LxxxL
motif in its TMD (L14, L18), as does also EXTL3 (Fig. 4.9). It may be possible that SPPL3
can recognise the LxxxL motif and cleave about 15 amino acids C-terminally of this motif. By
replacing the two glycines with leucines, a new LxxxL site is created that could potentially
shift SPPL3 cleavage towards the juxtamembrane region where the conditions are more
hydrophilic and could account for an increased shedding. Mass spectrometry analysis could be
used in order to analyse the cleavage sites of mutated GnTV similarly to the analysis
performed by Kuhn et al. (Kuhn et al. 2015). For the cleavage of APP by γ-secretase, it is
known that mutations in the TMD of APP close to presenilin’s cleavage site can be a cause of
FAD. The exact way these mutations can affect the processing by the protease is not fully
understood but it appears that they can shift the sequential cleavage of C99 to a more
pathological product line (Chavez-Gutierrez et al. 2012, Weggen and Beher 2012).
Intracellular stainings of the G to A mutants suggest that their localisation has not changed
compared to WT GnTV (Fig. 4.4). Despite the localisation of the other mutants not having
been analysed yet, the shedding of WT GnTV, as well as all the GxxxG mutants is
significantly decreased in SPPL3 KO cells (Fig. 4.13). All these data together suggest that
SPPL3 is still capable of cleaving these substrates to a great extent. Since SPPL3 is capable
of cleaving a wide variety of glycosidases and glycosyltransferases, complete lack of this
processing would have a detrimental effect on the organism. Thus, it is expected that other
proteases are also capable of cleaving these substrates, though possibly to a lesser extent. It
has already been shown for instance for some sialyltransferases that BACE1 is capable of
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cleaving these enzymes leading to their secretion (Kitazume et al. 2005, Kitazume et al.
2006, Kuhn et al. 2012). Due to this, the remaining secretion of GnTV upon SPPL3 KO is
not surprising and can most likely be attributed to another protease. However, the preference
of each protease for the substrate might be affected by slight changes in the amino acid
sequence like those introduced in this study. Interestingly, the G to L mutants that behaved
most unexpectedly in regards to their shedding (GL and LL, Fig. 4.3) seem to be less sensitive
to the SPPL3 absence (Fig. 4.13).
Another important part of the amino acid sequence of a substrate is the cleavage site. For
rhomboids, extensive analysis has shown that these proteases have numerous preferences
regarding the cleavage site. These preferences include the cleavage taking place directly after
a small amino acid (position P1), while being flanked on both sides (P4 and P2’) by large
hydrophobic amino acids (Akiyama and Maegawa 2007). For γ-secretase, it is seen that the
size of the amino acids surrounding the cleavage site is of importance as they might interfere
with the fitting of the substrate in the enzyme’s pockets. Such interferences can shift the
product line of Aβ (Bolduc et al. 2016). To explore such possibilities regarding SPPL3,
mutations were designed surrounding the cleavage site that has been previously identified
(Voss et al. 2014a) (Fig. 4.5). Remarkably, the sequence -LLHF-, directly C-terminally of
GnTV’s cleavage site, is shared between GnTV and TNFα, a substrate of SPPL2a/b (Fluhrer
et al. 2006).
However, the majority of the mutations introduced in GnTV either do not alter shedding or
cause an increase in shedding. It is interesting to note that the running behaviour of sGnTV
of the different cleavage-site mutants is altered (Fig. 4.6). This could be attributed either to
changes in the glycosylation of GnTV mutants or to shifting of the cleavage site for the
mutants resulting to a longer or shorter soluble peptide. Efforts to determine the exact
cleavage site of the mutants have not been fruitful so far and this point would need to be
further investigated. Only one position (H31, P3’) appears to have a negative correlation with
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the processing of GnTV (Fig. 4.6, 4.7). Taking into account that histidine is most likely
charged at the pH of the Golgi and that EXTL3, another substrate of SPPL3 of which the
cleavage site is still unknown, also has a histidine in a similar part of the TMD, further
experiments were focused on that amino acid. To this end, additional mutations were
designed to explore the effect of charge and α-helical-stability at this position. To assess the
role of charge, a different positively charged amino acid was introduced (arginine, R), as well
as a negatively charged (aspartic acid, D). In order to stabilise the α-helix around the cleavage
point an alanine or a leucine was introduced (Fig. 4.9).
Mutating the histidine at the border of the GnTV TMD to alanine or leucine should increase
the α-helical-stability and maybe extend the TMD. Although the initial hypothesis was that
the histidine could play the same role in both substrates, the results of the mutations on
GnTV and EXTL3 appear quite different (Fig. 4.10, 4.11). Alanine and leucine both
significantly decrease cleavage of GnTV as it would be expected by a more rigid α-helix at the
cleavage site, however they only cause a 30% decrease (Fig. 4.10). On the contrary, the
leucine mutation has no effect on EXTL3 secretion, while the alanine mutation increases
shedding of EXTL3 by 6-fold. Exchanging histidine for a different positively charged amino
acid, arginine, causes a non-significant increase in cleavage of GnTV but a significant decrease
in EXTL3 cleavage. However, what these two substrates seem to have in common is that
cleavage of both is increased when the positive charge is replaced by a negatively charged
aspartic acid (Fig. 4.10, 4.11). It is important to note here that the TMD neither of GnTV
nor of EXTL3 have been properly investigated. All assumptions for the exact location of the
histidine within the two TMDs are based on predictions and could be problematic. If the
location of the histidine in the TMD significantly differs for the two substrates, it could
account for the differences we see on the processing of the mutants.
Although, the subcellular localisation of the alanine mutants of GnTV does not seem to
change (Fig. 4.8), interestingly, secretion of all but one of the mutations targeting the
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cleavage site in both substrates appeared to be less dependent on SPPL3 than the secretion
of both WT substrates (Fig. 4.14). In the search for the protease responsible for cleaving the
mutants, EXTL3 H48A was further analysed.
Shedding of EXTL3 H48A appears to be SPPL3-independent but sensitive to treatment with
(Z-LL)2-ketone (Fig. 4.15A-C). It is known that this inhibitor targets substrate processing by
SPP, SPPL2a and SPPL2b, but has no effect on SPPL3 or γ-secretase (Mentrup et al.
2017b). Efforts to identify the protease responsible for the cleavage have been not successful
so far, as knockdown of SPP or SPPL2a or SPPL2b did not seem to have any effect on the
cleavage of EXTL3 H48A (Fig. 4.15D).
Further work will be needed to determine the responsible protease and a wide range of
inhibitors, as well as rhomboid inhibitors might help determine the mysterious protease.
Identifying the cleavage site of EXTL3 WT and possibly of all the mutants would prove of
great help for better interpreting these results.
The fact that the results of all these mutations do not seem to come to a strong conclusion
most probably points to the lack of specific substrate requirements and a consensus-sequence
in SPPL3 substrates. Instead, small changes affecting the α-helical-stability can make a
substrate more or less efficiently cleaved without, however, turning it into a “non-substrate”.
Two main obstacles exist currently that prohibit us from better understanding how SPPL3
selects its substrates. The first is the lack of an in vitro assay, such as the one existing for
γ-secretase (Edbauer et al. 2003), that would eliminate effects of other proteases and
missorting of substrates. The second is the absence of a SPPL3 non-substrate that could be
used to compare differences and similarities between the two proteins as has been done for the
SPPL2b substrate Bri2 and the non-substrate Bri3 (Martin et al. 2009).
Our understanding of substrate selectivity of intramembrane proteases is far from complete.
Even proteases like rhomboids that have numerous prerequisites and substrate requirements,
are capable of cleaving theoretical “non-substrates” when the membrane properties are altered
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(Moin and Urban 2012, Urban and Moin 2014). Regarding SPPL3, all data so far point to
numerous different factors being involved in the substrate specificity without any of them
proving indispensable. Only with further analyses, will we get closer to deciphering substrate
recognition.
5. Indications for SPPL3 in vivo function
To understand thoroughly the SPP/SPPL family in general and SPPL3 in particular, it is
fundamental to study the physiological function of these proteases. This has already been done
extensively for SPPL2a, which was shown to have a role in B lymphocyte development and,
hence, is a possible target to tackle some autoimmune disorders (Beisner et al. 2013, Bergmann
et al. 2013, Schneppenheim et al. 2013, Schneppenheim et al. 2014a, Schneppenheim et al.
2014b, Mentrup et al. 2017b).
5.1 Results
5.1.1 Reproduction of SPPL3 deficient mice
The SPPL3 deficient mouse line was previously established by insertion of a genetrap between
exons 6 and 7 of Sppl3, causing the absence of SPPL3 transcripts and protein in the
homozygous knockout mice (SPPL3-/-) (Tang et al. 2010). These mice were generated in a
mixed background of C57BL/6J and 129S5/SvEvBrd (B6;129S5). Infertility was observed for
male SPPL3-/- mice in the initial analysis (Tang et al. 2010).
5.1.1.1 Reproduction of mixed genetic background SPPL3 deficient mice
Fig. 5.1: Matings of SPPL3 deficient mice in a mixed
background. Graph depicting the results of mating an SPPL3
heterozygous mouse (SPPL3+/-) with an SPPL3 KO mouse
(SPPL3-/-) from the mixed B6;129S5 background, n=8 litters.
On the left side are the expected Mendelian ratios and on the right
side the ratios that resulted after analysing the litters. Orange
bars depict heterozygous mice and red the knockout.
Further analysis of B6;129S5 SPPL3 deficient
mice over the course of several matings (n=8
litters) between heterozygous (SPPL3+/-) and
knockout (SPPL3-/-) mice, did not confirm
infertility of male knockout mice. The litter
size was in average 8.4 pups per litter, however
3.3 pups were in average born dead in each
litter. The Mendelian ratios of the alive
progeny of these matings were analysed and
were found to be altered. According to the
Mendelian principles, mating between a +/- animal and a -/- animal should give a 50:50 ratio
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of +/- and -/- offspring. However, in the case of SPPL3 deficient mice, only 20% of the
offspring where knockout (SPPL3-/-), while 80% were heterozygous (SPPL3+/-) (Fig. 5.1).
5.1.1.2 Reproduction of pure genetic background SPPL3 deficient mice
The B6;129S5 SPPL3 deficient mouse line was also crossed back over 10 generations to
C57BL/6J (Voss 2014) and to 126S6 background (129S5 is not available anymore). The
Fig. 5.2: Matings of SPPL3 heterozygous C57BL/6J mice.
Matings of SPPL3 heterozygous C57BL/6J mice. Graph
depicting the results of mating two SPPL3 heterozygous mice
(SPPL3+/-) of the pure C57BL/6J background, n=18 litters. On
the left side, the expected Mendelian ratios are depicted and on
the right side the actual ratios that resulted after analysing the
litters. Green bars depict wildtype mice, orange heterozygous and
red knockout. The red bar with the black lines symbolizes KO
pups that were found dead shortly after birth.
matings of SPPL3 heterozygous C57BL/6J
mice were analysed. The average number
of pups per litter of n=18 litters were
6.1 and in average 1.5 were born dead.
According to Mendelian ratios, mating of
two heterozygous animals (+/- x +/-)
should give a ratio of 25:50:25 of wildtype
(+/+), heterozygous (+/-) and knockout
(-/-) animals, respectively. However, the
progenies from SPPL3+/- C57BL/6J litters
consisted of 30-35% wildtype mice, 60-65%
heterozygous and only approximately 5%
stillborn knockout mice (Fig. 5.2). In the 129S6 background, some knockout animals survived
after birth the number is extremely low and still require further analysis (data not shown).
5.1.2 SPPL3 deficient mice are characterised by a reduced weight
phenotype
Already following the initial characterisation of SPPL3 deficient mice by Tang et al., it was
observed that both male and female knockout animals displayed delays in their growth
characterised by reduced weight and size compared to their wildtype littermates (Tang et al.
2010). To investigate this point, the growth of wildtype and knockout littermates was
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followed by regular weighing between the ages of 8 and 40 weeks. Separate groups consisting
of either males or females were weighed weekly, however, due to technical limitations, breeding
ratios and dropouts of some animals due to disease etc, the numbers of animals measured for
each time point/gender/genotype vary from 2 to 7. Nevertheless, the vast majority of
measurements for wildtype and knockout animals included 3 or more mice allowing for
statistical calculations. Both male and female SPPL3 knockout animals demonstrated reduced
Fig. 5.3: Weight progression of SPPL3 deficient mice and littermates. A. Graph depicting the weights of SPPL3 KO mice (red)
and wildtype littermates (green) for both female and male mice (left and right, respectively). The weight was measured biweekly
and the n numbers varied from n=2-8 for each gender. 2-way ANOVA test with multiple comparisons and Sidak correction was
used to calculate the statistics of time points with n≥3, *p<0.05, **p<0.01 ***p<0.001 B. Graphs depicting the same WT mice
as in A but comparing them to the measurements from heterozygous mice (orange).
weight at the initial measurement at an age of 8 weeks compared to their wildtype littermates.
This difference in weight appeared to increase with age, as the wildtype animals continued
gaining weight up to the end of the measurement period (40 weeks of age), while the
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knockout littermates stopped gaining weight between 24 and 30 weeks of age (Fig. 5.3 A).
The reduced weight phenotype had a complete penetrance, as all the knockout animals were
smaller and lighter than their littermates. Additionally, the phenotype remained consistent
following embryo-transfer to a new animal facility. The weight of heterozygous animals tended
to be between that of wildtype and knockout littermates. All over, heterozygous animals were
never as thin as the knockout mice, but overweighed the wildtype in some cases (Fig. 5.3 B).
Fig. 5.4: Food consumption of mice during metabolic cage
measurements. All mice were placed in the cages on day 1 until
day 5 and the remaining food was measured at the beginning
and end of each day (24h). The average daily consumption is
depicted in this graph (Mean +SD) of the four days measured.
In order to determine whether the reduced
weight of the wildtype was due to a
decreased appetite and food consumption,
metabolic cages were used. Food and
water intake, as well as secretions of two
knockout mice were followed for five days in
metabolic cages, together with heterozygous
and wildtype littermate controls. During
this period, the knockout animals did not
consume significantly different amounts of
food than their littermate controls (Fig. 5.4)
and secretions were in a similar range between all mice (data not shown).
5.1.2.1 SPPL3 deficient mice have reduced adipose tissue
To unravel the reason for the reduced weight phenotype of the SPPL3 deficient mice more
precisely, it is important to understand whether it is caused by an overall smaller size of the
mouse or by reduction of a specific tissue/organ. Visual inspection of the mice during sacrifice
for organ collection revealed reduced adipose tissue in at least three adipose deposits. In
knockout mice, visceral fat was severely reduced to almost non-existant, subcutaneous fat
was almost absent and the adipose layer surrounding the kidneys and the genitals was greatly
reduced compared to wildtype mice (data not shown). Prompted by these observations, further
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tissue analysis was planned for these mice.
Fig. 5.5: Detailed analysis of body weight of SPPL3 deficient mice and littermate controls. A. Four graphs depicting the results
of the total weight and organ weight from 4 pairs of age and gender matched littermate mice. Each organ’s weight is depicted
in either g or mg, as indicated. B. The weight difference for each organ/tissue was calculated for each mouse pair and the mean
value +/- SD for all pairs is depicted. C. The percentage of adipose fat was calculated compared to the total weight for each
mouse and is depicted per pair. D. The mean of "adipose to total weight" percentage was calculated per genotype, mean + SD.
Unpaired, two-tailed t test, *p<0.05, n=4 WT and 4 KO. WTs are depicted in green and KOs in red.
To this end, 4 pairs of age and gender matched mice were analysed at the Veterinary Clinic of
Munich by Dr. Nadja Herbach. Each pair consisted of one wildtype and one knockout mouse
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from the same litter. The mice were approximately one year of age when they were analysed.
The total weight of the mice was analysed, as well as the specific weight of a number of organs,
namely abdominal fat, intestines, liver, kidneys, spleen, pancreas, heart and lungs. The graphs
depict all measurements for each mouse in the matched pairs (Fig. 5.5 A).
In all four pairs, regardless of age or gender, the KO mouse is clearly weighing less than the
wildtype littermate. Interestingly, the most notable difference in weight between each pair was
mainly due to reduced abdominal fat, while other organs such as kidneys, spleen and heart were
not reduced in size. This observation became more apparent when the difference in weight
for each organ/tissue was calculated between each pair of mice (KO-WT) and the mean of all
those differences is depicted in Fig. 5.5 B (mean +/- SD). It is clear that the only tissue that is
consistently and significantly decreased in the knockout mice is the abdominal adipose tissue.
In order to confirm that the reduction in adipose tissue is not solely due to a smaller mouse
size, the percentage of fat was calculated for each mouse compared to the total body weight of
that mouse (Fig. 5.5 C). The "adipose to total weight" percentage of each mouse was taken
into account when calculating the average for each genotype. There is a significant difference
between wildtype and knockout mice, with the knockout mice having significantly less adipose
tissue even when the total weight is taken into consideration (Fig. 5.5 D). All results from
these measurements point to an effect of SPPL3 on the generation and/or storage of adipose
tissue.
5.1.3 Generation of SPPL3 knockout Stem Cells Lines
Due to the troublesome breeding of the SPPL3 deficient mice and the complexity of studying
the accumulation of adipose tissue in the mouse, we considered establishing an SPPL3
knockout stem cell line as a useful tool for further investigation. For this purpose, E14 stem
cells (ESCs) were used and were subjected to CRISPR/Cas9 genome editing. Using two
commercially available gRNA constructs, three single cell knockout clones that completely
lack SPPL3 expression were successfully generated. The first gRNA targeted the second exon
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Fig. 5.6: Genomic, mRNA and amino acid sequence of SPPL3 KO stem cells. Three different SPPL3 knockout (KO) stem cells
clones are shown. For each clone first the comparison of the wildtype mouse Sppl3 genomic DNA with that of the KO clone is
depicted confirming the presence of homozygous mutations. Below, for each clone the mRNA sequence following the deletions and
the amino acid sequence it would code for is given. In all three clones, an early stop-codon is generated as indicated by red arrows.
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of Sppl3 and the second gRNA targeted exon 3. Following single cell sorting and analysis of
the genome of a number of clones, three SPPL3 KO clones were selected (3.2.2.2.2). One
clone was treated with gRNA1 (27), while two clones were treated with gRNA2 (38, 40). All
three clones had homozygous deletions close to the binding position of the gRNA and in all
cases, these deletions lead to an early stop codon in the SPPL3 mRNA (Fig. 5.6).
Fig. 5.7: Nicastrin glycosylation in
SPPL3 KO ESCs. As expected, protein
levels of SPPL3 are only detectable in
the WT ESCs. The upper blot depicts
both mature and immature Nicastrin.
Calnexin was used as a loading control.
Similar to MEF cells, ES cells can handle the absence of SPPL3
without any visible difficulties and appear morphologically similar
to their wildtype source (data not shown). Western Blot
analysis of the SPPL3 protein levels confirmed the absence of
the protein in all three clones compared to the WT ESCs (Fig.
5.7). As mentioned before (1.3.2.4.4), SPPL3 is capable of
reducing active glycosidases and glycosyltransferases within the
cell via proteolytic removal of their active site. According to
that, a hyperglycosylation of certain glycoproteins is expected
in SPPL3 KO ESCs. Indeed, the glycoprotein Nicastrin is
hyperglycosylated in the KO cells compared to the control, confirming a reduction in SPPL3
levels (Fig. 5.7).
5.1.3.1 Differentiation of ESCs to adipocytes
Following the protocol published by Cuaranta-Monroy et al. (Cuaranta-Monroy et al. 2014),
stem cells were differentiated to adipocytes over a period of 27 days. Due to the complexity
of this procedure, only the wildtype and one KO clone (27) were used. Stem cells cultured to
confluency were treated with a variety of growth factors and reagents including ascorbic acid,
retinoic acid, dexamethasone, insulin and others (3.2.2.2.3). Light microscopy and Oil Red
Stainings were used to assess the success of differentiation. With light microscopy, colonies of
adipocytes were identified based on their gross morphology (Fig. 5.8 A). Oil Red stains the lipid
content of adipocytes, while at the same time the cell nuclei were stained blue by hematoxylin
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(Fig. 5.8 B). Both techniques showed a severely reduced number and size of adipocytic colonies
in the KO cells compared to the WT controls (Fig. 5.8). However, despite the reduced number
and size of colonies, the size of the adipocytic cells appeared similar in both WT and KO ESCs.
Fig. 5.8: Differentiation of ESCs to adipocytes. A. Wildtype stem cells (ES WT) and SPPL3 knockout stem cell clone 27
(ES 27) were differentiated to adipocytes for 27 days and then visualised by light microscopy. On the left hand side some of the
biggest colonies are shown for each cell line, in the middle the smallest WT and average ES 27 colonies and on the right, a higher
magnification is included. B. Oil Red Staining of the differentiated cells. On the left side one cover slip for each cell line of 1cm
diameter is depicted and on the right a higher magnification of a selected area with adipocytes. Red staining is indicative for the
present of adipocytes due to the staining of their lipids.
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5.1.4 SPPL3 deficient mice demonstrate age-dependent motor
deficiency
The motor coordination abilities of SPPL3 deficient mice were compared to that of wildtype and
heterozygous littermate controls with the use of a Rotarod Performance Test. The ability and
endurance of the mice was tested while walking on a rotating beam, the rotation speed of which
was steadily increasing with time. The time each mouse spends on the beam before falling is
indicative of the balance, grip strength and motor coordination of the mouse. Untrained mice
had three-four sessions, each consisting of three trials for each littermate group, with 15 minutes
of break in between (3.2.6.2).
Due to breeding limitations, only a small number of mice was available for participating in this
study. Two different age groups were tested, one consisting of mice that were older than one
year at the time of the first session (55 weeks) and one consisting of mice that were 5-6 months
old at the first session. Each group, comprised one mouse of each gender and each genotype,
however, one mouse was not willing to participate in the test and was excluded. Looking at the
average of all sessions for each mouse, it is clear that in the older mice, the knockout animals
have an overall weaker performance compared to their heterozygous and wildtype littermates
(Fig. 5.9 A). The same analysis of the younger mice revealed a very high variation in the
performance of all mice and especially the knockout animals (Fig. 5.9 B).
The performance of each mouse in each of the sessions was also analysed to observe any
learning abilities or physical deterioration. The results of the old mice indicate that although
the knockout animals in both genders were the weakest performers, there was some ability to
learn and improve their performance similarly to the wildtype (Fig. 5.9 C). Regarding the group
of younger mice, the performance of all three genotypes, but especially of the knockout seems
to be deteriorating as they approach one year of life, to levels similar to the older mice (Fig.
5.9 D).
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Despite the fact that the n numbers in the rotarod analysis are extremely low, one additional
phenotypic characterisation that supports a motor deficiency is the hindlimb clasping response.
The mice were gently lifted by their tails and their response to spread or clasp their hind legs
was observed for 10 seconds. A grade of 0 was given for completely stretched legs, if one
limb showed tendencies to clasp for more than 5 sec it was graded with 1, if both limbs were
retracted for more than 5 sec it was marked with 2 and if both limbs were completely retracted
and clasping for more than 5 sec it was ranked a 3 (Guyenet et al. 2010). Wildtype and
heterozygous animals were always graded with 0, while knockout animals had an average of 2.5
scoring always between 2 and 3.
Fig. 5.9: Rotarod performance test. A, B. Graphs depicting the average performance of SPPL3 deficient mice and their littermates
in the rotarod test measured in seconds. Graph A summarises mice above 1 year of age at the first session, while in B mice under
one year of age at the first session are shown. The bars depict the mean of all trials +/- SD, while the single performances are
visualized by circles C, D. Graphs depicting the average of three trials for each session for each mouse +/- SD. Wildtype mice are
always depicted in green, heterozygous in orange and knockout in red.
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5.2 Discussion
Despite the lack of SPPL3 homologues in single-cell organisms, all multi-cellular organisms
comprise an SPPL3 homologue. Even more interestingly, the degree of conservation in the
amino acid sequence of SPPL3 between the various organisms suggests SPPL3 must have a
crucial physiological role (Voss et al. 2013). Presence of an almost identical protein in all
metazoan suggests its necessity for the successful survival and reproduction of the organism.
In agreement with these indications, the SPPL3 deficient mouse line that was created in a
mixed B6;129S5 background, fails to reproduce with Mendelian ratios. In contrast to a
previous study where infertility of male SPPL3-/- mice was reported (Tang et al. 2010), we
found both male and female knockout mice capable of breeding but with an increased
mortality rate in the pups. However, the percentage of knockout progeny when mating a
knockout and a heterozygous animal is 20% instead of the expected 50% (Fig. 5.1). Even
more striking is the effect of the SPPL3 deficiency in a pure genetic background. B6;129S5
SPPL3-/- mice are not viable (Fig. 5.2).
It was previously postulated that the C57BL/6 background might be less capable to adjust to
the lack of SPPL3 due to the mouse line’s inbreeding factor. At the same time, it was
thought that the 129S5 background might harbour protective characteristics, so this could
explain why the SPPL3 deficient mice survive in a mixed background (Voss 2014). Following
this notion, the B6;129S5 mouse line was crossed for 10 generations with 129S6 mice
(successor of 129S5 mouse line that is no longer available). Analysis of this mouse line is
ongoing only for approximately 6 months and only two SPPL3-/- mice have arisen from the
matings indicating a persistent phenotype with progeny numbers too low to investigate the
phenotype in depth (data not shown).
Based on the current results, it appears that SPPL3 deficiency can be best tolerated only in a
mixed background and in order to achieve more in depth analysis of the phenotype in a
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reproducible background, a conditional knockout mouse line is needed. The observation that a
protein deficiency can be differently tolerated based on the genetic background of the mouse
line has been seen before. However, what makes it more interesting is that background
dependency is often seen in mouse-lines with complex N-glycosylation deficiencies. Such
background dependent phenotype severity is seen for instance in both Mgat2 and Mgat5
deficient mice (Wang et al. 2001, Dennis et al. 2002, Lee et al. 2012).
It has been already shown and also further investigated in this study that SPPL3 can cleave
glycosyltransferases reducing their activity inside the cell (Voss et al. 2014a, Kuhn et al.
2015). A previous study, has already shown that SPPL3 absence in vivo reproduces the effects
observed in cells and causes hyperglycosylation of glycoproteins due to reduced shedding, and
thus accumulation of active glycan-modifying enzymes (Voss et al. 2014a). Given this
connection between GnTV (encoded by Mgat5) and SPPL3, SPPL3 deficiency would be
expected to mimic an over-expression model of GnTV and other glycosyltransferases, and not
the knockout in vivo models.
However, one characteristic that is common in both SPPL3 and Mgat5 deficient mice is the
lack of soluble GnTV, due to the lack of cleavage in absence of SPPL3 and due to the
complete lack of GnTV, respectively. The presence of soluble glycosyltransferases in bodily
fluids is already known since the early 1980s (Beyer et al. 1981) and it was soon understood
that they derive via proteolytic cleavage of the membrane spanning intracellular forms
(Lammers and Jamieson 1989, Paulson and Colley 1989). It has also been shown that
proteolytic release of glycosyltransferases is a dynamic process that can take place as a
response to certain stimuli. For instance, conditions that cause hepatopathological liver
inflammation induce the release of soluble ST6GalI in the acute response stage (Kitazume et
al. 2009). Despite these results suggesting specific functions of soluble glycosyltransferases, it
remains unclear what these functions really are (Saito et al. 2002, Varki et al. 2009). A
possible explanation why the SPPL3 deficient mice mimic parts of the phenotype of the
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Mgat5 deficient mice would be the disturbance of the function of secreted GnTV, which in
turn accounts for some of the phenotype similarities observed. Alternatively, it is known that a
very tight regulation of glycosylation is required for optimal function of the organism.
Possibly, the disruption of a glycoprotein’s function either by hyper- or hypo-glycosylation,
could lead to the same phenotype in vivo. However, rigorous experimentation will be needed
to discover possible connections between these two mouse models.
In C57BL/6 background, very few SPPL3 deficient mice surpass the embryonic stages and
even those were found dead shortly after birth (Fig. 5.2). The small size of the litters
suggests that embryo resorption takes place during pregnancy. Efforts to analyse the reason of
embryonic/post-natal death of SPPL3 deficient mice remain so far unsuccessful due to the
high variability in the stage that miscarriage or death occurs.
The physical abilities of the SPPL3 deficient mice also seem to be affected and they
deteriorate with aging. Trembling and peculiarities during walking were often observed (data
not shown). This prompted us to use a rotarod performance test and also assess the hindlimb
clasping tendency of the knockout mice. Hindlimb clasping is a marker of motor neuron
deficiency and cerebellar ataxia (Chou et al. 2008) and while the wildtype mice had
consistently a score of zero, knockout mice had an average of 2.5 according to a published
scoring system (Guyenet et al. 2010) (5.1.6). Their performances on the rotarod were more
variable and a higher n-number will be needed to analyse this phenotype in depth, however, a
tendency for knockout animals to perform more poorly especially at an older age was observed
(Fig. 5.9). It is unclear if the reason is of neurological or a musculature source. For Mgat5
deficient mice, reduced muscle satellite cells, osteogenic activity and an early aging phenotype
has been reported. If we assume there is some connection between these two deficiencies, this
could also explain why the SPPL3 deficient mice look and perform better at a younger age
and deteriorate faster with age (Cheung et al. 2007).
The most reproducible characteristic observed in all SPPL3-/- mice regardless of gender, age
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or animal facility is their reduced weight phenotype. Both male and female mice have a
consistently lower body weight as compared to wildtype animals of the same age. Regular
weighing has revealed that the difference is already present shortly after birth and tends to
increase with age (Fig. 5.3A). Heterozygous animals of the same age seem unaffected by the
lack of one SPPL3 allele as their weight is comparable to that of WT mice and sometimes
exceeds it (Fig. 5.3B). Analysis of different tissues and organs in wildtype and knockout mice
revealed that although most organs were of comparable size, abdominal fat was significantly
reduced in all knockout animals (Fig. 5.5A, B). To correct for a potential smaller body size of
the knockout mice, the percentage of abdominal fat compared to the total mouse weight was
calculated. Even considering this, the knockout animals had approximately one third to half
the percentage of abdominal fat of the wildtype (Fig. 5.5C).
One point that needs further investigation and was only briefly addressed in this study is
whether the reason for the reduced weight is behavioural. To answer the question whether the
knockout animals consume less food than the wildtype, six mice (one of each genotype for
each gender) were placed in metabolic cages for five days, however, the knockout mice did not
appear to consume less food than their littermates (Fig. 5.4). To confirm these results, the
metabolic cage experiment should be repeated with a higher n-number and additionally the
energy consumptions in form of exercise could be taken into account. Interestingly, GnTV
knockout mice are also characterised by a lean phenotype, however it only appears after a
high-fat diet, as they are resistant to weight gain (Cheung et al. 2007).
The defective reproduction of SPPL3 deficient mice poses as an obstacle for the further
analysis of the reduced adipose phenotype of the mice and for discovering the molecular
mechanism behind this phenotype. To this end, we opted for a simpler but at the same time
very potent tool to further study this aspect. Using the CRISPR/Cas9 technology, SPPL3
deficient embryonic stem cell lines were generated (Fig. 5.6). All three single cell clones that
were generated kept the hyperglycosylation phenotype that has already been seen in cells
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(HEK293, MEF) and in mice (Fig. 5.7) (Voss et al. 2014a).
Following existing protocols, wildtype and one SPPL3 deficient ES cell line were differentiated
into adipocytes (Cuaranta-Monroy et al. 2014). It was clear in both the size and the number
of colonies that the knockout cells differentiated less efficiently than the wildtype cells (Fig.
5.8). These results are very exciting because similarly to the phenotype observed in SPPL3-/-
mice, adipose cells are not completely absent, but their number is strongly decreased
compared to control cells. Although these results are very interesting as they would perfectly
mimic the in vivo phenotype, they need to be considered with caution since they remain
preliminary. Additional repetitions including the other ES clones would be needed to confirm
the results and exclude off-target effects of the genetic manipulation. Another point that
needs to be further investigated is whether the differentiation into adipocytes is per se failing
or whether adipocytes are formed but are not capable of storing lipids and were thus, not
stained by the Oil Red staining (Fig. 5.8B). This could be analysed by checking the expression
of various differentiation markers as performed in Cuaranta-Monroy et al. 2014.
As ES cells are pluripotent and can be differentiated into numerous cells lines, it would be of
value to investigate their differentiation efficiency into other cell lines. Cell types from all
three embryonic germ layers could be tried. As adipocytes derive from the mesodermal germ
layer, another cell type that can be easily tried from the same layer are cardiomyocytes (van
den Berg et al. 2016). For the ectoderm, neuronal cells would be a feasible option
(Wongpaiboonwattana and Stavridis 2015) and for the endoderm, hepatocytes (Zhou et al.
2010). These experiments could help us understand if SPPL3 holds a key role specifically in
adipocyte formation or if there is a general mechanism and differentiation deficiency.
Over a decade ago, the effect of adipose-specific knockout of raptor was analysed in vivo
(Polak et al. 2008). An adipose-specific knockdown of raptor was used in Polak et al. study
as mice lacking raptor in all tissues die during embryonic stages (Guertin et al. 2006). Raptor
is an indispensable component of the mammalian target of rapamycin complex 1 (mTORC1),
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which in turn holds a crucial role in cell growth and metabolism. mTORC1 also has a central
role in development and aging, participating at the same time in the pathology of various
diseases such as cancer, diabetes and obesity. mTORC1 is a protein kinase that
phosphorylates numerous other proteins as its substrates. mTORC1 is controlled by
“external” factors such as insulin, nutrients, growth factors, amino acids and others
(Ben-Sahra and Manning 2017).
The decrease in adipocyte differentiation efficiency reported in Polak et al. highly resembles
the results obtained from the ES cell differentiation (Fig. 5.8). Additionally, raptorad-/- mice
display a lean body phenotype with reduced adipose levels that is very similar to that of
SPPL3-/- mice (Fig. 5.3, 5.5) (Polak et al. 2008). It would be very interesting to investigate
whether metabolic changes observed in the raptorad-/- mice, like increased mitochondrial
respiration, also hold true for the SPPL3 deficiency. Furthermore, unpublished data from AG
Fluhrer that are not part of this study suggest that physiological SPPL3 levels in HEK293
cells can also be regulated by metabolic cues present in the cell culture media, so a further
connection between mTORC1 and SPPL3 might exist. Given the ability of mTOR to affect
also other functions, such as muscle mass and aging, it seems crucial to investigate a
potential link between SPPL3 and the mTOR pathway.
In summary, SPPL3 deficiency in vivo can only be tolerated in a mixed background, without
ever reaching Mendelian ratios in reproduction. In contrast, SPPL3-/- mice display numerous
phenotypes, the most penetrant of which is the reduced presence of adipose tissue. SPPL3
knockout ES cells are being used to mimic the adipose phenotype in a simple model system.
Next step would be to establish connections with potent pathways that could mechanistically
explain this phenotype.
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6. SPPL2c impairs vesicular trafficking
Despite the accumulation of knowledge regarding SPP, SPPL2a, SPPL2b and SPPL3, and the
fact that the SPP/SPPL family has been discovered in 2002 (Grigorenko et al. 2002, Ponting
et al. 2002, Weihofen et al. 2002), the understanding of SPPL2c has not progressed through
the years. Analysis of the glycosylation of ectopically expressed SPPL2c in HEK293 cells points
to the protease being localised in the ER or early Golgi (Friedmann et al. 2004a). However,
in spite of the detection of SPPL2c mRNA in a variety of tissues in the past (Friedmann et
al. 2004a), no endogenous protein levels of SPPL2c have been detected so far, pointing to
a possible false positive result due to the lack of introns in the SPPL2C gene. The lack of
endogenous protein expression and the absence of SPPL2c substrates need to be addressed in
order to increase our understanding of this protease.
6.1 Results
6.1.1 SPPL2C is not a pseudogene
SPPL2C has been believed since its discovery to be a pseudoprotease and a pseudogene lacking
any functional expression (Golde et al. 2009, Voss et al. 2013). However, analysis of testis
samples from humans and mice revealed SPPL2c protein expression (Fig. 6.1A), while SPPL2c
protein levels were only detected in testis and not detected in brain, kidney, spleen, or liver
of Black6 mice (Fig. 6.1B). The specific expression suggests of a functional role of SPPL2c
in testis. However, the lack of any identified substrate remained an obstacle in determining
whether SPPL2c is a catalytically active protease and discovering its physiological function.
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Fig. 6.1: SPPL2c is expressed in testis from human and mice. A. Western blot of membrane preparations from HEK293 inducibly
expressing SPPL2c, human and mouse testicular tissue. 2 μg of membrane preparation is loaded for each of the organs and 0.04 μg
of HEK293 cell lysate. B. Western blot of membrane preparations from five different organs of WT Black6 mice, same amounts
of protein were loaded, 10 μg. The asterisk points an unspecific band.
6.1.2 Mass Spectrometric analysis of SPPL2c expressing HEK293
cells
To identify potential SPPL2c substrates, protein label-free quantification (LFQ) mass
spectrometric analysis was used. T-RexTM-293 (HEK293) cells that stably express SPPL2c
under a doxycycline-inducible promoter were compared to control cells with no SPPL2c
expression. 4841 proteins were identified in membrane preparations of each condition by at
least two peptides. 3726 of those proteins were quantified relatively based on at least three of
the six biological replicates of control and SPPL2c expressing cells. These proteins were
subjected to statistical analysis and 917 were altered with a p-value less than 0.05. Finally,
following the false discovery rate (FDR) correction for multiple hypotheses, 451 proteins were
found significantly altered. The changes in the abundance of proteins under the two
conditions are depicted in a volcano plot (Fig. 6.2). As expected, SPPL2c is the most
predominantly increased protein of all, confirming the successful overexpression of the protein
in those cells. Considering that intramembrane cleavage of a substrate, in most cases, leads to
its release from the membrane, any potential SPPL2c substrates are expected to be decreased
upon protease overexpression in membrane preparations. SPP/SPPLs are known to cleave
TM proteins with type-II (and type-IV in the case of SPP) orientation (1.3.2.4.2-4). For this
reason, only the 25 decreased type-II and type-IV TM proteins were considered as potential
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Fig. 6.2: Volcano plot of proteome analysis of SPPL2c expressing HEK293 cells. The negative log10 of the p-value (y-axis) is
plotted versus the log2 LFQ ratio of SPPL2c overexpressing and control cells (x-axis) of each identified protein. A permutation
based FDR correction for multiple hypotheses was applied (p = 0.05; s0 = 0.1; dashed line). Grey open circles indicate non-
significantly altered proteins in SPPL2c expressing cells, red open and filled circles indicate significantly altered proteins after FDR
correction. Filled red circles with red labels indicate type-IV membrane proteins and filled blue circles with red rim and blue labels
indicate type II proteins altered in SPPL2c expressing cells. On the right hand side of the graph, the proteins that were increased
in the samples expressing SPPL2c are depicted and on the left hand side the decreased proteins.
SPPL2c substrates (table 6.1). Regarding the orientation of the proteins, the Uniprot
annotations were taken into account. Two of the most strongly decreased proteins,
cytochrome b5 type A and B, were not annotated as either type-II or type-IV on Uniprot but
were included in the analysis since they appear to have a similar structure to type-IV TM
proteins.
116 6. SPPL2c impairs vesicular trafficking
Table 6.1: Significantly decreased type-II and type-IV TM proteins upon SPPL2c ectopic expression in HEK293 cells. Proteins
are sorted based on their fold change and are manually annotated as type-II or -IV according to their Uniprot profile. Proteins that
have already been linked to SPPL3 as substrates in previous studies are marked in bold (Voss et al. 2014a, Kuhn et al. 2015).
Proteins involved in glycoprotein homeostasis are labelled in italics.
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6.1.3 Pathway analysis of SPPL2c candidate substrates
Fig. 6.3: Pathway analysis of SPPL2c candidate substrates. The online STRING
10.5 software (https://string-db.org/) was used to demonstrate possible networks
of type-II and type-IV membrane proteins significantly decreased in the proteomic
analysis following overexpression of SPPL2c (see Table 1). Each candidate
substrate is represented by a nodule and the interactions are depicted by lines,
the thickness of which indicates the degree of confidence in the prediction of the
interaction.
The 25 proteins that are type-II
or -IV and were decreased upon
SPPL2c expression, making them
potential SPPL2c substrates were
uploaded to the STRING 10.5
software (https://string-db.org/)
to generate a protein-protein
interaction network (Fig. 6.3).
This online software can link
proteins based on their physical
and functional associations
as it draws information from a
number of studies and databases.
Although a number of these
potential substrates do not interact with each other (eg. POMGNT2, ST3GAL6 etc.), there
was a tight interaction network comprising eight single pass type-IV TM SNARE proteins with
a confidence rate between 0.75 and 0.999, and an FDR of 1.01e-07 (Fig. 6.3, table 6.2).
Additionally, a much smaller network consisted of four single pass type-II TM proteins with a
confidence rate between 0.44 and 0.966, and an FDR of 2.6e-04 (Fig. 6.3, table 6.2).
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Table 6.2: Biological pathways and processes suggested by STRING 10.5 for proteins in Table 6.1 All proteins were uploaded
and then automatically sorted into interaction groups and assigned to different pathways. Listed below are the pathways identified
according to either the “Kyoto Encyclopaedia of Genes or Genomes” (KEGG) or to the Biological Process of the Gene Ontology
(GO) project, including the FDR.
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6.1.4 SPPL2c is not a pseudoprotease and can cleave SNARE
proteins
In order to confirm that SPPL2c has indeed a proteolytic ability, selected SNARE proteins
were validated as SPPL2c substrates. To this end, the same cells as for the mass
Fig. 6.4: Validation of type-IV SPPL2c substrates.
Western blot of endogenous protein levels of VAPA,
VAPB, VAMP8, Syntaxin 8, 18 (Stx8 & Stx18) and
Membrin in HEK293 cells ectopically expressing wild
type SPPL2c (SPPL2c WT) or a catalytically inactive
SPPL2c (SPPL2c D/A). Non-transfected cells (-) or
stably transfected but non induced SPPL2c WT cells
(n/i) served as controls, expression levels of SPPL2c
are depicted and Calnexin serves as loading control.
spectrometry analysis were used with the addition of
cells expressing an inactive SPPL2c mutant, SPPL2c
D448A (SPPL2c D/A). The vesicle-associated
membrane protein-associated protein A (VAPA) and
B (VAPB), the vesicle-associated membrane protein 8
(VAMP8), Syntaxin 8 and Membrin (encoded by the
gene Golgi reassembly-stacking protein 2, GOSR2) all
showed decreased levels in cells expressing SPPL2c
wildtype (WT) (Fig. 6.4). This suggests that
SPPL2c releases the proteins from the membrane
via proteolytic cleavage, followed by degradation of
the proteins causing the observed decrease in total
levels. In the case of Syntaxin 18, it appears that the
cleavage product is more stable than for the other
substrates, which is why it is readily detectable in
the Western Blot analysis as a smaller sized band.
Importantly, at the same time Syntaxin 8 was also
identified as a substrate of SPPL2c in vivo in a similar
Mass Spectrometry analysis of whole testis preparations from SPPL2c-/- mice (Niemeyer et al.
2019). In summary, SPPL2c is able to cleave a number of SNARE proteins in vitro, proving for
the first time that it is a catalytically active GxGD aspartyl protease.
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6.1.5 SPPL2c expression reduces SPPL3 protein levels
The second interaction network that was identified by STRING (3.2.11) consists of type-II
TM enzymes involved in glycosaminoglycan biosynthesis (Fig. 6.3). Additionally, the levels of
a number of glycosidases and glycosyltransferases were found to be affected either positively
or negatively upon expression of SPP2c (table 6.3). Interestingly, some of these enzymes have
been already identified as SPPL3 substrates (Voss et al. 2014a, Kuhn et al. 2015) and were
found to accumulate in SPPL3-/- MEF cells and/or to be reduced upon SPPL3 overexpression
in HEK293 cells. For this reason, the levels of endogenous SPPL3 expression in HEK293 cells
that ectopically express SPPL2c were analysed.
Fig. 6.5: SPPL2c reduces SPPL3 levels. A. Western blot depicting the endogenous SPPL3 levels in non-transfected cells (-),
SPPL2c WT transfected but non-induced cells (n/i) and cells that inducibly express either the active (WT) or the inactive SPPL2c
(D/A). B. The endogenous SPPL3 expression of three HEK293 clones inducibly expressing SPPL2c WT (4, 5 and 10) was analysed
before (n/i) and after the induction of SPPL2c (ind.) by western blot. C. Quantification of three replicates for each clone of figure
B. Endogenous SPPL3 protein levels were normalized to Calnexin. Depicted are the ratios of SPPL3 expression before and after
induction of SPPL2c overexpression by doxycycline. SPPL3 expression of all three clones at non-induced conditions is set to 1
(SPPL2c-Dox). Mean +/- SD, n=3. D. Western Blot analysis depicting the ectopic SPPL2c expression of the three independent
HEK293 clones under induced conditions. Calnexin served as loading control.
It was observed that catalytically active SPPL2c has the capability of reducing SPPL3 levels,
while the inactive mutant SPPL2c D/A showed no such tendencies (Fig. 6.5A). To exclude
the possibility of this being a clonal effect, three SPPL2c expressing cell clones were analysed
(Fig. 6.5B-D). It was also observed that the decrease of SPPL3 levels seems to correlate with
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the expression levels of SPPL2c, as clones with lower expression of SPPL2c have a less
pronounced reduction of SPPL3 (clone 10). Other members of the SPP/SPPL family were
not affected for example, SPP levels remain unchanged upon SPPL2c expression (Fig. 6.6).
Table 6.3: Glycan-modifying type-II TM proteins decreased or increased upon SPPL2c ectopic overexpression in HEK293 cells.
Table includes all glycan-modifying proteins that showed a change of at least 20% upon SPPL2c expression and they are sorted
according to their fold-change. Proteins that have already been linked to SPPL3 as substrates in previous studies are marked in
bold (Voss et al. 2014a, Kuhn et al. 2015).
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Fig. 6.6: SPP expression is not affected
by SPPL2c overexpression. Western Blot
analysis depicting the endogenous expression
levels of SPP in control untransfected cells
(-), cells overexpressing WT SPPL2c or
catalytically inactive mutant, SPPL2c D/A.
Stably transfected but non-induced (n/i) cells
were used as controls and ectopic expression of
SPPL2c WT and D/A was confirmed. Calnexin
served as loading control.
Next, it was analysed whether the decrease in SPPL3
levels upon SPPL2c expression was due to an increase
in the degradation of SPPL3 via the proteasome or due
to a decrease in the mRNA levels of SPPL3. Neither
of the possibilities seems to apply as treatment with
two different proteasome inhibitors (Epoxomycin and
MG132) showed no accumulation of full-length SPPL3
upon SPPL2c expression (Fig. 6.7A). Additionally, the
normalised mRNA levels of SPPL3 from qPCR analysis
upon induction of WT SPPL2c also showed no decrease
compared to untransfected cells, non-induced controls or
to cells expressing the inactive mutant of SPPL2c (D/A)
(Fig. 6.7B).
Even if the reduction in SPPL3 levels would explain the accumulation of certain SPPL3
substrates upon SPPL2c expression (table 6.3), it would certainly not explain the decreased
levels of some other SPPL3 substrates (table 6.1, in bold).
Fig. 6.7: Reduction of SPPL3 levels is not due to proteasome degradation or reduction of SPPL3 mRNA. A. The endogenous
SPPL3 expression of HEK293 control cells, as well as non-induced control cells (n/i) and cells inducibly expressing SPPL2c WT
or the inactive mutant D/A were analysed by western blot. Cells were either untreated or treated with proteasome inhibitors (1
μΜ Epoxomycin, 10 μM MG132). B. The mRNA levels of SPPL3 were analysed by qPCR of three biological replicates in control
HEK293 cells, non-induced cells and HEK293 cells inducibly expressing WT SPPL2c or SPPL2c D/A. mRNA levels in control cells
were set to 1, two sided unpaired ttest was performed ns = non-significant.
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6.1.6 Substrate spectra of SPPL2c and SPPL3 do not overlap
Fig. 6.8: Effect of SPPL2c on validated SPPL3 substrates.
Western blot of endogenous protein levels of EXTL3, B4GALT1,
OGFOD3 and GnTV in lysates of cells treated with control siRNA
(siCtr) or siRNA targeting SPPL3 (siSPPL3) and cells ectopically
expressing either SPPL2c or SPPL3. The secreted forms of
each protein (sEXTL3, sB4GALT1, sOGFOD3, sGnTV) were also
analysed in the corresponding supernatant. Endogenous and
ectopic expression of SPPL3 is also analysed in the lysates, as
well as the ectopic expression of SPPL2c. Calnexin was used as
a loading control.
To analyse whether there is a
potential overlap of the substrate
spectra between SPPL2c and SPPL3, certain
glycosyltransferases that have already been
validated as SPPL3 substrates were chosen
(Voss et al. 2014a, Kuhn et al. 2015) and
it was tested if they are cleaved by SPPL2c
(Fig. 6.8). Four different SPPL3 substrates
were analysed: exostosin-like 3 (EXTL3),
β1,4 galactosyltransferase (B4GALT1),
2-oxoglutarate and iron-dependent oxygenase
domain-containing protein 3 (OGFOD3)
and β1,6-N-acetylglucosaminyltransferase V
(GnTV). EXTL3 levels were found unchanged
according to the mass spectrometry
analysis, B4GALT1 and OGFOD3 were found
decreased by 40% and 30% respectively, and
GnTV was found increased by approximately
50% but with a non-significant p-value of
0.06 (table 6.3). GnTV was included in the
analysis because it is the best-characterised
SPPL3 substrate to date (Voss et al. 2014a).
The levels of SPPL3 were similarly decreased
in the SPPL3 targeting siRNA treated
cells (KD) as in cells ectopically expressing
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SPPL2c. In both SPPL3 KD and SPPL2c expressing cells, a severe reduction in the secretion
of the four substrates was observed (Fig. 6.8). However, in contrast to the SPPL3 KD cells,
expression of SPPL2c causes a substantial decrease of the mature proteins within the cells
(lysate).
If the reduction of SPPL3 by SPPL2c would be the only reason for reduced glycosyltransferase
secretion, mature glycosyltransferases should remain stable or accumulate within the cell,
similarly to the SPPL3 KD cells. However, the reduction of mature proteins is similar to that
observed upon SPPL3 overexpression. So, although SPPL3 acts, as expected, like a sheddase
of the four proteins analysed (Voss et al. 2014a, Kuhn et al. 2015), SPPL2c clearly has a
different effect than SPPL3 on these proteins. SPPL2c does not cleave these
glycosyltransferases, as observed by the lack of secretion, but also does not solely block their
secretion, as observed by the lack of intracellular accumulation, demonstrating that the
substrate spectra of the two proteases do not overlap. The fact that overexpression of the
proteolytically inactive SPPL2c D/A has no effect on the glycosyltransferases, together with
glycosyltransferases not being direct SPPL2c substrates suggests a non-direct proteolytic
relation as reason for the observed phenotype.
6.1.7 SPPL2c interferes with the transport of SPPL3 substrates
It is shown that SPPL2c affects the protein levels and secretion of some SPPL3 substrates,
but it is also shown this is neither via the reduction of SPPL3 levels, nor through direct
cleavage of these proteins. Thus, potential mechanisms for this effect are reduced
transcription of these proteins, increased degradation or altered intracellular trafficking. The
last possibility appears the most plausible because it was already shown that SPPL2c can
cleave certain SNARE proteins involved in transport within the secretory pathway (6.1.4).
The impairment of vesicular trafficking would lead to an accumulation of glycosyltransferases
in the ER/ERGIC in their immature form, however only mature endogenous
glycosyltransferases can be detected by the antibodies available (Voss et al. 2014a).
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Fig. 6.9: SPPL2c inhibits GnTV trafficking and maturation. A. Western blots depicting the processing of ectopically expressed
double-tagged GnTV (Flag-GnTV-V5) in lysates and conditioned media (sup.) of SPPL2c WT or SPPL2c D/A expressing cells.
Non-transfected cells (-) or stably transfected but non-induced SPPL2c WT cells (n/i) served as controls. Maturation of the
glycoproteins Nicastrin (NCT), Lamp2 and SPPL2a was monitored by detection of the respective mature (mat) and immature
(im) version. Expression levels of the ectopically expressed SPPL2c proteases are shown and Calnexin serves as loading control.
B, C. Immunofluorescence stainings of ectopically expressed GnTV with anti-V5 antibody either in control cells (Ctr) or in cells
co-expressing either SPPL2c WT or SPPL2c D/A. The ER was stained using anti-BiP antibody (B) and the Golgi with anti-TGN46
antibody (C). Scale bar 5 μm.
As shown by Voss et.al. in 2014 (Voss et al. 2014a), the immature form of GnTV can be
readily detected by western blot analysis when GnTV is expressed ectopically. Thus,
proteolytically active SPPL2c (WT) or the inactive SPPL2c mutant (SPPL2c D/A) was
co-expressed with N-terminally Flag- and C-terminally V5-tagged GnTV. Regarding the
secretion of soluble GnTV (sGnTV), the reduction in secretion observed with the endogenous
GnTV was reproduced and confirmed that only the catalytically active SPPL2c has an effect
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on the glycosyltransferase. The most prominent band of ectopically expressed GnTV in the
lysates is immature GnTV. An accumulation of immature GnTV can be observed only upon
co-expression with SPPL2c WT (Fig. 6.9A). This accumulation is also in agreement with the
results from the mass spectrometry analysis that detected an increase in cellular GnTV (table)
and may be explained by impairment in the trafficking of GnTV from the ER to the Golgi.
Only mature glycosyltransferases that are in the Golgi are active and can add the complex
glycans to the proteins. To confirm that GnTV and other glycan modifying enzymes are
indeed not reaching an active state, selected endogenous glycoproteins, like Nicastrin,
lysosomal protein Lamp2 and SPPL2a were analysed. All three glycoproteins were found to be
hypoglycosylated in HEK293 cells expressing SPPL2c WT, as indicated by the lower molecular
weight in western blot (Fig. 6.9A). They additionally accumulate at an immature state, which
most likely points to impairment of cellular trafficking affecting also their transport. To
further support our theory, ectopically expressed GnTV was visualised via its V5 tag in control
cells and cells expressing either active or inactive SPPL2c by immunofluorescence. Using the
ER resident protein BiP or the Golgi protein TGN46 as markers, it was shown that the
localisation of GnTV changes upon co-expression with WT SPPL2c. Under control conditions,
GnTV was found in both the ER and Golgi, but predominantly in the latter. However, in
presence of WT SPPL2c the glycosyltransferase appears to be retained in the ER. This was
not observed upon expression of catalytically inactive SPPL2c D/A (Fig. 6.9B).
In conclusion, SPPL2c causes an impaired maturation of glycosyltransferases via prohibiting
them from reaching the Golgi, which in turn leads to their reduced secretion and to the
hypoglycosylation of various glycoproteins. These results suggest that instead of SPPL2c
directly interacting and cleaving some of the SPPL3 substrates, it alters their transport
through processing of SNARE proteins.
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6.1.8 SNARE proteins identified by Mass Spectrometry are not
responsible for GnTV trafficking
Therefore, the next step was to assess whether one of the SNARE proteins validated as SPPL2c
substrates was responsible for the impaired maturation of GnTV and whether cleavage of the
substrate by SPPL2c would inhibit intracellular transport of GnTV. To imitate the decrease in
each SNARE’s protein levels caused by SPPL2c cleavage, cells ectopically expressing GnTV were
treated with targeted siRNA to mediate knockdown of each SNARE protein individually. The
siRNA treatment did indeed mimic the reduction of the respective SNARE protein by SPPL2c
overexpression (Fig. 6.10). Apart from the secretion of soluble GnTV and the maturation
of intracellular GnTV, the glycosylation of SPPL2a as a representative glycoprotein was also
analysed and all three read-outs were compared to the overexpression of SPPL2c. Only Syntaxin
18 and Membrin had a minimal effect on GnTV, slightly reducing the secretion of soluble GnTV
but did not alter the maturation of cellular GnTV (Fig. 6.10E, F). SPPL2a glycosylation was
slightly altered upon Syntaxin 8 knockdown, but not reaching a level comparable to the SPPL2c
overexpression (Fig. 6.10D).
In conclusion, none of the proteins tested could reproduce all effects observed by SPPL2c
overexpression, pointing either to a combinatory mechanism or to the existence of additional
substrates that have not been identified in the mass spectrometry screen.
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Fig. 6.10: Validated SPPL2c substrates have only minimal effects on GnTV trafficking and glycoprotein maturation. Endogenous
protein levels of the validated SPPL2c substrates VAPA (A), VAPB (B), VAMP8 (C), Syntaxin 8 (Stx8) (D), Syntaxin 18 (Stx18)
(E) and Membrin (F) were reduced by specific siRNAs. Non-targeting siRNA served as negative control (Ctr) and cells overexpressing
SPPL2c WT were used as positive control. Non-transfected cells (-) or stably transfected but non-induced SPPL2c WT cells (n/i)
served as additional controls for antibody specificity. Calnexin served as loading control and ectopic expression of SPPL2c WT was
confirmed using an SPPL2c specific antibody. Western Blotting was used to follow the processing and maturation of ectopically
expressed GnTV and the maturation of endogenous SPPL2a.
6.1.9 Identification of an additional SPPL2c substrate
In order to narrow down the search for additional SPPL2c substrates, the pathway analysis
was used. The online software STRING 10.5 (https://string-db.org/) offers the possibility to
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extend an interaction network by adding proteins that were not in the initial uploaded protein
set but are known to interact closely with them. Using the “More”-function additional proteins
involved in vesicular trafficking and more specifically membrane fusion were identified (Fig.
6.11A). Since proteins the trafficking of which is affected by SPPL2c are detected at a low
maturation/glycosylation level, it appears that they are trapped before reaching the appropriate
Golgi localisation to continue their maturation. For this reason Syntaxin 5 and Syntaxin 6 that
are known for being involved in the ER to Golgi and TGN trafficking, respectively were further
analysed (Rowe et al. 1998, Jung et al. 2012). Looking at the protein levels of Syntaxin 5
and 6 in lysates of cells expressing catalytically active SPPL2c compared to control cells or cells
expressing inactive SPPL2c D/A, it was found that Syntaxin 6 is not a SPPL2c substrate, while
Syntaxin 5 gets cleaved and produces a stable cleavage product (Fig. 6.11B).
Fig. 6.11: An additional substrate of SPPL2c. A. The type-IV membrane proteins identified as candidate substrates in the
proteomic analysis served as basis for extending the protein network with the function “More” of the STRING 10.5 software.
Additional candidate SPPL2c substrates associated with vesicular trafficking were identified. B. Western Blotting of endogenous
Syntaxin 5 (Stx5) and Syntaxin 6 (Stx6) levels was used to assess the processing of these candidate substrates by SPPL2c WT.
Non-transfected cells (-), stably transfected but non-induced SPPL2c WT cells (n/i) and induced cells stably expressing SPPL2c
D/A served as controls. Calnexin served as loading control.
6.1.10 Processing of Stx5 by SPPL2c impairs trafficking of GnTV
As before, siRNA mediated knockdown of Stx5 was used to reduce its protein levels to a
similar extend as with SPPL2c expression. The HEK293-GnTV expressing cells treated with
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siRNA for Stx5 convincingly mimicked the effects observed in cells expressing SPPL2c.
Maturation of GnTV was reduced, immature GnTV accumulated and secretion of GnTV was
blocked to a significant extent. At the same time, it became clear that Syntaxin 5 is not the
Fig. 6.12: Stx5 interferes with GnTV maturation and
secretion. Western blot analysis of the processing and
maturation of ectopically expressed GnTV, as well as the
glycosylation of the endogenous glycoproteins Nicastrin
(NCT) and SPPL2a. Protein levels of Syntaxin 5 were down
regulated with specific targeting siRNA, while non-targeting
siRNA (Ctr) was used as control. Ectopic expression of
SPPL2c WT was confirmed. Calnexin was used as a loading
control.
only substrate responsible for the effects observed
upon SPPL2c overexpression, since Nicastrin
maturation and glycosylation was impaired upon
Syntaxin 5 knockdown but SPPL2a glycosylation
remained unaffected (Fig. 6.12).
Total levels of Syntaxin 5 were hardly decreased
upon expression of SPPL2c due to the formation
of a stable cleavage product. This could explain
why Syntaxin 5 was not detected as a candidate
substrate in the mass spectrometry scan.
One potential mechanism, via which the cleavage
of Syntaxin 5 by SPPL2c could cause the
observed effect on GnTV trafficking, would be a
changed localisation of Syntaxin 5. To this end,
immunofluorescence stainings were performed to
detect the localisation of endogenous Syntaxin 5
in control cells compared to cells expressing active
(WT) or inactive (D/A) SPPL2c. Indeed, under
control conditions, Syntaxin 5 localises mainly in
the Golgi and expression of inactive SPPL2c D/A
does not change its localisation. However, expression of catalytically active SPPL2c caused a
more diffused staining of Syntaxin 5 that co-localised neither with the Golgi marker TGN, nor
with the ER marker BiP (Fig. 6.13A). These data suggest that Syntaxin 5 loses its ability
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to mediate membrane fusion at the cis-Golgi due to processing by SPPL2c and is most likely
trapped in an intermediate compartment, likely in the ERGIC.
Fig. 6.13: SPPL2c alters localisation of Stx5, which in turn inhibits trafficking of GnTV. A. Endogenous Syntaxin 5 was visualized
in control cells without SPPL2c expression (Ctr) and in cells overexpressing SPPL2c WT or SPPL2c D/A by immunofluorescence.
BiP was used to mark the ER and TGN46 the Golgi. White arrow indicates cells with disturbed Golgi and Syntaxin 5 staining. B.
Ectopically expressed GnTV was visualized using anti-V5 antibody in cells treated either with non-specific siRNA (siCtr) or with
siRNA targeting Syntaxin 5 (siStx5). BIP was co-stained as ER marker protein and TGN46 as Golgi marker protein. Scale bar 5
μm.
Consequently, SPPL2c alters the localisation of Syntaxin 5 (Fig. 6.13A) and also clearly affects
the localisation of GnTV (Fig. 6.9). In order to confirm that Syntaxin 5 is the main SPPL2c
substrate the cleavage of which impairs trafficking of GnTV, immunofluorescence stainings were
performed in the cells stably expressing tagged GnTV upon treatment either with control siRNA
or with siRNA targeting Syntaxin 5 (Fig. 6.13B). In agreement with the previous findings, and
using BiP and TGN46 to visualise the ER and the Golgi, GnTV localisation visibly shifts from
more Golgi-based to more ER-based in the absence of Syntaxin 5.
Collectively, these results indicate that cleavage of Syntaxin 5 by SPPL2c causes the loss of its
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SNARE function making it responsible for the hiatus in GnTV trafficking that leads to reduced
maturation and shedding.
6.1.11 SPPL2c overexpression in HEK cells affects compartment
structures
So far, we have shown that through cleavage of different proteins associated to vesicle
trafficking, SPPL2c is capable of blocking the exchange of proteins and membranes between
the ER and the Golgi. However, in order to maintain its organelle integrity, the Golgi requires
a continuous exchange of vesicles with the ER (Ward et al. 2001).
For this reason the effect that prolonged SPPL2c expression would have on the integrity of ER
and Golgi in HEK293 cells expressing catalytically active SPPL2c was investigated. Using
different markers for ER (BiP), cis/medial-Golgi (Giantin), trans-Golgi (TGN46) and whole
Golgi (Cab45), the effect of WT SPPL2c expression was assessed in a time-dependent manner
(24 and 48 hours) and it was compared to expression of catalytically inactive SPPL2c D/A.
BiP, Giantin and Cab45 were significantly mislocalised in a time-dependent manner upon
expression of WT SPPL2c (Fig. 6.14). The results obtained from the immunofluorescence
stainings indicate that disturbance of transport by SPPL2c is capable of disturbing the
integrity of these compartments and the effect becomes stronger the longer the protease is
present. TGN46 was also altered upon SPPL2c expression, however to a lesser extent. It is
important to point out that although high expression of a polytopic, ER-resident, membrane
protein, such as SPPL2c D/A, might be a source of ER-stress, no effect on the localisation of
the organelle markers was observed upon expression of catalytically inactive SPPL2c (Fig.
6.14).
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Fig. 6.14: SPPL2c disturbs the integrity of subcellular compartments. Control cells and cells with inducible expression of SPPL2c
WT and the inactive mutant D/A were cultured for 72h. Expression of SPPL2c WT and D/A was either non-induced (n/i) or
induced by addition of doxycycline for either 24h or 48h, as indicated. Anti-BiP antibody was used to stain the ER, anti-Giantin for
the cis/medial-Golgi, anti-TGN46 for the trans-Golgi Network and Cab45-specific antibody for all Golgi subcompartments. Upon
expression of catalytically active SPPL2c, the morphologies of ER and cis-Golgi were altered compared to controls. Scale bar 5μm.
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6.1.12 SPPL2c has a proteolytic function in vivo
SPPL2c expression has only been detected in testis tissues from humans and mice (6.1.1).
Through this study, we gained a better understanding of the effect that SPPL2c expression
has on a cell and it has become clear that under most physiological conditions, an impairment
of vesicular transport by SPPL2c would be detrimental for an organism. Analysis of
maturation of the glycoproteins Nicastrin and SPPL2a in testis, kidney, brain, spleen and liver
from wildtype C57BL/6 mice, revealed a hypoglycosylation and an accumulation of immature
glycoproteins in testis (Fig. 6.15A). These results are in accordance to what was observed in
vitro.
Fig. 6.15: SPPL2c retains functionality in vivo. A. Endogenous Nicastrin (NCT) and SPPL2a were analysed by western blot
in membrane preparations from testis, kidney, brain, spleen and liver in littermate male C57BL/6 mice. Immature proteins (im)
accumulate in testis compared to other tissues. SPPL2c protein is only detected in testis tissue. B. Analysis of Syntaxin 8 (Stx8)
in whole testis from SPPL2c-/- mice compared to wildtype (Wt) littermates. SPPL2c is absent in the SPPL2c-/- mice as expected,
TMEM192 serves as loading control. C. Quantification of Western Blot in panel B, Syntaxin 8 protein levels were normalized to
those of TMEM192. Syntaxin 8 levels of wildtype mice were set to 1. Bars represent mean values of n=3 animals +/- SD, *
p<0.05. D. Syntaxin 8 (Stx8) mRNA levels in testis of SPPL2c-/- and the wildtype mice were analysed by real-time qPCR and
normalized to that of Tuba1a. Stx8 mRNA level of wildtype animals was set to 1. n=6 individual animals from two independent
experiments +/- SD. For statistical analysis an unpaired Student’s t-test was performed. ns = not significant. Experiments in B-D
performed by Torben Mentrup.
To confirm that SPPL2c is indeed a catalytically active protease also in vivo that can alter
vesicular trafficking, testis from SPPL2c deficient mice were analysed for accumulation of
already verified SPPL2c substrates. In collaboration with Torben Mentrup and Bernd
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Schröder from Dresden, an accumulation of Syntaxin 8 in whole testis membrane preparations
of the SPPL2c deficient mice compared to control littermates was successfully demonstrated
(Fig. 6.15B). Transcription levels of SPPL2c mRNA were not altered in the SPPL2c deficient
mice, so the accumulation of Syntaxin 8 can be attributed to lack of SPPL2c processing (Fig.
6.15C-D).
6.1.13 SPPL2c supports intracellular reorganisation in maturing
spermatids
Fig. 6.16: SPPL2c interferes with the proper localisation of Cab45
in spermatids. Immunohistochemical stainings of seminiferous tubular
cross-sections of SPPL2c+/+ and SPPL2c-/- mice using anti-Cab45
antibody. Closer magnifications are indicated with dashed lines and black
arrows mark pre-acrosomal structures. Experiment performed by Artur
Mayerhofer.
The physiological expression of SPPL2c
in the testis is remarkably high, only 5 μg
of protein from whole testis membrane
preparations of humans or mice are
sufficient to detect amounts similar to
1:50 dilution of membrane preparations
from cells ectopically expressing SPPL2c
(Fig. 6.1). As has been shown
by Niemeyer et al. 2019, SPPL2c
expression in vivo can only be detected
in a limited type of cells in the testis,
the maturing spermatids. The fact that
endogenous SPPL2c derives from only a
limited number of cells within the testis,
points to an extremely high expression
of SPPL2c in these specific cells with
levels similar to the HEK293 cells that
homogeneously overexpress SPPL2c.
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Fig. 6.17: Quantification of Cab45 stainings in seminiferous tubular cross sections. A. Pre-acrosomal resembling structures
stained with Cab45 (Fig. 6.16, black arrows) were quantified in n=14 stage VII/VIII seminiferous tubules (n=6 SPPL2c+/+ and
n=8 SPPL2c-/-). On the right hand side of the table, the averages of the stainings counted for each single picture as well as
the single measurements of each field (microscopic fields 1-3) are depicted. The genotype of each mouse is indicated, as well
as the blinded-assignment of the pictures by five independent people, accompanied by the number and percentage of correct
evaluations, the wrongly guessed images are marked in red. B. Graph depiction of the average Cab45 stainings per image according
to genotype. The average number of stainings per tubule is depicted for each genotype, mean +/- SD. Unpaired, two-sided Welch’s
t test. ***p<0.001 (p=0.0004)
Spermatids, the cell type that expresses SPPL2c, are one step before spermatozoa in the
differentiation process of spermatogenesis. At this stage cells undergo the loss of parts of the
cytosol and many organelles, including ER and Golgi, in order to form the acrosome (Berruti and
Paiardi 2011). To assess the potential role of SPPL2c in this procedure, SPPL2c-/- mice were
compared to their wildtype littermates, SPPL2c+/+. More precisely, in a collaborative analysis,
seminiferous tubular sections from these mice were stained with Cab45 and were analysed on
stages VII/VIII of spermatogenesis as defined by Meistrich and Hess (Meistrich and Hess 2013).
The localisation of this Golgi resident protein was severely affected by the presence or not of
SPPL2c in the HEK cells (Fig. 6.14). In wildtype mice, Cab45 localised in precise and dense
structures adjacent to the cell nuclei, while in SPPL2c-/- mice, Cab45 staining appeared more
diffused and less focused on specific structures (Fig. 6.16).
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To further confirm the observed differences, 14 images from both genotypes were used to
quantify the average number of structures per tubule and also 5 individuals blindly evaluated
the pictures regarding the genotype. Both tests gave positive results with approximately 50%
reduction of the quantified dense structures in knockout animals compared to wildtype and
an 86% average hit rate in the blinded assignment of genotypes (Fig. 6.17). This evidence
suggests that SPPL2c is necessary in order for the compartmental reorganisation in spermatids
to take place successfully.
6.1.14 The glycome fingerprint of SPPL2c-/- sperm is altered
Fig. 6.18: Volcano plot of a lectin microarray analysis of sperm lysates
from SPPL2c-/- mice compared to SPPL2c+/+. Each circle represents
one lectin, with grey circles being lectins with non-significantly changed
binding affinity. Significantly altered lectins are marked in light blue,
above the dashed line p-value>0.05. Lectins on the left side of the blot
demonstrate reduced binding while UEA-I on the right side has increased
binding in SPPL2c-/- spermatozoa. Experiment performed by Merav
Shmueli.
The formation of the
acrosome is just one of the alterations
that take place during the maturation
of sperm. Another characteristic
of spermatozoa that plays a crucial role
for successful fertilization of the ovum
is the glycocalyx. This complex glycan
structure covers the sperm head and
holds the key for the species selectivity
(Pang et al. 2011). In a collaborative
analysis, we were able to analyse
the glycome fingerprint of mature
spermatozoa that were isolated from
the cauda epididymis of SPPL2c+/+
and SPPL2c-/- mice. The analysis was
performed using a lectin chip microarray (LecChip) containing 45 different plant lectins. The
total lysates from mature spermatozoa were analysed and the reactivity of 10 lectins was
significantly reduced in the SPPL2c-/- sperm, while the reactivity of one lectin was increased
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in the same sperm compared to the wildtype littermates (Fig. 6.18). One of the lectins that
was found decreased in the SPPL2c-/- sperm, Pisum sativum (PSA), has been reported as a
marker of the acrosome content (Benoff 1997). The reduction of another lectin, Wheat Germ
Agglutinin (WGA), is an established marker for teratozoospermia (Benoff 1997). These data
indicate that either directly or, most likely, indirectly via the disturbance of the cellular
reorganisation, SPPL2c is also capable of affecting the glycan structures within and
surrounding the mature sperm. Thus, lack of SPPL2c expression at the right step of sperm
maturation negatively affects both the formation of the acrosome and the correct
glycosylation of cellular structures.
6.2 Discussion
In this study, it is demonstrated for the first time that SPPL2c is actually an active protease,
not a pseudoprotease or a pseudogene lacking any functional expression, as it was believed
since its discovery (Golde et al. 2009, Voss et al. 2013). Additionally, it is shown that the
GxGD-motif that characterises this family of proteins is not only functional but also
indispensable also for SPPL2c, as the SPPL2c mutant D448A (SPPL2c D/A) lacks any
proteolytic activity.
Microarray analysis in human tissues in the past had detected mRNA levels of SPPL2c in
brain, skin, heart and testis, although no protein levels were detected (Friedmann et al.
2004a). That lack of SPPL2c protein levels created doubts concerning the mRNA results that
could also be explained by contamination of the mRNA with the intronless cDNA of SPPL2C,
which would give a false positive mRNA expression. In this analysis, we were capable to
detect SPPL2c protein expression for the first time. SPPL2c expression was not detected in
tissues like brain, kidney, spleen and liver, but was only detected in testis from humans and
mice (Fig. 6.1). This very specific expression pattern of SPPL2c suggests that it is not a
pseudoprotease but it should have a specific functional purpose.
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To shed light into the function of SPPL2c, proteomic screening of HEK293 cells
overexpressing ectopic SPPL2c was performed compared to control cells, lacking SPPL2c
expression (Fig. 6.2). Although SPPL2c is not expressed at all in the control cells, a small
amount of the protein must have been carried-over during the measurements from the
SPPL2c positive cells, which at the end allows the high-fold change presented in the volcano
plot. This technique allowed us to identify the first potential substrates of SPPL2c, which
were narrowed down to type-II or type-IV TM proteins based on the specificity of the
SPP/SPPL family (Voss et al. 2013, Mentrup et al. 2017a). Potential substrates clustered to
two main pathways, vesicular trafficking and protein glycosylation (Fig. 6.3). A number of the
SNARE proteins involved in vesicular trafficking through membrane fusion, were validated as
SPPL2c substrates. Their processing also demonstrated the importance of the GxGD motif as
catalytic site of the protease (Fig. 6.4). Additionally to those SNARE proteins that were
identified as substrates via the proteomic screen (Fig. 6.3), Syntaxin 5 was also considered
and identified as a substrate through the extended pathway analysis (Fig. 6.11).
SPPL2c is believed to reside in the early compartments of the secretory pathway like ER,
ERGIC or even cis-Golgi (Friedmann et al. 2004b). Taking that into consideration, it is most
likely that the cleavage of the substrates takes place within these early compartments, as all
of these proteins either function in this compartment or pass-through during their maturation.
The processing of these substrates seems to differ with only two of the substrates, Syntaxin 5
and 18, giving rise to stable cleavage products, while the majority of substrates show
decreased protein levels but no cleavage product (Fig. 6.3, 6.11). The absence of a cleavage
product suggests a rapid degradation, possibly through ERAD, which would be enhanced due
to the high protein accumulation of the substrate protein in the ER upon SPPL2c expression.
The presence of a stable fragment, especially in the case of Syntaxin 5, results in almost no
change in the total protein levels of Syntaxin 5, which could explain why this substrate was
not identified in the proteomic screen. Despite the recognition of at least seven SNARE
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proteins as SPPL2c substrates in the current study, it also appears that SPPL2c has some
specificity, as another SNARE protein, Syntaxin 6, was not processed by the protease (Fig.
6.11). One reason why SPPL2c maybe does not recognise Syntaxin 6 as a substrate can be
that although Syntaxin 6 contains a C-terminal transmembrane domain, it has a high
homology with the SNAP-25 family and is actually considered a member of that family (Jung
et al. 2012). These data suggest that SPPL2c has specific substrate requirements and
cleavage mechanism, as is common for other members of the SPP/SPPL family (Lemberg and
Martoglio 2002, Martin et al. 2009, Fluhrer et al. 2012). Further analysis would be required
to shed more light into both the mechanism of cleavage and the substrate requirements.
Cleavage of Syntaxin 5 by SPPL2c leads to a mislocalization of the SNARE protein. Following
the processing, Syntaxin 5 appears incapable to properly reach the Golgi, and even the
morphology of the Golgi appears to be negatively affected (Fig. 6.13A). We believe that
cleavage of Syntaxin 5 in close proximity to its TMD probably leads to the release of the
protein, which can no longer perform its role of triggering the specific fusion of membranes
during vesicle transport (Fig. 6.19). This observation is in accordance with a study published
in 1998, where it is suggested that Syntaxin 5 is not only essential for the transport of cargo
from the ER to the Golgi, but also for the assembly of pre-Golgi intermediates (Rowe et al.
1998). As we already observed that cargo proteins, such as glycosidases and
glycosyltransferases do not reach their final destination but are most likely retained in the ER
(Fig. 6.8, 6.9), it seems very convincing that Syntaxin 5 indeed plays a role in their transport.
It was successfully shown that absence of Syntaxin 5 is enough to block the maturation and
secretion of GnTV, as well as decrease the glycosylation of certain glycoproteins, most
probably by inhibiting GnTV from reaching the Golgi (Fig. 6.12, 6.13B). A similar effect
would be expected when Syntaxin 5 can no longer mediate the transport to the Golgi because
of SPPL2c expression (Fig. 6.19).
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Fig. 6.19: Hypothetical model demonstrating the effect of SPPL2c expression on vesicular trafficking. A. Protein synthesis
of membrane-spanning glycosyltransferases (represented here by GnTV in green) and members of the SNARE family (dark and
light blue representing t- and v-SNAREs, respectively) starts on the ER and the proteins are then inserted in the ER. The
glycosyltransferases are transported to the Golgi via vesicle transport and the presence of SNARE proteins is required for the vesicle
fusion at its destination. These glycan-modifying enzymes move within the different compartments of the Golgi. They mature
and as they make their way towards the trans-Golgi, they either meet SPPL3 (red) that can shed and liberate their active site,
or they catalyse glycosylation of proteins (glycoprotein depicted in purple). B. SPPL2c expression is localised to the ER, where
selective SNARE proteins are proteolytically processed. This processing leads either to the release of the SNARE proteins from the
membrane and/or to their rapid degradation. Numerous SNARE proteins are processed in this step as they all pass through the ER
before reaching their final destination. C. Cleavage of SNARE proteins impairs vesicle fusion at the cis-Golgi and amongst other
cargo proteins, immature glycosyltransferases accumulate in the ER, while their amount in the Golgi decreases. The lack of mature
glycosyltransferases leads to a decrease in protein glycosylation and at the same time, SPPL3 (red) protein levels are decreased.
Decrease of SPPL3 is most likely a secondary-response effect in order to preserve the activity of the small amount of glycoproteins
that have reached the Golgi.
142 6. SPPL2c impairs vesicular trafficking
The rest of the SPPL2c substrates that were identified in the mass spectrometry screen are
not directly involved in the transport of proteins from the ER to the Golgi so it is not
surprising that their cleavage by SPPL2c does not result in decreased maturation and
shedding of GnTV (Fig. 6.10). However, additional phenotypes can be expected regarding the
trafficking between different organelles involved in the secretory pathway. The proteins levels
of VAPA, VAPB, VAMP8, Stx8, Stx18 and Membrin were all affected by SPPL2c (Fig. 6.4).
Amongst other functions, VAPA can interact with Oxysterol-binding protein-related protein 3
(OSBPL3) and together they are implicated in the export of specific proteins and lipids, such
as ceramide, from the ER (Wyles et al. 2002, Wyles and Ridgway 2004). Although VAPB
shares a number of common functions with VAPA (Huttlin et al. 2015), it has been found to
play an important role in amyotrophic lateral sclerosis through its participation in the ER UPR
(Chen et al. 2010). VAMP8 (endobrevin) is thought to participate in multiple procedures,
such as the fusion of late endosomes, together with Syntaxin 8 (Antonin et al. 2000), the
release of granules from human platelets (Polgar et al. 2002), the fusion of lysosomes and
autophagosomes (Furuta et al. 2010), and the exocytosis in the exocrine pancreas (Wang et
al. 2004a). Membrin, encoded by the gene GOSR2, plays a role in ER to Golgi trafficking and
although it is ubiquitously expressed, it seems to have a significant role especially in the
nervous system (Praschberger et al. 2017). The effect of SPPL2c expression on these
processes will need to be investigated in further studies.
Some of the proteins that showed significantly decreased protein levels in the proteomic screen
have been previously reported as substrates of SPP (Cyb5a) (Boname et al. 2014) or SPPL3
(B4GALT1, OGFOD3) (Kuhn et al. 2015) (Fig. 6.2). Regarding the SPP substrate, it was
shown that Cyb5a is not a substrate of SPPL2c (Niemeyer et al. 2019), as well as that SPP
levels remain unchanged upon SPPL2c overexpression (Fig. 6.6). As this study successfully
shows that SPPL2c overexpression can inhibit the transport of proteins out of the ER and into
the Golgi, a plausible explanation for the increased cleavage of Cyb5a is its prolonged stay at
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the ER, where also SPP resides.
Regarding SPPL3, it was apparent that endogenous protein levels were decreased
proportionally to the expression of catalytically active SPPL2c (Fig. 6.5). It has been
previously shown that SPPL3, which resides in the Golgi, is capable of cleaving mature
glycosidases and glycosyltransferases (Voss et al. 2014a, Kuhn et al. 2015). In this context,
decreased levels of SPPL3 can preserve a higher amount of glycan modifying enzymes in the
Golgi, where they are active (Fig. 1.15). Since SPPL2c expression, blocks the maturation of
glycan modifying enzymes and inhibits the substrates of SPPL3 from reaching their final
location in the trans-Golgi (Fig. 6.8, 6.9), it is tempting to consider that the decrease of
SPPL3 is due to a secondary effect of the SPPL2c expression and a counter-mechanism to
preserve the remaining active glycan modifying enzymes (Fig. 6.19). However, so far efforts
to attribute this decrease to proteasome degradation or reduced transcription levels have
failed (Fig. 6.7). Thus leaving other forms of degradation and/or translational regulation as
possible causes.
We have seen that SPPL2c can inhibit vesicular transport and affect the protein levels of
numerous proteins, but the next aim was to understand how the expression of SPPL2c could
affect the intracellular morphology of the cell. To this end, SPPL2c was overexpressed in
HEK293 cells and a time-dependent fragmentation of the Golgi and collapse of the ER was
observed (Fig. 6.14). The trans-Golgi network seems less affected by the overexpression;
however, it is possible that longer expression of SPPL2c is needed for the effects to be more
pronounced further down the secretory pathway.
Thus, expression of SPPL2c not only affects vesicular trafficking, glycosylation and secretion
of proteins, but it can alter the whole cell structure, making expression of this protein highly
restricted under healthy conditions. Indeed, expression of SPPL2c has so far only been found
in the mature male reproductive system and even more specifically, only in maturing
spermatids (Niemeyer et al. 2019). Mass spectrometry analysis of whole testis membrane
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preparations from SPPL2c-/- mice compared to littermate controls also identified Stx8 as a
SPPL2c substrate and its processing was validated by Western Blotting ((Niemeyer et al.
2019), Fig. 6.15B-D). Unfortunately, no accumulation of any of the other verified SPPL2c
substrates was detected. This is most likely due to the very restricted expression of SPPL2c in
the testis on a cellular level. While SNARE proteins are almost ubiquitously expressed,
SPPL2c is exclusively found in spermatids, a small subpopulation of the testis cells. It appears
logical that the accumulation of a SPPL2c substrate only in such a small population of cells
would be very hard to detect in total testis lysates. Given that the two analyses were also
performed in different species (human vs mouse), it is not possible to exclude that species
specificity might also play a role for the substrates that do not overlap. Similar results were
also obtained during the analysis of HEK293 cells overexpressing SPPL3 and MEF cells from
SPPL3-/- mice (Kuhn et al. 2015), with the two proteomic analyses identifying few
corresponding substrates and mostly singular hits.
SPPL2c expression in maturing spermatids is proving to be considerably high as whole testis
membrane preparations have SPPL2c levels comparable to 1:50 dilution of the HEK293 cells
(Fig. 6.1). This indicates that the overexpression system is not far off the actual in vivo
situation and indeed, analysing the glycosylation of Nicastrin and SPPL2a in different mouse
tissues, testis significantly accumulate immature glycoproteins compared to the other tissues
(Fig. 6.15A). A similar hypoglycosylation is observed in the HEK293 cells upon SPPL2c
overexpression (Fig. 6.9A).
Maturing spermatids are a special type of cell as they are the first haploid cells during sperm
maturation. In this stage, cells undergo comprehensive reorganisation of their intracellular
compartments and plasma membrane to eventually form spermatozoa (Berruti and Paiardi
2011). A key feature of mature spermatozoa is the lack of intracellular organelles, such as the
Golgi and ER, but the presence of a different membrane organelle, the acrosome. Formation
of the acrosome starts at the stage of spermatids through fragmentation of the Golgi into
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proacrosomic granules that later fuse to form acrosomic granules that finally come to close
contact with the nuclear envelope (Abou-Haila and Tulsiani 2000). Given the highly specific
expression of SPPL2c in this stage, the effect of SPPL2c overexpression on the intracellular
structures of HEK293 cells and the requirement for specific SNARE expression during the
formation of the acrosome, it seems likely that SPPL2c is involved in this procedure.
Stainings of proacrosomic structures in maturing spermatids indeed point to a defect during
the formation of the acrosome in absence of SPPL2c (Fig. 6.16, 6.17). SPPL2c-/- mice
appear to have a decreased number and/or decreased integrity of proacrosomic structures that
could be attributed to problems in the formation and fusion of these granules, which possibly
requires a specific pattern of SNARE protein expression.
Spermatozoa are also characterized by very specific glycosylation pattern, especially in the
glycocalyx that surrounds them and ensures the species specificity while mating (Pang et al.
2011). Using a lectin microarray it was shown that the altered glycosylation patterns observed
in HEK293 cells expressing SPPL2c are represented also in vivo. Only in this case, SPPL2c
expression is required to reach the wanted glycosylation pattern and lack of it results to
profound changes in the glycan fingerprint of the sperm (Fig. 6.18). A number of lectins
showed reduced binding activity in the SPPL2c-/- sperm, amongst them also WGA that is an
established marker of teratozoospermia. Other reduced lectins are considered indicative of the
sperm maturation and fertility, as well as the content of the acrosome (Benoff 1997, Xin et al.
2016).
These results regarding acrosome formation and protein glycosylation, in combination with the
study by Niemeyer et al. 2019 that shows altered Ca2+ signaling upon lack of SPPL2c could
explain the decreased breeding capabilities observed in the SPPL2c-/- mice. However, we only
hold part of the puzzle pieces, as it is not clear how SPPL2c deficiency affects reproduction
and why the deficient male mice have normal litters when mated with wildtype female mice,
or how SPPL2c deficiency might affect female mice. As it was shown that SPPL2c expression
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starts with sexual maturity, it is possible that SPPL2c does not hold a key role but rather has
a “booster function” aiming to improve the maturation of sperm. Further studies are needed
to investigate other factors/mechanisms that could be the missing pieces to sperm maturation
in absence of SPPL2c and the possible expression of SPPL2c in the female reproduction
system.
In summary, this study shows that SPPL2c is an active aspartyl protease that can cleave
numerous SNARE proteins in vitro and at least Syntaxin 8 in vivo. Cleavage of the SNARE
proteins interferes with their role of mediating vesicle fusion in vesicular transport and thus,
numerous cargo proteins accumulate in the early stages of the secretory pathway. This leads
to a decreased maturation and secretion of glycan-modifying proteins, as well as to
hypoglycosylation of glycoproteins and an alteration of compartmental structures in the cell.
In vivo, SPPL2c is so far exclusively found in maturing spermatids in the male reproduction
system and can affect fertility. It is required for optimal maturation of sperm, in regards of
both glycosylation and acrosome formation. It remains to be discovered what other types of
cells might be able to express SPPL2c upon very specific circumstances that might require
altered Ca2+ signalling or intracellular reorganisation.
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Abbreviations
AD Alzheimer’s disease
ADAM a disintegrin and metalloproteinase
AICD APP-ICD
APH-1 anterior pharynx defective-1 protein
APP amyloid precursor protein
AsA ascorbic acid
ATF6 activating transcription factor 6
AU Airy Unit
Aβ Amyloid β
B3GALT β3-galactosyltransferase
B3GAT3 β3-glucuronosyltransferase
B4GALT β4-galactosyltransferase
BACE β-site of APP cleaving enzyme
BSA bovine serum albumin
CD74 cluster of differentiation 74
CNS central nervous system
COP coat proteins
CRISPR clustered regularly interspaced short palindromic repeats
CTF C-terminal fragment
CYB5A cytochrome B5A
DAPI 4’,6-Diamidin-2-phenylindol
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl
ester
DNA deoxyribonucleic acid
dsDNA double stranded DNA
DTT dithiothreitol
ECL enhanced chemiluminescence
EGFR epidermal growth factor receptor signalling
ER endoplasmic reticulum
ERAD endoplasmic-reticulum-associated-protein-response
ERGIC ER-Golgi intermediate compartment
ESC embryoinic stem cell
EXTL3 exostosin like glycosyltransferase 3
FAD Familial AD
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FasL Fas ligand
FCS fetal calf serum
FDR false discovery rate
FL full length
Fvenv foamy virus envelope protein
GAGs glycosaminoglycans
gDNA genomic DNA
GlcNAc N-acetylglucosamine
GnTs N-acetylglucosaminyltransferases
GnTV N-acetylglucosaminyltransferase V
GOSR2 Golgi reassembly-stacking protein 2
gRNA guide RNA
HO-1 heme-oxygenase-1
HSPGs heparan sulfate proteoglycans
ICD intracellular domain
I-CLIPs intramembrane cleaving proteases
IF Immunofluorescence
IH Immunohistochemistry
ITM2B integral membrane protein 2B
JMD juxtamembrane domain
LFQ label-free quantification
MEF mouse embryonic fibroblasts
MHC major histocompatibility complex
mLIF mouse leukaemia inhibitory factor
mTORC1 mammalian target of rapamycin complex 1
NK natural killer cells
NRG1 neuregulin 1
NSF N-ethylmaleimide-sensitive factor
NTF N-terminal fragment
OGFOD3 2-oxoglutarate and iron-dependent oxygenase domain-containing
protein 3
PCR polymerase chain reaction
PEN2 presenilin enhancer-2
PFA paraformaldehyde
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PM plasma membrane
PS Presenilin
PSA Pisum sativum
PVDF polyvinylidene fluoride
qPCR Quantitative Real-Time PCR
RAMP4 ribosome-associated membrane protein 4
Rce1 Ras converting enzyme
RHBDL rhomboid-like proteins
RIP regulated intramembrane proteolysis
RNA ribonucleic acid
RT room temperature
S1P site-1 protease
S2P site-2-protease
SAGE submerged agarose gel electrophoresis
sAPP soluble APP
sEXTL3 soluble EXTL3
sGNTV soluble GnTV
SNAP soluble NSF attachment protein
SNARE soluble NSF attachment protein receptor
SNPs single nucleotide polymorphisms
SP Signal Peptidase
SPECS secretome protein enrichment with click sugars
SPP Signal Peptide Peptidase
SPPL Signal-Peptide-Peptidase Like
SREBP2 sterol regulatory element-binding protein 2
TCA Trichloroacetic acid
TfR1 transferrin receptor 1
TGN trans-Golgi network
TM transmembrane
TMD transmembrane domain
TNFα tumour necrosis factor α
TR T-RexTM-293
t-SNARE target-membrane SNARE
UPR unfolded protein response
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VAMP vesicle associated membrane protein
VAP vesicle-associated membrane protein-associated protein
v-SNARE vesicle-membrane SNARE
WB Western Blot
WGA Wheat Germ Agglutinin
XBP1u X-box binding protein 1
XYLT xylosyltransferase
α-Man I, II α-mannosidase I, II
(Z-LL)2-ketone 1,3-di-(N-carboxybenzoyl-L-leucyl-L-leucyl)-amino acetone
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